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SUMMARY 
Introduction 
The discovery of Doxorubicin in the 1960s has drastically improved the survival rates of cancer 
patients, however, its success is limited by dose-dependent cardiotoxicity. While much of the literature 
has focused on acute cardiotoxicity which is minor and generally reversible, chronic cardiotoxicity 
poses a serious threat to cancer survivors since it can lead to dilative cardiomyopathy, congestive heart 
failure and even death. The mechanisms that contribute to cardiotoxicity are still a matter of 
controversy, however, oxidative stress-induced myocardial damage and apoptosis are thought to be the 
major role players. Reperfusion injury, also characterized by oxidative stress and apoptosis, occurs as a 
result of restoring blood flow to an ischemic heart. Fortunately, pre- and post-conditioning are 
techniques employed to minimize this damage and are thought to do so by activating the reperfusion 
injury salvage kinase (RISK) and survivor activating factor enhancement (SAFE) pathways. The RISK 
pathway involves the pro-survival kinases, Erk1/2 and Akt, while the SAFE pathway, triggered by 
TNF-α, involves Jak2 and STAT3. Since both reperfusion injury and Doxorubicin-induced 
cardiotoxicity share similar characteristics, this study aimed to determine whether the RISK and SAFE 
pathways are activated in response to long-term Doxorubicin treatment. Furthermore, this study aimed 
to determine whether TNF-α is produced during treatment, since its role in Doxorubicin-induced 
cardiotoxicity is still relatively unknown. 
Methods 
H9c2 cardiomyocytes and differentiated C2C12 myotubes were treated daily with increasing 
concentrations of Doxorubicin for a total of 120 hours. Cell viability, apoptosis and necrosis were 
assessed using the MTT, Caspase-Glo
®
 3/7 and lactate dehydrogenase assays respectively. TNF-α 
production was measured using Quantikine
®
 ELISA kits and various assays were used to assess 
oxidative stress, anti-oxidant capacity and anti-oxidant status. The protein expression of the RISK and 
SAFE pathways were analysed by western blotting using both phospho-specific and total antibodies. 
Results and Discussion 
Treatment with Doxorubicin caused a time- and dose-dependent decrease in cell viability in both cell 
lines and this was accompanied by an increase in apoptosis. In the H9c2 cardiomyocytes, treatment 
with 0.2 μM Doxorubicin yielded significant levels of TNF-α after 120 hours and we can speculate that 
these low levels partially protected the cells from the toxic effects of Doxorubicin by activating the 
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SAFE pathway, since both Jak2 and STAT3 were phosphorylated at this concentration. Treatment with 
1 μM Doxorubicin caused a larger and biphasic pattern of TNF-α release, which may have then 
contributed to the decrease in cell viability, since the SAFE pathway was not activated at this 
concentration. Akt was phosphorylated during the first 72 hours of treatment with the low dose of 
Doxorubicin, but chronic treatment prevented this phosphorylation. While Erk1/2 was not 
phosphorylated at all at the low dose of Doxorubicin, neither Akt nor Erk1/2 was phosphorylated at the 
high dose and their inhibition may contribute to the cardiotoxic effects of Doxorubicin. In the C2C12 
myotubes, a significant amount of TNF-α was produced after 120 hours of treatment with the low dose 
of Doxorubicin. Treatment with the high dose of Doxorubicin induced significant TNF-α production at 
every time point. While STAT3 was phosphorylated at the serine residue after treatment with the low 
dose of Doxorubicin, treatment with the high dose induced phosphorylation at the tyrosine residue in a 
time-dependent manner. p-Jak2 expression was significantly down-regulated at both concentrations of 
Doxorubicin, suggesting that STAT3 proteins can by-pass activation by Jak2. The Erk1/2 leg of the 
RISK pathway was also not activated for the majority of the treatment period, however, p-Akt 
expression was increased at the low concentration of Doxorubicin relative to total Akt expression.  
Conclusion 
These observations indicate that treatment with Doxorubicin causes a severe, dose-dependent loss in 
viability which is likely to mediated by high concentrations of TNF-α (induced by high concentrations 
of Doxorubicin) and down-regulation of protective signaling pathways. TNF-α may confer partial 
protection at low concentrations by activating the SAFE pathway. However, activation of the SAFE 
pathway could not provide sufficient protection from Doxorubicin, most probably because the RISK 
pathway was not simultaneously activated. Our results also clearly highlight the differences between 
acute and chronic treatment since a single high dose of Doxorubicin produced vastly different 
responses to cumulative treatment with a low dose. Before one can extrapolate these results into the 
clinical setting, further research is required to provide a better understanding of the RISK and SAFE 
pathways and whether stimulation thereof will provide a protective effect. In addition, although our 
study has shown that TNF-α is produced in response to Doxorubicin treatment, its true role, whether 
beneficial or detrimental, remains to be determined. 
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OPSOMMING 
Inleiding 
Die ontdekking van Doksorubisien (DOKS) in die 1960’s het die oorlewingsyfer van kankerpasiënte 
drasties verhoog, maar DOKS-gebruik gaan egter ook gepaard met dosis-afhanklike kardiotoksisiteit. 
Terwyl die literatuur grootliks fokus op akute kardiotoksisiteit, wat minimaal en algemeen omkeerbaar 
is, hou kroniese kardiotoksisiteit ‘n ernistige bedreiging vir kankeroorlewendes in, aangesien dit kan lei 
tot dilatiewe kardiomiopatie, kongestiewe hartversaking, en selfs dood. Die spesfikieke meganismes 
wat bydrae tot kardiotoksisiteit is tans steeds onbekend, maar oksidatiewe stres-geinduseerde 
miokardiale skade en apoptose word beskou as hoof bydraende faktore. Reperfussie skade, ook 
gekaraktiseer deur die teenwoordigheid van oksidatiewe stres en apoptose, kom voor as gevolg van die 
herstel van bloedtoevoer na ‘n isgemiese hart. Om die skade te minimaliseer word voor- en na-
kondisionerings tegnieke geïmplimenteer wat die RSHK (Reperfussie Skade Herwinnings Kinase) en 
OAFV (Oorlewerings Aktiverings Faktor Versterkings)-weë aktiveer. Die RSHK weg maak gebruik 
van pro-oorlewings kinases Erk1/2 en Akt, terwyl die TNF-α geaktiveerde OAFV weg Jak2 en STAT3 
betrek. Aangesien beide reperfussie skade en DOKS-geinduseerde kardiotoksisiteit soortgelyke 
eienskappe deel, is die doel van hierdie studie om vas te stel of die RSHK en OAFV-weë geaktiveer 
word in langtermyn DOKS behandeling. Boonop is nog ‘n doel van hierdie studie om vas te stel of 
TNF-α geproduseer word tydens behandeling, aangesien die rol daarvan in DOKS-geinduseerde 
kardiotoksisiteit steeds onbekend is. 
Metodes 
H9c2 kardiomiosiet en gedifferensieerde C2C12 miobuise was daagliks behandel met toenemende 
konsentrasies van Dox vir 120 ure. Die effekte van DOKS op sel lewensvatbaarheid, apoptose en 
nekrose is onderskeidelik ondersoek deur middel van die MTT, Caspase-Glo
®
 3/7 en LDH toetse. 
TNF-α produksie is bepaal deur van die Quantikine® toets gebruik te maak, en verskeie metodes is 
gebuik om die oksidatiewe stres, anti-oksidantkapasiteit en anti-oksidantstatus te bepaal. Die 
proteïenuitdrukking van die RSHK (Erk1/2 en Akt) en OAFV (Jak2 en STAT3) weë was ontleed deur 
middel van westerse afklattingstegniek deur van beide fosfospesifieke en totale teenliggaampies 
gebruik te maak. 
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Resultate en Bespreking 
Behandeling met DOKS het ‘n tyd en dosis-afhanklike afname in sel lewensvatbaarheid in beide 
sellyne veroorsaak, wat gepaard gegaan het met ‘n toename in apoptose. In die H9c2 kardiomiosiete, 
het ‘n lae DOKS dosisbehandeling (0.2 μM) betekenisvolle vlakke van TNF-α na 120 uur opgelewer en 
ons kan spekuleer dat hierdie lae vlakke gedeeltelik die selle van die toksiese effekte van DOKS deur 
die aktivering van die OAFV weg beskerm het omrede beide Jak2 en STAT3 by hierdie konsentrasie 
gefosforileer is. Die hoë DOKS dosis (1 μM) het ‘n groter en bifasiese patroon van TNF-α vrystelling 
vertoon, wat kon bydra tot die DOKS-geinduseerde afname in sel lewensvatbaarheid. Akt is gedurende 
die eerste 72 uur van behandeling gefosforileer met die lae DOKS dosis, maar kroniese behandeling het 
hierdie fosforilering verhoed. Terwyl Erk1/2 glad nie gefosforileer is by die lae DOKS dosis nie, is nie 
Akt of Erk1/2 by die hoë dosis gefosforileer nie, en kan hierdie inhibering bydrae tot die kardiotoksiese 
effekte van DOKS. In die C2C12 miobuise, is ‘n betekenisvolle hoeveelheid TNF-α na 120 uur van 
behandeling geproduseer by die lae DOKS dosis. Behandeling met die hoë DOKS dosis het 
betekenisvolle TNF-α produksie geinduseer by elke tydspunt. Terwyl STAT3 gefosforileer is by die 
serienresidu na behandeling met die lae DOKS dosis, het behandeling met die hoë dosis fosforilering 
by die tirosienresidu op ’n tydsafhanklike wyse plaasgevind. p-Jak2 uitdrukking was betekenisvol 
verminder by beide DOKS konsentrasies, wat aanduidend is dat die STAT3 proteïene nie geaktiveer 
hoef te word deur Jak2 nie. Die Erk1/2 been van die RSHK weg is ook nie geaktiveer gedurende die 
oorhoofse behandelingstydperk nie, alhoewel, p-Akt wel uitgedruk is by die lae konsentrasie van 
DOKS relatief tot die totale Akt uitdrukking.  
Gevolgtrekkings 
Die resultate van hierdie studie toon dat DOKS-behandeling tot ‘n dosis-afhanklike verlies in sel 
lewensvatbaarheid lei. Hierdie effek word waarskynlik bemiddel deur die teenwoordigheid van hoë 
konsentrasies TNF-α, en ook die afregulering van die beskermende seinweë. TNF-α kan moontlik 
gedeeltelike beskerming bied by lae konsentrasies deur aktivering van die OAFV weg. Die aktivering 
van die OAFV weg kon egter nie voldoende beskerming teen DOKS bied nie; moontlik as gevolg van 
die afwesigheid van die gelyktydige RSHK weg aktivering. Ons resultate vertoon die verskille tussen 
die akute en kronies behandeling aangesien ‘n enkele hoë-dosis van DOKS, in vergelyking met ‘n 
kumulatiewe lae-dosis, grootliks verskillende resultate opgelewer het. Voordat hierdie resultate klinies 
verder ondersoek kan word is verdere navorsing nodig om TNF-α en die RSHK en OAFV-weë beter te 
verstaan, en om vas te stel of stimulering van hierdie seinoordragpaaie ‘n beskermende effek teweeg sal 
bring. 
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CHAPTER 1 
1.1 Doxorubicin and its Discovery 
Cancer is a major global health concern (Siegel et al., 2014) with an estimated 12.7 million new 
cases and 7.6 million deaths worldwide in 2008 (Ferlay et al., 2010). Interestingly, 56% of these 
cancer cases and 63% of cancer deaths occurred in the less developed nations of the world 
(Ferlay et al., 2010). In South Africa, the incidence of breast cancer particularly is on par with 
worldwide statistics; however, because the last report by the National Cancer Registry was done 
in 2005, the true incidence of cancer in our country is likely to be underestimated (Vorobiof et 
al., 2001). Anthracyclines are rated amongst the best anti-cancer drugs ever developed (Barrett-
Lee et al., 2009; Minotti et al., 2004a) due to their wide spectrum of activity against virtually all 
human cancers (Cortés-Funes and Coronado, 2007). Doxorubicin (DOX) and Daunorubicin 
(DNR) were the first anthracyclines to be discovered and were isolated from Streptomyces 
peucetius in the early 1960s (Minotti et al., 2004a). The chemical structure of DOX and DNR are 
almost identical (Figure 1.1), both containing aglyconic and sugar moieties (Minotti et al., 
2004b). The aglycone, known as doxorubicinone, consists of a tetracyclic ring (A – D) 
containing adjacent quinone-hydroquinone moieties in rings B and C, while the sugar moiety, 
known as daunosamine, is attached to carbon number 7 by a glycosidic bond (Sies and Packer, 
2004). The only difference between the two is that DOX terminates with a primary alcohol 
whereas DNR terminates with a methyl group (Minotti et al., 2004a). Although small, this 
difference plays an important role on the spectrum of action of these two drugs. 
 
 
 
 
 
Figure 1.1: Chemical structure of DOX (Doxorubicin) and DNR (Daunorubicin). The chemical 
structures illustrated above indicate the aglyconic tetrapeptide rings (A – D) and the sugar moiety at C7 in 
both DOX and DNR. However, the side chains of the two molecules differ, with the side chain (indicated 
by an arrow) of DOX terminating in an alcohol and the side chain of DNR terminating in a methyl group. 
Adapted from Minotti et al., (2004a). 
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While DNR is used primarily for the treatment of myeloblastic and lymphoblastic leukemias, 
DOX is used to treat several human malignancies including breast cancer (Minotti et al., 2004a; 
Vander Heide and L’Ecuyer, 2007), solid tumours of the bile duct, oesophagus and liver (Di 
Marco et al., 1969; Gewirtz, 1999), soft tissue sarcomas, osteosarcomas and the more aggressive 
lymphomas (Gewirtz, 1999; Minotti et al., 2004a; Takemura and Fujiwara, 2007). The 
introduction of anthracyclines such as DOX to chemotherapeutic regimens has been one of the 
great successes of oncology. This is particularly evident in childhood cancers where the 5-year 
survival rate increased from approximately 30% in the 1960s to 70-80% today (Gatta et al., 
2002; Vander Heide and L’Ecuyer, 2007). Despite being more than 50 years old, DOX remains 
an integral part of the chemotherapeutic regimens used today (Weiss, 1992). 
Even though DOX has been used for the last five decades, the mechanisms of action against 
cancer cells are not yet fully understood (Eom et al., 2005; Gewirtz, 1999; Minotti et al., 2004a; 
Swift et al., 2006) Despite being a controversial subject, several mechanisms have been 
proposed: i) DNA intercalation, thereby preventing the biosynthesis of macromolecules; ii) DNA 
damage through inhibition of topoisomerase II; iii) DNA binding and alkylation; iv) interference 
with DNA unwinding, strand separation and helicase activity; v) DNA cross-linking; vi) direct 
membrane effects; vii) generation of free radicals leading to lipid peroxidation and viii) 
apoptosis as an end result of the above mentioned events (Gewirtz, 1999).  
In order to evaluate the mechanisms by which DOX works, one must first consider the clinical 
concentrations of the drug that are observed in patients undergoing treatment. During a single 
administration of between 15 - 90 mg/m
2
, the peak plasma concentration detected was 5 µM 
(Greene et al., 1983), while the minimum was 0.3 µM (Gewirtz, 1999). Generally, plasma 
concentrations lie between 1 – 2 µM but decline within an hour to a steady-state of 25 – 250 nM 
(Muller et al., 1993). However, many in vitro experiments that have been reported in the 
literature have made use of DOX concentrations that are too high compared to peak and steady-
state concentrations observed in patients. It has therefore been suggested that caution must be 
taken when evaluating cell studies that have used concentrations of DOX greater than 1 – 2 µM 
(Minotti et al., 2004a). Bearing this in mind, it is important to realize that even though these 
studies may highlight the potential mechanisms of DOX’s actions, they are unlikely to indicate 
the mechanisms associated with clinical concentrations of the drug (Gewirtz, 1999). 
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1.2 Proposed Mechanisms of Action 
1.2.1 Inhibiting the Biosynthesis of Macromolecules 
Some of the earliest studies on the mechanisms of DOX reported its ability to inhibit the 
biosynthesis of both DNA and RNA (Kim and Kim, 1972; Meriwether and Bachur, 1972), 
possibly by intercalating with DNA and inhibiting DNA polymerase. DOX is taken up into the 
nucleus very rapidly, where it binds with a high affinity to DNA through intercalation between 
base pairs (Cutts et al., 2005). Kim and Kim (1972) have shown significant inhibition of DNA 
synthesis in HeLa cells at concentrations as low as 0.02 mM DOX, however, several other 
studies have failed to detect any inhibition at the lower ranges of DOX (Gewirtz, 1999). For 
example, Meriwether and Bachur, (1972) reported that at least 2 µM DOX is required to inhibit 
DNA and RNA synthesis in a leukemic cell line. 
1.2.2 Inhibition of Topoisomerase II 
Topoisomerases are important enzymes that mediate DNA unwinding for transcription and DNA 
replication (Swift et al., 2006). They modify DNA topology without changing DNA sequence 
and/or structure (Minotti et al., 2004a). Topoisomerases cause single- or double-stranded breaks 
in DNA that are resealed once the conformation of the double helix has been changed (Minotti et 
al., 2004a). Shortly after the discovery of DOX, studies by Ross et al. (1978) reported the 
induction of strand breaks in both single- and double-stranded DNA which were gradually and 
incompletely repaired once DOX was removed from the cells. Ten years later, numerous studies 
identified topoisomerase II as one of the main target sites for DOX, which then became known 
as a “topoisomerase II poison” (Burden and Osheroff, 1998; Cutts et al., 2005). Unlike other 
enzyme-targeting drugs, DOX does not kill cancer cells by inhibiting the catalytic activity of 
topoisomerase. Instead, DOX stabilizes a reaction intermediate in which strands of DNA are cut 
and linked to the tyrosine residue of topoisomerase II, and by doing so, prevents resealing of the 
DNA (Chen et al., 2007). The subunits of the enzyme remain locked onto the 5’ end of the DNA 
molecule after the cleavage reaction is complete (Gewirtz, 1999; Minotti et al., 2004a). DOX 
therefore ‘poisons’ topoisomerase by increasing the concentration of DNA cleavage complexes, 
resulting in double-stranded DNA breaks (Burden and Osheroff, 1998). This DNA damage 
results in growth arrest at the G1 and G2 phase, as well as programmed cell death (Chen et al., 
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2007). The formation and stability of the DOX-DNA-topoisomerase complex ultimately relies on 
the structure of the anthracycline since the planar ring system of DOX is important for its 
intercalation into DNA as rings B and C overlap with adjacent base pairs, and ring D passes 
through the site of intercalation (Minotti et al., 2004a). However, the idea that topoisomerase 
enzymes are the primary targets during DOX-induced cytotoxicity is now being rejected, as this 
phenomenon is not observed at clinical concentrations of the drug. Although it is possible that 
inhibition of topoisomerase II does contribute to the mechanism of action of DOX, other 
mechanisms may play more important roles at clinically relevant concentrations (Cullinane et al., 
2000; Cutts et al., 2005). 
1.2.3 DNA Adduct Formation and DNA Cross-linking 
Anthracyclines are known to form covalent bonds with DNA, however, even though there are 
very early studies reporting the formation of DOX-DNA adducts, it was not until 1990 that the 
specific adduct sites were revealed (Cutts et al., 2005). Two types of covalent bonding exist, 
namely unstable drug-DNA adducts and more stable drug-DNA cross-links (Minotti et al., 
2004a). Studies by Phillips et al. (1989) have described the formation of DNA adducts in both 
single- and double-stranded DNA following treatment with 10 µM DOX. It was hypothesized 
that DOX binds to DNA via a quinone methide intermediate, formed when the semiquinone 
produced during redox cycling is reduced even further (Cullinane and Phillips, 1990). Cummings 
et al. (1992) also reported the chemically activated binding of DOX to DNA at concentrations of 
50 µM and 1 mM. Others have explored the possibility that DOX-DNA binding may cause DNA 
cross links, but such studies have again been performed at elevated drug concentrations that are 
not achievable in patients (Cullinane and Phillips, 1990). These studies therefore provide little 
pathophysiological relevance. 
In vitro studies have shown that the rate of formation of DNA adducts is the same as the rate of 
formation of DNA cross-links, suggesting that adduct formation and DNA cross-links are one 
and the same (Cullinane et al., 2000). It has been shown that DOX-DNA adducts are formed 
almost solely at guanine-cytosine-rich (GC) regions (Phillips et al., 1989), an interaction that is 
stabilised by bonds mediated by cellular formaldehyde. Formaldehydes are produced in free 
radical reactions using carbon sources such as lipids (Yang et al., 2014). This reaction involves 
the formation of a covalent bond on one side of a DNA strand and a hydrogen bond on the other 
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side of the DNA strand (between DOX and guanine) resulting in a mono-adduct (Cullinane et 
al., 2000). This mono-adduct is then stabilized by hydrogen bonds between the intercalated DOX 
and the guanine on the opposite strand of DNA, producing a virtual DNA cross-link (Cullinane 
et al., 2000). The structure of the DOX-DNA adduct has now been determined using 2-
dimensional nuclear magnetic resonance spectroscopy, which has confirmed that DOX 
intercalates alongside GC sequences (Cullinane et al., 2000).  
1.2.4 Interference with Strand Separation and DNA Helicase 
Studies by Gewirtz (1999) have shown that low concentrations (0.05, 0.1 and 0.5 µM) of DOX 
interfere with the unwinding of DNA in MCF-7 breast cancer cells. This result may possibly be 
related to the DNA cross-linking described previously, however, the concentration of DOX used 
in this study was twice as low as those found to cause DNA cross-linking. Alternatively, DOX 
may interfere with DNA unwinding at the level of the helicases. Since binding of DOX to GC 
sites increases overall DNA duplex stability, helicases are unable to separate DNA strands and 
hence their action is prevented (Bachur et al., 1993). Importantly, the concentrations of DOX 
required to block helicase activity fall within a clinically relevant range (0.4 µM) (Bachur et al., 
1993). 
1.2.5 The Free Radical Hypothesis 
It is well documented that under suitable conditions, the chemical structure of DOX allows for 
the production of reactive oxygen species (ROS) (Singal and Iliskovic, 1998; Zhang et al., 2009). 
A one-electron reduction of the C ring of DOX results in the formation of a semiquinone free 
radical which, following a reaction with oxygen, produces superoxides, peroxides and hydroxyl 
radicals (Montaigne et al., 2012; Olson et al., 1981; Sinha, 1989). Electrons are then donated 
back to DOX whose structure is regenerated (Keizer et al., 1990). This process is known as 
“redox cycling” (Figure 1.2) and is particularly damaging as only a small amount of DOX is 
required to produce large amounts of superoxide radicals (Keizer et al., 1990; Montaigne et al., 
2012). The semiquinone free radicals generated by DOX are known to cause cleavage and 
degradation of DNA. Due to the quinone moiety in its structure, DOX acts as an electron 
acceptor in a reaction facilitated by enzymes such as P450 reductase, NADH dehydrogenase and 
xanthine oxidase (Keizer et al., 1990; Sinha, 1989), suggesting that redox-cycling of DOX can 
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take place within the cytoplasm, mitochondria, endoplasmic reticulum (Doroshow, 1983) and 
nucleus (Bachur et al., 1982). Whether these free radicals are produced at clinical concentrations 
of DOX and at normal oxygen tension are questions that still remain unanswered (Gewirtz, 
1999). When clinically relevant concentrations of DOX were used, there was a lag between 
administration of DOX and the detection of free radicals. This may be because free radicals are 
produced as a delayed response to cellular disturbances, or simply because the current methods 
for the detection of free radicals lack sensitivity (Minotti et al., 2004a). 
 
 
 
 
 
 
Figure 1.2: Reactive oxygen species are generated through “redox cycling” of DOX. A one-electron 
reduction of ring C produces a semiquinone free radical. Adapted from Takemura & Fujiwara (2007). 
Free radicals are also generated through interactions between DOX and iron, since a one-electron 
reduction of DOX causes the release of iron from intracellular stores (Minotti et al., 2004a). 
Binding of DOX to the iron results in a 3: 1 drug-iron complex that converts superoxide (O2
•−
) 
and hydrogen peroxide (H2O2) into more potent hydroxyl radicals (
•
OH) (Olson and Mushlin, 
1990). 
•
OH radicals were observed to cause DNA damage in a cytochrome P450 reductase-based 
system following treatment with 100 µM DOX (Feinstein et al., 1993). Utilizing both an 
enzyme- and cell-free system Eliot et al. (1984) reported iron-mediated damage to DNA, as well 
as the generation of 
•
OH radicals, using 10 – 30 µM of DOX. Others have reported that the 
minimum concentration of DOX necessary for the detection of ROS after 4 hours is 4 µM, again 
far exceeding that which is obtained in a patient (Ubezio and Civoli, 1994). These findings 
emphasize the need for more sensitive methods in determining the levels of ROS at clinically 
relevant concentrations of DOX. However, studies have indicated that free radical release and 
subsequent damage to the cell may only occur at higher concentrations of DOX, while damage 
A B C D 
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caused by topoisomerase II inhibition occurs at lower concentrations of the drug (Fornari et al., 
1994). 
DOX-induced generation of free radicals is likely to lead to lipid peroxidation of the cell 
membrane. When free radicals are produced close to cell membranes, 
•
OH radicals attack the 
fatty acids within the membrane, generating a carbon-centered free radical (Horenstein et al., 
2000). Carbon-centered free radicals then react with oxygen to form peroxyl radicals which in 
turn form lipid hydroperoxides that increase membrane permeability. Lipid hydroperoxides can 
also form toxic byproducts such as malondialdehyde (MDA) which can damage membrane 
proteins and render membrane-bound enzymes inactive (Horenstein et al., 2000). MDA is a 
mutagen in human and bacterial cells and carcinogenic in rats and causes large insertions and 
deletions of DNA at GC-rich regions (Niedernhofer et al., 2003) Studies assessing lipid 
peroxidation have been carried out under non-physiological conditions and at elevated 
concentrations of DOX, conditions which alone will promote oxidative stress (Gewirtz, 1999). 
Although a handful of studies have used clinically relevant concentrations of DOX while 
assessing lipid peroxidation, the levels of lipid peroxidation did not change significantly over the 
concentration range, suggesting that lipid peroxidation is unlikely to play a major role in the 
cytotoxic action of DOX (Gewirtz, 1999). 
Glutathione (GSH) reduces harmful peroxides into less harmful alcohols in the presence of 
glutathione peroxidase-1 (GSH-Px1) and in doing so becomes oxidized to glutathione disulphide 
(GSSG). GSSG is then recycled back into GSH in the presence of glutathione reductase and 
NADPH (Olson et al., 1981). GSH is abundant in the cytosol, nucleus and mitochondria, 
highlighting the importance of this antioxidant within a cell (Valko et al., 2007). GSH protects 
against oxidative stress by i) assisting detoxifying enzymes such as GSH-Px1, ii) participating in 
amino acid transport through the plasma membrane, iii) scavenging hydroxyl radicals and 
detoxifying hydrogen and lipid peroxides and iv) regenerating the most important antioxidants 
back to their active forms (Masella et al., 2005). Unfortunately, however, treatment with DOX 
can deplete endogenous GSH and inhibit GSH-Px1 (Mukherjee et al., 2003; Siveski-Iliskovic et 
al., 1994) 
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1.3 Doxorubicin and the Heart 
The heart is a truly remarkable organ. However, unlike other cell types, cardiomyocytes are 
unable to undergo cellular repair (Ewer and Ewer, 2010). Nevertheless, the heart still has the 
capacity to increase cardiac output during exercise, survive the loss of myocytes through insults 
such as myocardial infarction (MI) and undergo lifetime stressors like hypertension (Ewer and 
Ewer, 2010). According to the latest American Heart Association statistics, approximately 83.6 
million (1 in 3) adult Americans suffer from at least one type of cardiovascular disease (CVD) 
(Go et al., 2013). Of this population, 15.4 million suffer from coronary heart disease including 
MI, angina, heart failure and stroke (Go et al., 2013). Sadly, it is projected that by 2030, 40.8% 
of the American population will have some form of CVD (Go et al., 2013). Like CVD, cancer 
affects millions of people worldwide and its incidence increases with advancing age (Ewer and 
Ewer, 2010; Gustafsson and Gottlieb, 2003). Although many forms of cancer do metastasize to 
the heart, cancer therapies as a risk factor for aggravating underlying heart disease or initiating 
de novo heart conditions did not become a major concern until the early 1970s (Ewer and Ewer, 
2010). Despite this, anthracyclines have enabled oncologists to effectively control malignancies, 
however, the cardiac problems associated with these drugs were not anticipated. 
1.4 Doxorubicin-induced cardiotoxicity 
Despite its widespread use and clinical efficacy, the success of DOX is limited by cardiotoxicity. 
One of the most well documented shortcomings of DOX is cumulative, dose-dependent, 
myocardial damage which can lead to dilative cardiomyopathy, congestive heart failure (CHF) 
(Mercuro et al., 2007; Swain et al., 2003), a reduced quality of life or even death (Mercuro et al., 
2007). It is estimated that nearly two million Americans are at risk of developing cardiotoxicity 
after treatment with DOX (Gianni et al., 2008). Although much of the literature has focused on 
the resulting cardiomyopathy, this condition is one of many. The effects on vasculature can result 
in ischemia or changes in blood pressure and within the pericardium there may be imbalances in 
fluid equilibrium, pericardial swelling, as well as an increased risk of arrhythmias (Ewer and 
Ewer, 2010). Furthermore, all of the above mentioned conditions may be further exacerbated by 
the cancer itself, possibly through the inflammatory response (Ewer and Ewer, 2010). 
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Cardiotoxicity, defined as a broad range of adverse effects on heart function induced by 
therapeutic molecules (Montaigne et al., 2012), went undetected in the pre-clinical animal 
studies and was only documented during early clinical trials. In the late 1970s, clinical studies 
showed convincing evidence that the cardiac disturbances observed during treatment were 
directly related to repeated administration of DOX (Šimùnek et al. 2009). In a retrospective 
analysis, Von Hoff et al. (1979) identified that the total cumulative dose of DOX is a major risk 
factor for heart failure (Figure 1.3). In addition, it was observed that increasing age and previous 
or simultaneous radiation therapy (Bristow et al., 1978) or chemotherapy (Minow et al., 1977) 
were associated with an increased risk of DOX-induced CHF. Since DOX-induced cardiotoxicity 
is dose-dependent (Unverferth et al., 1983; Vander Heide and L’Ecuyer, 2007), the incidence of 
developing CHF is 3% when the cumulative dose exceeds 400 mg/m
2
 of body surface area (Von 
Hoff et al., 1979). This incidence rises to 7% when the dose is 551 – 600 mg/m2 and increases to 
18% at doses exceeding 601 mg/m
2
 (Von Hoff et al., 1979), however, other studies indicate that 
these incidences are in fact under-estimated. Swain et al., (2003) observed a 5% risk at a 
cumulative dose of 400 mg/m
2
, 26% at 550 mg/m
2
 and 48% at 700 mg/m
2
. Interestingly, of 630 
patients taking part in this retrospective analysis, 5.1% developed DOX-induced CHF (Swain et 
al., 2003). Patients who had shown no symptoms at the time of remission all had a significantly 
higher incidence of cardiovascular complications four to twenty years after the last treatment 
(Singal et al., 1997). Moreover, it has previously been estimated that the risk of death from 
cardiac events associated with the use of DOX was 8.2 fold higher than that of the normal 
population, even 25 years treatment (Lipshultz et al., 2004). DOX-induced cardiotoxicity carries 
a poor prognosis since it has proven to be lethal in 60% of patients (Von Hoff et al., 1979).
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Figure 1.3: Cumulative risk of DOX-induced heart failure. Following exposure to cumulative doses of 
DOX once every 3 weeks, the risk of developing chronic heart failure increases in a proportional manner. 
The graph shown above further categorizes this risk according to age. Image obtained from Barrett-Lee et 
al., (2009). 
Cumulative, dose-dependent, DOX-induced cardiotoxicity implies that irreversible damage 
occurs to the heart with each additional administration of the drug. The second administration 
thus further suppresses the already damaged heart, leading to cardiomyocyte death (Barrett-Lee 
et al., 2009; Chen et al., 2007). Since the heart has a limited capacity for regeneration (Chen et 
al., 2007), incremental administrations of DOX compromise the heart even further until it can no 
longer meet the body’s demands. When the heart’s compensatory mechanisms become 
overwhelmed, heart failure develops and with any additional drug exposure, death may follow 
(Ewer and Ewer, 2010). 
1.4.1 Classification of cardiotoxicity 
Anthracycline-induced cardiotoxicity has been classified into 4 different types: i) “acute” 
cardiotoxicity occurs during or immediately after anthracycline administration and usually 
occurs when the drug is administered as a bolus or via rapid intravenous infusion (Montaigne et 
al., 2012; Šimùnek et al., 2009). Acute cardiotoxicity is generally minor and reversible and 
typically leads to vasodilatation, hypotension and disturbances in cardiac rhythm (tachycardia) 
(Lefrak et al., 1973). Acute myocardial injury can usually be detected by elevated levels of 
cardiac troponin I (Barrett-Lee et al., 2009), which also predicts the future development of left 
ventricular contractile dysfunction and its severity (Cardinale et al., 2002) ii) “Subchronic” 
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cardiotoxicity is extremely rare and presents itself as pericarditis-myocarditis syndrome within 1 
– 3 days after treatment iii) “Early chronic” cardiotoxicity develops weeks to months after the 
completion of chemotherapy and is characterised by dilated cardiomyopathy, left ventricular 
contractile dysfunction and CHF (Šimùnek et al., 2009). Histopathological changes are 
distinctive and consist of dilation of the sarcoplasmic reticulum of myocytes, cytoplasmic 
vacuolization, mitochondrial swelling (Figure 1.4A) and loss of myofibres (Figure 1.4B) (Chen 
et al., 2007; Lefrak et al., 2006; Minotti et al., 2004a; Šimùnek et al., 2009). These 
morphological characteristics are also seen in experimental models using rats (Weinberg and 
Singal, 1987), mice (Lambertenghi-Deliliers et al., 1976) and rabbits (Olson et al., 1974), 
indicating that the final morphological damage is species-independent. 
 
 
 
 
 
Figure 1.4A and B: Case report of DOX-induced cardiotoxicity in 1971. (A) The remaining myofibres 
exhibit widened, disrupted Z-lines which are separated by swollen mitochondria (arrows) (30 000x). (B) 
Image clearly shows considerable loss in the number of muscle fibers and an increase in the amount of 
interstitial tissue (300x). Image obtained from Lefrak et al., (2006). 
Finally, iv) “delayed” or “late-onset chronic” cardiotoxicity was first described in the 1990s and 
is typically seen amongst survivors of childhood cancers, decades after the completion of 
treatment (Lipshultz et al., 1991). A study in 2006 showed that 30-year childhood cancer 
survivors had a 15-, 10- and 9-fold higher risk of heart failure, other CVDs and stroke, 
respectively (Oeffinger et al., 2006). The Childhood Cancer Survival Study showed that 30 years 
after treatment, the incidence for chronic health complications was as high as 73%, with 42% of 
these patients suffering from disabling, life threatening conditions (Oeffinger et al., 2006). Some 
of the characteristics associated with chronic DOX-induced cardiotoxicity include a significant 
drop in blood pressure, an elevated heart rate, a decrease in ejection fraction and ultimately heart 
A B 
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failure (Lefrak et al., 1973). Yi et al., (2006) demonstrated that seven out of nine mice died 
during the first six weeks after the last DOX injection, similar to what is observed in humans 
who succumb to heart failure months or years after the end of their chemotherapy. 
Acute cardiotoxicity is not a considered a major clinical problem as it usually resolves shortly 
after an infusion, however, the chronic forms of cardiotoxicity are serious and drastically affect 
the morbidity and mortality of patients requiring long-term therapy (Šimùnek et al., 2009). In 
addition to the cumulative dose of DOX aiding in the development of cardiotoxicity, other 
important risk factors include age at treatment (both low and high), long-standing hypertension, 
pre-existing cardiac abnormalities, previous chemotherapy and a history of cardiac disease 
(Zuppinger et al., 2007). In an effort to demonstrate the dangers of DOX, Lefrak et al., (2006) 
indicated that 11 out of 399 advanced-stage cancer patients receiving DOX developed sudden 
onset CHF. Furthermore, these patients had no prior history of cardiac disease. Eight of these 
eleven patients died within three weeks of the first symptoms. What should have been a highly 
promising drug now adds to the already cumbersome burden of CVD and cancer. 
When evaluating papers on anthracycline cardiotoxicity, it is important to take the different 
experimental conditions into consideration. Clearly, the best and most appropriate data would be 
that obtained from human patients, however, human myocardial biopsy samples are extremely 
difficult to obtain. In addition, patients are treated with different multidrug regimens and thus 
their biopsies may be very heterogeneous. It is thus necessary to make use of experimental 
models in order gain insight into the molecular mechanisms of anthracycline cardiotoxicity. One 
of the simplest models involves the cell culture of primary neonatal or adult rat cardiomyocytes. 
It has also become widely accepted to make use of cardiomyocyte-derived cell lines, particularly 
H9c2 rat embryonic cardiomyoblasts (L’Ecuyer et al., 2001). Ex vivo studies make use of 
isolated atria, papillary muscles or whole hearts for perfusions, whereas in vivo studies, 
commonly using mice, rats, rabbits, pigs and dogs, allow for repeated administration of 
anthracyclines to simulate chronic cardiotoxicity (Šimùnek et al., 2009).  
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1.5 Mechanisms of Doxorubicin-induced Cardiotoxicity 
1.5.1 Doxorubicin and Free Radicals 
The two main mechanisms for DOX-induced cardiotoxicity that have been proposed are: i) 
damage to membranes by DOX-generated free radicals and ii) DNA uncoiling due to DOX-DNA 
binding (Unverferth et al., 1983). Other mechanisms include inhibition of DNA and protein 
synthesis (Monti et al., 1995), mitochondrial abnormalities, changes in sarcolemmal calcium 
(Ca
2+
) homeostasis (Olson et al., 1974; Singal and Pierce, 1986) and imbalances in myocardial 
electrolytes (Olson et al., 1974). It is well documented that DOX-induced cardiotoxicity is 
associated with the generation of oxygen-derived free radicals, unstable chemical species 
containing unpaired electrons (Olson et al., 1981). Supporting this theory are studies making use 
of free radical scavengers such as α-tocopherol, among others, which protected mice against 
DOX-induced cardiotoxicity while still allowing DOX to inhibit the synthesis of DNA in the 
tumor (Myers et al., 1977). Other studies have shown that transgenic mice over-expressing 
superoxide dismutase (SOD) in their cardiac mitochondria are protected from DOX-induced 
cardiotoxicity following treatment with clinically relevant doses (Yen et al., 1996). 
The enzymatic pathway for the production of free radicals involves the mitochondria (Vander 
Heide and L’Ecuyer, 2007). DOX has a high affinity for cardiolipin, a phospholipid that is richly 
embedded in the inner mitochondrial membrane. DOX therefore targets the mitochondria where 
it accumulates over time (Childs et al., 2002). Intracellular concentrations of DOX have been 
reported to be 10 times that of extracellular concentrations. In other words, when plasma 
concentrations are between 0.5 – 1 µM, the concentration within the mitochondria is 
approximately 50 – 100 µM (Kalyanaraman et al., 2002). NADH dehydrogenase, present within 
the mitochondria, converts DOX into a semiquinone which, following redox cycling, produces 
O2
•−
 and H2O2. In vitro studies have demonstrated that O2
•−
, a product of DOX redox cycling, is 
small enough to enter ferritin transprotein channels and reduce the iron core of ferritin, releasing 
iron in the ferrous (Fe
2+
) form and H2O2.  Fe
2+ 
and H2O2 combine to generate a more potent 
perferryl iron or 
•
OH (Kalyanaraman et al., 2002). It is therefore suggested that O2
•−
 , H2O2, iron, 
•
OH and Ca
2+
 are also responsible for the cardiotoxic effects of DOX, causing damage by 
inhibiting important proteins and enzymes involved in the mitochondrial respiratory chain 
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(Singal and Panagia, 1984). Interestingly, while semiquinones in liver microsomes prefer to react 
with oxygen producing relatively harmless superoxide radicals, semiquinones formed in the 
mitochondria of the heart preferentially react with H2O2 to produce highly reactive 
•
OH (Nohl 
and Jordan, 1983).  
Following treatment with DOX, cardiomyocytes also undergo apoptosis in response to redox 
cycling and the formation of O2
•−
 and H2O2 (Gustafsson and Gottlieb, 2003). Apoptosis however, 
can be attenuated when the cells are treated with cell-permeable free radical scavengers (Minotti 
et al., 2004a). Since apoptosis can be prevented by treatment with free radical scavengers and 
iron chelators, the apoptotic effects of O2
•−
 and H2O2 are thought to be mediated by a cellular 
store of low molecular weight iron (Sawyer et al., 1999). However, one question still remains: 
how are pools of intracellular iron formed considering that cells have minimal free iron available 
for free radical reactions? One possibility is that prior to apoptosis, cardiomyocytes undergo 
extensive disruptions in iron homeostasis, resulting in iron release from intracellular stores 
(Minotti et al., 2004a).  
1.5.2 Apoptosis 
While the mechanisms of DOX cytotoxicity and DOX-induced cardiotoxicity may share 
similarities, it is important to note that the responses of different cell types, namely cardiac and 
cancer, to these mechanisms, are likely to be very different. Until recently, apoptosis was 
disregarded as a major mechanism for cardiotoxicity, but recent research has altered this picture. 
Apoptosis is a tightly regulated suicide program that is characterized by chromatin condensation, 
DNA fragmentation, membrane blebbing and cell shrinkage (Gustafsson and Gottlieb, 2003; 
Zhang et al., 2009). A handful of researchers have reported the induction of apoptosis at drug 
concentrations of between 0.05 and 10 µM, while others have demonstrated that the cell death 
observed at elevated concentrations of the drug is not due to apoptosis, but more likely due to 
necrosis (Chen et al., 2007). Necrosis, in contrast to apoptosis, is an uncontrolled, irreversible 
process that is characterized by cell swelling and membrane disruption (Gustafsson and Gottlieb, 
2003). DOX-induced cardiotoxicity may be caused by the activation of p53 in response to DNA 
damage in the heart (Liu et al., 2008). p53 is a tumor suppressor protein which, once activated, is 
phosphorylated at serine
15
. p53 then translocates to the nucleus where it upregulates the 
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expression of genes associated with cell cycle arrest, DNA repair and apoptosis. A study by Liu 
et al., (2008) showed that DOX causes a time-dependent increase in p53, by up to 9-fold, when 
compared to control cells.  
Apoptosis can occur via two pathways: the intrinsic (mitochondrial) pathway and the extrinsic 
(death receptor) pathway (Figure 1.5) (Gustafsson and Gottlieb, 2003). In the extrinsic pathway, 
appropriate ligands bind to cell membrane receptors from the tumor necrosis factor (TNF) 
superfamily. These death receptors contain death domains that are critical for their pro-apoptotic 
function (Chinnaiyan et al., 1995). Following ligand binding, death receptors such as Fas and 
tumor necrosis factor receptor 1 (TNFR1) form a homotrimeric complex that recruits adaptor 
proteins like FADD (Fas-associated death domain) and TRADD (TNFR-associated death 
domain) (Tolosa et al., 2005). Studies of DOX-induced cardiotoxicity have reported over-
expression of Fas, but it’s down-regulation can reduce apoptosis in cardiomyocytes (Nakamura 
et al., 2000). Cardiomyocytes exhibit functional TNF receptors and undergo apoptosis following 
treatment with relatively high concentrations of TNF-alpha (TNF-α) (Krown et al., 1996), 
however, on the other hand, studies have suggested that TNF-α may play a cardio-protective role 
at certain concentrations (Gustafsson and Gottlieb, 2003). 
Treatment with DOX increases oxidative stress and disrupts calcium homeostasis within the cell 
(Zhang et al., 2009). ROS raises calcium levels by promoting its release from the sarcoplasmic 
reticulum. This in turn creates a vicious cycle where elevated Ca
2+
 levels then increase ROS 
production through Ca
2+
-sensitive ROS-producing enzymes (Zhang et al., 2009). Since the 
mitochondria are situated in close proximity to the Ca
2+
-release site, they are exposed to large 
quantities of Ca
2+
. The overwhelming levels of ROS, together with elevated levels of Ca
2+
 
beyond the threshold, trigger the opening of the mitochondrial permeability transition pore 
(mPTP). This causes a loss in mitochondrial membrane potential and ultimately the release of 
cytochrome c (Zhang et al., 2009). Cytochrome c, located in the inner mitochondrial membrane, 
(Chen et al., 2007; Childs et al., 2002) forms part of the intrinsic apoptotic pathway.  
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Figure 1.5: Schematic representation of the intrinsic and extrinsic apoptotic pathways. The 
extrinsic pathway involves the death receptors Fas and TNFR1. Ligand binding (such as DOX-induced 
TNF-α) triggers this pathway which results in the activation of caspase-8 which subsequently activates 
caspase-3 and -7. The intrinsic pathway is activated in response to oxidative stress. An increase in ROS 
releases cytochrome c from the mitochondria. An apoptosome is then formed which activates caspase-3. 
Both pathways result in apoptosis. Abbreviations: SR, sarcoplasmic reticulum, MTC, mitochondria, Cyt c, 
cytochrome c. 
It is well known that mitochondria are abundant in the myocardium and are able to detect several 
cellular stress signals including a loss of growth factors, hypoxia, oxidative stress as well as 
changes in calcium homeostasis (Gustafsson and Gottlieb, 2003). In response to these signals, 
mitochondria then release various pro-apoptotic factors such as cytochrome c, apoptosis-
inducing factor (AIF), Smac/Diablo and pro-caspases into the cytosol. Caspases are a family of 
proteases that cleave pro-survival molecules and structural proteins (Gustafsson and Gottlieb, 
2003). They are present in a cell as inactive procaspases and are activated through cleavage at a 
specific site in response to apoptotic stimuli. Activation of the death receptor pathway results in 
activation of caspase-8 (an initiator caspase) which is able to activate downstream caspases, 
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thereby triggering apoptosis (Hirata et al., 1998). Cytochrome c forms a complex with Apaf-1, 
adenosine triphosphate (ATP), and pro-caspase 9 (an initiator caspase), known as an 
apoptosome, which activates caspase-3 or -7 (effector caspases), culminating in apoptosis (Chen 
et al., 2007).  
Bax, a pro-apoptotic protein, can further aid in cytochrome c release by integrating itself into the 
inner mitochondrial membrane and facilitating the opening of the mPTP. Free radicals, 
particularly H2O2 produced during redox cycling, actively participate in the induction of 
cytochrome c releasing via the opening of the mPTP (Minotti et al., 2004a). This causes DNA 
fragmentation, with the end result being apoptosis (Chen et al., 2007). Accumulating research 
points to cross-talk between the extrinsic and intrinsic apoptotic pathways as evidenced by the 
ability of caspase-8 to cleave Bid (pro-apoptotic) to truncated Bid (t-Bid), which then 
translocates to the mitochondria where it stimulates the release of cytochrome c (Li et al., 1998). 
Based on the above, DOX induced apoptosis is essential for the elimination of cancerous cells, 
but equally important is its detrimental role during cardiotoxicity (Kalyanaraman et al., 2002). 
The topic of DOX-induced apoptosis in vivo remains a controversial one, despite solid evidence 
of apoptosis in vitro. Myocardial apoptosis has previously been reported in animal studies 
simulating DOX-induced cardiotoxicity, however, all markers of apoptosis declined to baseline 
before completion of the treatment period (Arola et al., 2000). Other studies have observed 
apoptosis at 4 days post treatment, a decline between days 10 and 16 and again a peak at 21 days 
after the last DOX injection (Kumar et al., 2001). These results suggest that there may be a 
period of apoptotic silence while DOX-induced cardiomyopathy develops. Clinically, evidence 
of myocardial apoptosis has been demonstrated hours after treatment with DOX where 
endomyocardial biopsies indicated mitochondrial swelling and chromatin condensation, both 
characteristic of apoptotic cell death (Unverferth et al., 1983). 
1.6 Why the heart? 
One of the reasons why cardiomyocytes are more susceptible to oxidative stress-induced 
apoptosis than other cell types is because cardiomyocytes contain low levels of anti-oxidant 
defenses such as catalase and SOD (Doroshow et al., 1980). Since organs such as the liver and 
the kidney generate free radicals during every day catabolism, they have much higher levels of 
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GSH than organs such as the heart which produces fewer free radicals (Doroshow et al., 1979). 
Furthermore, GSH-Px1 undergoes prolonged inactivation following treatment with DOX 
(Doroshow et al., 1980). When GSH-Px1 is inactive, an important defense mechanism is 
eliminated and apoptosis is induced (Minotti et al., 2004a). Moreover, DOX also causes a 
reduction in the activity and protein levels of cytosolic copper-zinc SOD. This is likely to be 
caused by an accumulation of damage at the transcriptional and translational level (Li et al., 
2002).  
As mentioned previously, cardiac cells are incredibly rich in mitochondria which makes them 
even more susceptible to ROS produced by these organelles (Keizer et al., 1990). Furthermore, 
DOX is known to have a high affinity for cardiolipin, a phospholipid found in the inner 
mitochondrial membrane (Schlame et al., 2000). Because of this property, DOX is likely to 
concentrate within cardiomyocytes, forming practically undissociable complexes with 
cardiolipin. This results in the inhibition of cytochrome c oxidase within the heart and impedes 
the flow of electrons through the respiratory chain (Gilliam et al., 2013; Schlame et al., 2000). 
Excess electrons can then be accepted by oxygen resulting in the production of free radicals 
(Schlame et al., 2000; Vander Heide and L’Ecuyer, 2007). Proteomic studies support this notion 
as significant changes to the subunits of complex one of the electron transport chain results in 
insufficient enzyme function of this complex (Štěrba et al., 2011).  
1.7 Potential treatments 
More than 500 anthracyclines have been synthesized in an attempt to improve cytotoxic action 
while simultaneously decrease the cardiotoxic side effects (Sinha, 1989). The results of such 
research have been disappointing and thus DOX remains the most widely used anthracycline 
today. Although there is currently no treatment for DOX-induced cardiotoxicity, clinicians 
instead aim to prevent existing cardiomyopathies from worsening. However, for patients who 
already exhibit end-stage heart failure, transplants remain their only option (Thomas et al., 
2002). One of the approaches used to minimize DOX-induced cardiotoxicity is to decrease the 
peak concentration of DOX in the plasma (Singal et al., 1997) and limit the cumulative dose of 
DOX. This can be achieved by administering DOX concomitantly with other drugs such as 
Vincristine and Cisplatin in a drug “cocktail” in order to limit the total amount of DOX used 
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(Singal and Iliskovic, 1998). A recommended, cumulative dose of 500 mg/m
2
 in a lifetime has 
also been established. This dose should only be exceeded under intensive cardiac monitoring and 
pharmacological cardioprotection (Šimùnek et al., 2009). A significant decrease in the incidence 
of cardiotoxicity has been observed when the drug is administered slowly over 6 – 96 hours, 
compared to a rapid infusion over 15 minutes (Legha et al., 1982; Torti et al., 1983). This 
method limits the peak levels of DOX and is associated with a lower risk of cardiotoxicity. 
However, slow infusions will increase hospital stays and add to the already high costs of 
chemotherapy.  
Adult cardiomyocytes have a highly oxidative metabolism with limited oxidative defenses, 
therefore anthracycline-induced injury could be reduced by increasing these defenses. 
Unfortunately, the promising results observed in animal models following treatment with various 
anti-oxidants were not observed in the human patients suffering from DOX-induced 
cardiotoxicity in clinical trials. This may suggest that the experimental models and the type of 
anti-oxidants used may play a role in the effectiveness of the anti-oxidant at providing 
protection. It is also crucial to carefully optimize the dose of the anti-oxidants used in each 
model (Singal et al., 1997). 
Unlike other antioxidants, melatonin is distributed in all subcellular compartments due to its 
solubility in both lipids and water, and can therefore enter cardiac cells to scavenge free radicals 
(Liu et al., 2002).  It has been reported by Zhang et al., (2013) that melatonin treatment 
substantially reduced DOX-induced myocardial injury in rats and protected against lipid 
peroxidation in this model. Believed to be one of the most potent anti-oxidants, melatonin has 
been shown to inhibit necrosis and apoptosis during DOX-induced cardiotoxicity (Liu et al., 
2002). One of the earliest anti-oxidants used to reduce cardiotoxicity was vitamin E, which was 
administered as an injection 24 hours prior to treatment with DOX. Vitamin E provided 
cardioprotection against DOX-induced cardiomyopathy and enhanced the antioxidant activity of 
the rat myocardium by increasing the activity of GSH-Px1 (Siveski-Iliskovic et al., 1994). 
However, subsequent research has shown that vitamin E only provides protection in acute 
models of cardiotoxicity and fails to offer protection during chronic cardiotoxicity (Mimnaugh et 
al., 1979). Similarly, in 1983, N-acetylcysteine (NAC) was highly effective in acute preclinical 
trials, but failed to show protection against chronic DOX-induced cardiotoxicity (Myers et al., 
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1983). The poor results obtained whilst using antioxidants in human studies also suggests that 
cardiotoxicity is caused by more than just the generation of ROS (Takemura and Fujiwara, 
2007). 
Despite several decades of intense research, only one drug has been approved for use in the 
clinical setting as a pharmacological cardioprotective agent. Dexrazoxane (DXZ/ICRF-187) was 
discovered accidently during its pre-clinical testing as an anti-cancer agent (Herman et al., 1979). 
DXZ was repeatedly identified to protect the myocardium from all forms of anthracyclines in 
both animal and human models (Šimùnek et al., 2009). DXZ is an iron-chelating agent that also 
abolishes the DNA and mitochondrial damage induced by DOX (Xiang et al., 2009), without 
compromising the ability of anthracyclines to inhibit the growth of tumours (van Dalen et al., 
2011). DXZ permeates the cell membrane, where it rapidly undergoes hydrolysis to its metal ion-
binding form, ADR-925 (Xiang et al., 2009). In this manner, DXZ provides protection from 
anthracyclines by chelating free iron and iron bound in DOX-iron complexes, thus preventing the 
formation of DOX-induced ROS and damage to mitochondria (Hasinoff et al., 2003). 
Consequently, pools of free iron are reduced and iron bound to DOX is displaced from the 
complex. In animal models, treatment with DXZ significantly reduced the occurrence of cardiac 
lesions associated with cardiotoxic doses of DOX and resulted in a significant increase in the 
survival rate (Cvetković and Scott, 2005). Others have shown that DXZ is more effective when 
administered prior to, or simultaneously with DOX treatment, rather than after DOX treatment 
(Hasinoff et al., 2003). In human studies, DXZ has also provided significant cardioprotection 
during DOX treatment. In phase III trials, the incidence of DOX-induced cardiac events was only 
0 – 15% in women with advanced breast cancer receiving DXZ, compared to 16 – 50% not 
receiving it (Swain et al., 1997). More specifically, DXZ significantly reduced the incidence of 
CHF from 8 – 27% in women not receiving DXZ, to 0 – 3% in women who were (Swain et al., 
1997). Unfortunately, the success of DXZ is limited by severe myelosuppression (Curran et al., 
1991). 
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1.8 Salvaging the heart from cardiotoxicity: what role does the RISK pathway 
play? 
The deleterious effects of DOX-induced cardiotoxicity share many characteristics with ischemia-
reperfusion injury, including the generation of ROS and apoptotic cell death (Frias et al., 2008). 
Following an acute coronary blockage with the risk of MI, cardiologists make use of reperfusion, 
a technique that is required to save the ischemic heart cells from dying. Although this procedure 
is beneficial, restoration of blood flow results in myocardial reperfusion injury, reducing the 
potential benefits of myocardial reperfusion (Yellon and Hausenloy, 2007). Within the first few 
minutes of restoring blood flow to the ischemic myocardium, a condition of oxidative stress 
arises (Zweier, 1988) as a result of elevated ROS production (Zhao, 2004). This burst of ROS 
causes myocardial injury and cardiomyocyte death. This phenomenon is known as the “oxygen 
paradox” since the reoxygenation of the ischemic myocardium is thought to generate a greater 
degree of damage than the ischemia itself (Hearse et al., 1973).  
Due to the paradoxical nature of ischemia reperfusion, novel strategies to protect the heart from 
reperfusion injury have been developed; namely pre- and post-conditioning. Protection is 
achieved by repeatedly, but briefly, exposing the heart to conditions of ischemia, before or after 
the potentially lethal ischemic insult (Lecour, 2009a). This reduces oxidative stress, Ca
2+
 
overload and inflammation (Hausenloy, 2009). Both pre- and post-conditioning are believed to 
protect from reperfusion injury via the activation of the RISK pathway (Figure 1.6, chapter 1.9) 
(Hausenloy and Yellon, 2004). This pathway involves the activation of the pro-survival kinases 
Akt/PKB and Erk1/2 (extracellular signal-related kinase). Studies have demonstrated that the 
activation of these kinases by pre- and post-conditioning, whether mechanically or 
pharmacologically, at the onset of reperfusion, reduces infarct size by 40 – 50% (Hausenloy, 
2009). Activation of the RISK pathway causes down-regulation of pro-apoptotic proteins and 
maintains the integrity of the mitochondria (Xiang et al., 2009). In the context of DOX-induced 
cardiotoxicity, damage to cardiomyocytes and cell death due to apoptosis are strongly believed to 
occur as a result of down-regulation of Akt and Erk1/2 both in vitro and in vivo (Lou et al., 
2005). 
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1.8.1 Erk1/2 
The mitogen-activated protein kinase (MAPK) pathway is initiated by G-protein coupled 
receptors, receptor tyrosine kinases and by stress stimuli (Sugden and Clerk, 1998). The two 
most well studied kinases involved in the MAPK cascade are Erk1 and Erk2 who are directly 
controlled by MEK1 and MEK2 of the MAPK family. All three members of the MAPK family 
are found to be activated during ischemia-reperfusion injury, as well as in samples obtained from 
humans with heart failure (Bueno and Molkentin, 2002). The activation of these MAPKs is 
thought to be mediated by an increase in oxidative stress (Lou et al., 2005). 
Within the heart, Erk1/2 are potently and quickly activated by growth factors and are involved in 
cell survival, differentiation, proliferation and apoptosis following ischemia-reperfusion injury, 
oxidative stress and exposure to anthracyclines such as DOX (Bueno and Molkentin, 2002; Lips 
et al., 2004; Lou et al., 2005). Although the mechanism by which this occurs is not certain, it is 
believed to involve the inactivation of pro-apoptotic proteins (Hausenloy and Yellon, 2004) and 
antagonization of apoptosis (Lips et al., 2004). Activation of Erk1/2 may possibly activate the 
p90 ribosomal S6 kinase (p90RSK), which then phosphorylates Bad and promotes cell survival 
(Xiang et al., 2009). Additionally, Erk1/2 inhibits cytochrome c-induced activation of caspases 
(Hausenloy and Yellon, 2004).  
Immunohistochemical analysis indicates that phospho-Erk1/2 (p-Erk1/2) translocates to the 
nucleus following activation by 1 µM DOX for up to 48 hours and this finding was confirmed by 
western blotting of nuclear fractions (Liu et al., 2008). However, it has been previously shown 
that phosphorylation of Erk1/2 was significantly decreased in a rat model of DOX-induced heart 
failure (Lou et al., 2005; Xiang et al., 2009), where the cumulative dose of DOX was 15 mg/kg, 
which may explain the increase in cell death following DOX treatment. In contrast, other studies 
have reported an increase in the level of p-Erk1/2 following acute treatment with DOX (Gharanei 
et al., 2013; Tang et al., 2002) and thus highlights its role as a cell survival protein. Supporting 
evidence can be found with the inhibition of Erk1/2 which leads to exacerbated DOX-induced 
apoptosis and cytotoxicity after treatment with 20 nM DOX for 48 hours (Brantley-Finley et al., 
2003). 
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These contradictory findings may suggest that the role played by these MAPKs is influenced by 
the cell-type, drug concentration, duration of exposure and the model of cardiotoxicity assessed 
(Fan and Chambers, 2001). Since p-Erk1/2 has been shown to play pro-apoptotic, anti-apoptotic 
and neutral roles, its function is clearly dependent on the context. Examples of this are 
summarized in table 1. Important comparisons can be made with regards to acute (Ichihara et al., 
2007; Li et al., 2006) versus chronic (Lou et al., 2005; Xiang et al., 2009) models and to studies 
that made use of clinically relevant (Liu et al., 2008) versus clinically unattainable (Das et al., 
2011) concentrations of DOX. In addition, Erk1/2 responses after treatment with DOX appears 
to be regulated differently depending on whether DOX is administered in vivo or in vitro, 
emphasizing the importance of the model being studied. Erk1/2 activation during ischemia 
reperfusion reduces the amount of reperfusion-injury-related apoptosis (Bueno and Molkentin, 
2002), therefore, in a similar manner that activation of Erk1/2 during IR reduces reperfusion-
injury-related apoptosis, it is highly plausible that activation of Erk1/2 during DOX treatment 
may protect the myocardium in our model of chronic DOX-induced cardiotoxicity 
1.8.2 Akt 
Akt is a serine/threonine kinase that promotes cell survival by modulating the pro-apoptotic 
function of anthracyclines (Chen et al., 2007). DOX-induced apoptosis of cardiomyocytes can be 
prevented through PI3-K/Akt signaling (Fukazawa et al., 2003). Akt is located in the cytosol in 
an inactive state and is activated in response to various growth factors, including insulin-like 
growth factor-1 (IGF-1), epidermal growth factor-3 (EGF-3) and interleukin-6 (IL-6) (Fukazawa 
et al., 2003) where it regulates cell survival, replication and apoptosis (Kim et al., 2008). IGF-1 
attenuates apoptosis by activating PI3K/Akt signaling, which subsequently inhibits caspase-9 
(Wu et al., 2000) as well as the pro-apoptotic protein Bad (Negoro et al., 2001). Evidence 
supporting the pro-survival properties of Akt has been demonstrated in patients receiving a GIK 
(glucose, insulin, potassium) cocktail during reperfusion. The presence of insulin in this cocktail 
stimulates Akt activation which is otherwise down-regulated during an ischemic insult. 
Activation of Akt subsequently reduces infarct size, preserves heart function, enhances 
contractility and increases glucose uptake during hypoxic conditions (Jonassen et al., 2001). 
As with Erk1/2, Akt also inhibits cytochrome c-induced apoptosis through the suppression of the 
opening of the mPTP (Hausenloy and Yellon, 2004). It has recently been postulated that a 
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cumulative dose of 20 mg/kg DOX down-regulates Akt signaling in vivo (Fan et al., 2008) and 
therefore interferes with the protective role that Akt may play in this context. This has been 
proven in studies making use of adenovirus-mediated delivery of a constitutively active Akt gene 
which protected the heart against DOX-induced cardiomyopathy (Taniyama and Walsh, 2002). 
Furthermore, inhibition of Akt results in increased apoptosis during DOX-induced cardiotoxicity, 
supporting the protective role that Akt plays (Zhao et al., 2004). Ichihara et al., (2007) observed 
that the levels of Akt are in fact elevated in mice following a single treatment with 15 mg/kg 
DOX (Ichihara et al., 2007) and it is believed to act as an endogenous, protective mechanism of 
the heart to defend against the toxic effects of this anthracycline (Gharanei et al., 2013; Ichihara 
et al., 2007). However, Gabrielson et al., (2007) observed that DOX-induced injury beyond an 
undefined threshold cannot be rescued by Akt. In fact, little is known about the effects of chronic 
Akt activation. Samples obtained from human patients with advanced heart failure displayed 
heightened Akt phosphorylation (Haq et al., 2001) which may suggest that prolonged Akt 
activation is not sufficient for long-term cardioprotection or that Akt may actually exert adverse 
effects after chronic stimulation (Nagoshi et al., 2005). Nevertheless, Akt is largely regarded as a 
pro-survival kinase and its effects during cardiotoxicity are likely to be beneficial. Table 1 
summarizes some of the mixed findings regarding Akt signaling in DOX-induced cardiotoxicity, 
indicating the concentration and duration of DOX exposure. Within the context of DOX-induced 
cardiotoxicity, it is thus speculated that Akt is up-regulated in a time- and dose-dependent 
manner, to provide protection from the cardiotoxic side effects of DOX. 
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Table 1: Comparison of Erk1/2 and Akt responses following treatment with DOX in different models of cardiotoxicity
                                                 
1
 P-Erk1/2 increased initially to a maximum after 4 hours, but declined significantly at the heart failure stage 
2
 Western blot analysis of p-Akt was performed 4 weeks after the last DOX injection 
3
 The cumulative dose of 9 mg/kg is equivalent to 630 mg per 70 kg man which is above the clinical threshold. Analysis was performed on day 28. 
Author Model [DOX] Duration of treatment 
Erk1/2 
response 
Akt response 
Xiang et al., (2009) Male Sprague-Dawley heart tissue 2.5 mg/kg Weekly for 6 weeks ↓ ↓ 
Lou et al., (2005) Male Sprague-Dawley heart tissue 2.5 mg/kg 6 doses over 2 weeks ↓1  
Li et al., (2006) C57BL/6J mice 15 mg/kg Single injection ↓ Unchanged 
Gabrielson et al., 
(2007) 
Female Sprague-Dawley heart 
tissue 
2.5 mg/kg Weekly for 6 weeks  ↑2 
Gharanei et al., 
(2013) 
Male Sprague-Dawley heart tissue 
following DOX perfusion 
1 µM 120 minutes ↑ ↑ 
Liu et al., (2008) H9c2 rat embryonic cells 1 µM 
1, 3, 6, 12, 24 and 48 
hours 
↑  
Ichihara et al., 
(2007) 
C57BL/6J mice left ventricle 15 mg/kg Single injection  ↑ 
Das et al., (2011) Male Swiss albino rats 3 mg/kg 3 doses over 4 days
3
 ↓ ↓ 
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1.9 The SAFE pathway 
For more than 2500 years, physicians have observed similar characteristics in patients with CHF 
and in those with chronic inflammatory disorders (Ferrari, 1999) and in more recent research it 
has become evident that the progression of heart failure may be influenced by the expression of 
various cytokines (Seta et al., 1996). According to the “cytokine hypothesis”, first proposed in 
the 1990s, the progression of heart failure is mediated by the cytokine cascade, which, following 
injury to the myocardium, exerts deleterious effects (Seta et al., 1996) in a state of chronic 
inflammation. Cytokines are a group of proteins with small molecular weights, secreted by cells 
in response to stimuli such as stress. Cytokines differ from hormones in that they are produced 
by several cell types and act over short distances, as opposed to hormones which are produced by 
specific cell types and act over longer distances (Seta et al., 1996) To date, two classes of 
cytokines have been identified: vasoconstrictor/anti-inflammatory cytokines (endothelin) and 
vasodepressor/pro-inflammatory cytokines such as IL-6 and TNF-α. 
TNF-α is a pleiotropic, pro-inflammatory cytokine that signals through two receptors, TNFR1 
(p55) and TNFR2 (p75) (Pfeffer, 2003). While the death domain of TNFR1 has been shown to 
be essential for apoptosis (Krown et al., 1996), the function of TNFR2 is not well understood 
(Monden et al., 2007). Even though TNF-α’s affinity for TNFR2 is five times higher than that of 
TNFR1, it is TNFR1 that is most active within the cell (Tartaglia and Goeddel, 1992). A TNF-α 
binding protein has also been identified in the mitochondria, suggesting the existence of a 
pathway that is able to deliver TNF-α directly to the mitochondria, by-passing the activation of 
the receptors (Ledgerwood et al., 1998). TNF-α is expressed as a 26 kDa transmembrane protein, 
from which a 17 kDa soluble subunit is cleaved (Bradley, 2008). Both the membrane-associated 
and soluble forms are active as homotrimers, although each may have distinct biological 
activities (Bradley, 2008). TNF-α was originally documented to induce apoptosis in tumor cells 
but it is now implicated in several cellular responses including inflammation, cell proliferation, 
survival, differentiation and cachexia (Ware, 2003). 
Studies have shown that ventricular dysfunction and dilated cardiomyopathy are associated with 
elevated circulating TNF-α levels (Hegewisch et al., 1988), which may also extend to DOX-
induced cardiotoxicity and how this drug causes injury to the heart. It is possible that TNF-α 
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contributes to DOX-induced cardiac injury through a local inflammatory response and 
cardiomyocyte apoptosis as it does after MI (Bryant et al., 1998; Krown et al., 1996; Schulz and 
Heusch, 2009). The mechanism of cytotoxicity is thought to be associated with the production of 
ROS (Busquets et al., 2003) since TNF-α can cause oxidative stress by increasing the activity of 
inducible nitric oxide synthase (iNOS) and the production of nitric oxide (NO) (Ferrari, 1999; 
Sugamori et al., 2002). Interestingly, neither TNF-α mRNA or protein is expressed in the heart 
under normal conditions, however, during times of stress, the heart is able to synthesize TNF-α 
mRNA and protein de novo (Bryant et al., 1998; Ferrari, 1999; Torre-Amione et al., 1996). DOX 
promotes the release of TNF-α from macrophages, and tumors themselves cause a further 
increase in TNF-α levels during DOX treatment (Shan et al., 1996). Since cardiac cells also have 
the ability to produce TNF-α, it is likely that TNF-α levels within the heart are much higher than 
in the surrounding tissue (Krown et al., 1996).  
1.9.1 The dual roles of TNF-alpha 
Several bodies of evidence demonstrate that the role TNF-α plays within the heart is a 
complicated one, since TNF-α can exert both beneficial and detrimental effects (Ferrari, 1999). 
A summary of these contrasting effects can be found in table 2. Several factors need to be 
considered when evaluating the role that TNF-α may play. Since TNF-α exerts such pleiotropic 
effects, its role is clearly dependent on the context and influenced by the duration and 
concentration of exposure. 
Several studies have provided evidence to suggest that TNF-α plays a detrimental role. Long 
exposure to high levels of TNF-α can exert anti-angiogenic effects (Heba et al., 2001) and induce 
apoptosis and inflammation (Chiosi et al., 2007). Research by Krown et al., (1996) indicated that 
treatment with TNF-α for 18 hours caused significant apoptosis in rat cardiomyocytes. They 
reported a maximum apoptotic effect at 0.4 nM (68 pg/mL) TNF-α, where after apoptosis 
declined even though additional TNF-α was administered. This may be due to down-regulation 
of the TNF-α receptors by receptor-mediated endocytosis, reducing TNF-α responsiveness. This 
study further reported that the extent of TNF-α induced apoptosis is directly proportional to the 
concentration of the cytokine. Of more relevance is the fact that the concentrations of TNF-α 
used in this study are within the range found in the serum of patients suffering MI. Mohamed et 
al., (2004) reported that DOX causes an increase in serum TNF-α in rats and it has been 
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suggested that it is DOX-induced oxidative stress that causes this increase, since treatment with 
garlic, known for its antioxidant properties, reduced the expression of myocardial TNF-α 
(Mukherjee et al., 2003). Chiosi et al., (2007) exposed H9c2 cells to 1 µM DOX for 24 and 48 
hours and observed a potent increase in apoptosis. Furthermore, co-treatment with 10 ng/mL 
TNF-α potentiated the DOX-induced apoptosis. Interestingly, TNF-α alone did not cause 
considerable apoptosis in their model, compared to control samples, suggesting a more beneficial 
role for TNF-α. 
Low levels and short exposure to TNF-α may aid in an adaptive response to stress (Chiosi et al., 
2007), promote angiogenesis (Heba et al., 2001) and reduce areas of infarction (Deuchar et al., 
2007). Lecour et al., (2002) have further indicated a beneficial role of TNF-α in the context of 
ischemic pre-conditioning, where they reported that exogenous TNF-α can mimic pre-
conditioning at doses of 0.5 ng/mL and 0.1 µg/kg in a cell culture and animal model respectively. 
Many attempts have been made to try to “neutralize” TNF-α using anti-TNF therapy in patients 
with heart failure, however, results of such trials actually showed that heart failure worsened and 
caused a time-and dose-dependent increase in hospitalization and death (Mann, 2002). 
Findings by Lou et al., (2004) showed that TNF-α mRNA and protein were not up-regulated in a 
rat model of sub-chronic DOX-induced heart failure and this is consistent with studies who have 
reported a time- and dose-dependent decrease in TNF-α expression after exposure to DOX 
(Safrit and Bonavida, 1992; Xu et al., 2008). During DOX treatment, cell death is observed 
earlier than the development of heart failure. Likewise, TNF-α is not detected in the early time 
points and it is only during the late stage that TNF-α declines below control samples. This 
suggests that TNF-α is not involved in DOX-induced heart failure and that other causative 
factors are at play (Lou et al., 2004). 
Although many studies have identified TNF-α as a harmful cytokine, many have reported 
improved left ventricular performance (Murray and Freeman, 1996), hypertrophy (Dibbs et al., 
2003) and adaptation to stress (Haudek et al., 2001) following TNF-α administration. It has also 
been reported that endogenous TNF-α may exert a protective effect during DOX-induced 
cardiotoxicity by up-regulating mitochondrial SOD (MnSOD) (Watanabe et al., 1996) and the 
anti-apoptotic members of the Bcl-2 family (Xu et al., 2008). TNF-α exerts its anti-apoptotic 
effects through NF-κB signaling, which may explain how TNF-α can play a protective role 
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during DOX-induced cardiotoxicity and heart failure (Xu et al., 2008). NF-κB is a transcription 
regulator that is localized in the cytoplasm and under the inhibitory control of IκB (Ozes et al., 
1999). However, TNF-α induces the formation of a signaling complex containing TNF-receptor 
associated factor 2 (TRAF-2), resulting in IκB phosphorylation and degradation by the 
ubiquitin/proteasome system (Ozes et al., 1999). This allows NF-κB to translocate to the nucleus 
where it activates the transcription of several target genes (Chiosi et al., 2007). Since TNF-α has 
been reported to induce anti-apoptotic effects through NFκB activation, decreased expression of 
TNF-α during the development of heart failure may modulate disease progression (Lou et al., 
2004). Binding of TNF-α to TNFR1 also induces phosphorylation of the p85 subunit of PI3K 
and Akt phosphorylation is increased in a time-dependent manner (Ozes et al., 1999). This 
mechanism may also possibly explain how TNF-α exerts its beneficial effects. 
Stellenbosch University  http://scholar.sun.ac.za
 30 
 
Table 2: Comparison of the roles and responses of TNF-α in in vivo and in vitro models 
                                                 
4
 Acute group sacrificed at the end of treatment, sub-chronic group sacrificed in week 6. 
5
 Myocardial mRNA and protein in the sub-chronic group 
6
 Endogenous TNF-α provides protection against DOX by inducing manganese SOD 
Author Model [DOX] [TNF-α] Incubation Result 
Krown et al., (1996) Neonatal rat cardiomyocytes  4 nM 18 hours Apoptosis 
Chiosi et al., (2007) H9c2 embryonic rat heart cells 1 µM 10 ng/mL 24 hours ↑ apoptosis 
   10 ng/mL 24 hours No apoptosis 
Tolosa et al., (2005) C2C12 myotubes  1- 40 ng/mL 48 hours ↑ apoptosis 
Mohamed et al., (2004) Adult male albino rats 12 mg/kg/week/6 weeks   
↑ TNF-α in 
plasma 
Xu et al., (2008) Wistar rat cardiomyocytes 
0.1 – 1 µM for 1, 4, 8 and 16 
hours 
  
↓ TNF-α in 
culture medium 
Mukherjee et al., (2003) Male and female Wistar rats 30 mg/kg (single dose)   
↑ TNF-α in 
myocardium and 
blood 
Lou et al., (2004) Male Sprague-Dawley rats 2.5 mg/kg x 6 over 2 weeks
4
   
↓ TNF-α mRNA 
and protein
5
 
Watanabe et al., (1996) Pancreatic carcinoma cell lines 0.002 – 200 uM 0.02 – 2000U/mL 72 hours 
TNF-α ↑ 
MnSOD
6
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When evaluating contradictory studies it is important to consider all the factors that may 
influence the results. The above mentioned studies have used both animal (Mohamed et al., 
2004) and cell culture models (Krown et al., 1996). Furthermore, several different cell types 
have been studied (Chiosi et al., 2007; Tolosa et al., 2005; Xu et al., 2008). Studies have 
evaluated acute (Xu et al., 2008) and chronic models (Lou et al., 2004), as well as clinically 
relevant and irrelevant doses of DOX (Watanabe et al., 1996). Clearly, the different responses 
induced by TNF-α exerts are undoubtedly context-dependent.  
1.9.2 TNF-alpha and its receptors 
Important and helpful findings are those of the TNF-α receptors, which have highlighted that 
receptor expression plays a vital role in modulating the cardiotoxicity of DOX and that the bi-
directional role of TNF-α may depend on which of its two receptors it binds to (Monden et al., 
2007; Schulz and Heusch, 2009). Since TNFR1 is the predominant receptor expressed within the 
heart (Krown et al., 1996), it is possible that TNF-α mediates its negative effects in 
cardiomyocytes via TNFR1 and not TNFR2 (Schulz and Heusch, 2009; Torre-Amione et al., 
1996). This fact is supported by Chiosi et al., (2007) who observed a significant increase and 
decrease in TNFR1 and TNFR2 respectively, in H9c2 cells after 1 µM DOX treatment. 
A study by Hamid et al., (2009). further outlined the ambivalent role that TNF-α plays by 
reporting that knockout of TNFR1 improved left ventricular ejection fraction, cardiomyocyte 
hypertrophy, apoptosis, inflammation and survival, whereas knockout of TNFR2 increased 
cardiomyocyte hypertrophy and apoptosis, in a model of MI. A genetic deficiency of TNFR1 
was found to protect the diaphragm against DOX-induced muscle weakness, confirming a 
negative role for TNFR1 signaling (Gilliam et al., 2011). Hence, TNF-α is likely to worsen 
cardiac function via TNFR1 and improve it via TNFR2 (Monden et al., 2007). 
Based on the above studies, it is clear that TNF-α can exert both beneficial and detrimental 
effects depending on its mode of secretion, concentration, receptor, duration of exposure, cell 
type, species and experimental model (Krown et al., 1996; Lou et al., 2004; Xu et al., 2008). 
Nevertheless, one can conclude that the TNF-α/TNF receptor axis is involved in DOX-induced 
cardiotoxicity and apoptosis of cardiomyocytes, and these events are modulated by receptor 
expression, however, its overall affect, whether pro- or anti-apoptotic, requires further research 
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in this context. Even though myocardial infarction and DOX-induced cardiotoxicity are two 
distinct, unrelated heart conditions, it is possible that TNF-α exerts similar effects in each 
scenario. Such studies can therefore be used to speculate the role that TNF-α may play in the 
context of DOX-induced cardiotoxicity. How and whether TNF-α contributes to cardiac injury 
during chronic DOX-induced cardiotoxicity remains to be elucidated. 
1.9.3 Jak2 and STAT3 
Although TNF-α has been reported to be a contributor to reperfusion injury, this cytokine is 
involved in the activation of a novel protective pathway termed the SAFE pathway (Figure 1.6) 
(Lecour, 2009b). This pathway includes the activation of Janus kinase (JAK) and signal 
transducer and activator of transcription 3 (STAT-3), which convey stress signals from various 
cytokines on the plasma membrane to the nucleus, where the transcription of several proteins is 
altered (Hausenloy, 2009). In the heart, JAK and STAT have been implicated in hypertrophy, 
apoptosis, inflammation (Kunisada et al., 2000) proliferation and defense (Kisseleva et al., 
2002). JAKs belong to a family of tyrosine kinases that play an important role in transducing 
signals from the cell surface to the nucleus (Imada and Leonard, 2000) and have been implicated 
in cell proliferation, differentiation and apoptosis (Rawlings et al., 2004). JAKs are constitutively 
associated with cytokine receptors, which, once activated by a ligand (e.g. TNF- α), activate 
JAK. This leads to tyrosine phosphorylation and homo-dimerization of the receptor, creating 
‘docking sites’ for STATs via their Src-homology-2 (SH2) domains (Boengler et al., 2008). 
Subsequently, the activated JAK then phosphorylates STAT-3 at a tyrosine residue 
approximately 700 residues from the N-terminus (Tyr
705
) (Kisseleva et al., 2002). STAT-3 then 
forms a homodimer and translocates to the nucleus where it up-regulates the transcription of 
target genes (Imada and Leonard, 2000). It is not yet clear whether phosphorylation on serine 
727 (Ser
727
) is of functional importance to all STATs, but it is believed that Erk1/2 is responsible 
for this phosphorylation event (David et al., 1995). Phosphorylation at this residue significantly 
enhances the transcriptional activity of STAT3 (Boengler et al., 2008). 
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Figure 1.6: Schematic representation of the RISK and SAFE pathways. Binding of G-protein coupled 
ligands to G-protein coupled receptors activates MEK and PI3K which subsequently activate Erk1/2 
(extracellular signal-related kinases) and Akt. Binding of TNF-α to TNF receptors activates JAK (janus 
kinase), which then activates STAT-3 (signal transducer and activator of transcription). Both pathways are 
likely to converge at the mitochondria where they enhance cardioprotection against ischemia reperfusion 
injury. Adapted from Lacerda et al., (2009) 
STAT3 belongs to the signal transducer and activator of transcription family and resides in the 
cytoplasm as an inactive form (Rébé et al., 2013). Once activated, STAT3 translocates to the 
nucleus within 15 minutes where it induces the transcription of several target genes (Darnell, 
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1997). In the heart, STAT proteins regulate the expression of the genes involved in 
inflammation, apoptosis, angiogenesis and cell signaling (Hilfiker-Kleiner et al., 2004), as well 
as growth, differentiation (Nakajima et al., 1996), cell death and cell survival (Fukada et al., 
1996). STAT3 has been observed in the heart during MI and ischemic preconditioning and its 
activation during ischemia-reperfusion injury suggests that it provides protection against stress 
(Negoro et al., 2001). Many of the cytoprotective actions of the SAFE pathway have been 
attributed to the activation of STAT3 specifically, however, since STAT3 is involved in the 
transcriptional up-regulation of such a vast array of genes, it is not quite clear which of the 
responses are required by the heart. Activation of the SAFE pathway increases the transcription 
of the anti-apoptotic gene Bcl-2 and reduces transcription of the pro-apoptotic genes Bax and 
Bad (Bolli et al., 2001; Hattori et al., 2001). In addition, cytokine signaling through the SAFE 
pathway has been shown to increase cell survival via PI3K/Akt (Tolosa et al., 2005). 
Kunisada et al., (2000) investigated the effects of STAT-3 over-expression in the context of 
DOX-induced cardiotoxicity. Three-month-old mice were given an intra-peritoneal injection of 
DOX as a single dose of 15 mg/kg. Subsequently, only 25% of the wild-type mice survived, 
compared to 80% of the mice over-expressing STAT-3. The dead mice were found to have 
significant pleural effusion and ascites, confirming DOX-induced heart failure. Caspase 
activation as well as apoptotic DNA fragmentation was increased in anti-STAT3 siRNA 
transfected cells (Frias et al., 2008), emphasizing the protective role of STAT3 against DOX-
induced apoptosis. To the best of our knowledge, these are the only studies of DOX-induced 
cardiotoxicity that have identified markers of the SAFE pathway. 
Although the SAFE pathway can function independently of the RISK pathway, studies aimed at 
delineating the role of potential crosstalk between the two pathways have revealed a complex 
interaction (Lacerda et al., 2009). If either the RISK or SAFE pathways are inhibited, the 
protective effects of these pathways are completely ablated (Lecour, 2009a; Suleman et al., 
2008). This suggests that dual functioning of both the RISK and SAFE pathways may be 
required for cardioprotection (Hausenloy, 2009). Evidence for cross-talk is found in STAT-3 
inhibition studies, where a parallel reduction in the phosphorylation of Akt was observed. 
Similarly, in the presence of Wortmannin, a PI3K/Akt pathway inhibitor, phosphorylation and 
hence activation of STAT-3 was inhibited (Suleman et al., 2008). Furthermore, the p85 
Stellenbosch University  http://scholar.sun.ac.za
 35 
 
regulatory subunit of PI3K promotes the phosphorylation of STAT-3 (Pfeffer et al., 1997) and 
JAK can phosphorylate Akt after recruiting to the p85 subunit of PI3K to the docking sites on the 
receptor (Rawlings et al., 2004). As mentioned before, serine phosphorylation of STAT3 is 
thought to involve members of the MAPK family (Aznar et al., 2001), therefore the 
administration of an Erk1/2 inhibitor strongly reduces the anti-apoptotic effect offered by 
prostaglandin E2 (PGE2)-induced STAT-3 activation during DOX treatment (Frias et al., 2008) 
and thus further highlights the possible cross-talk between the two pathways. Since DOX-
induced cardiotoxicity, like reperfusion injury, is also characterized by apoptosis and oxidative 
stress, it is possible that the SAFE pathway may provide protection in this context (Frias et al., 
2010; Mitra et al., 2007). 
1.10 Where to from here? 
As evident from the literature, unimaginable cross-talk exists within the human body in an 
attempt to maintain homeostasis. While a fair amount is known about DOX-induced 
cardiotoxicity, little is known about the involvement of the RISK and SAFE pathways in this 
context. Although various studies have reported up-regulation of Akt and Erk1/2, many of these 
studies have been performed at supraclinical concentrations of DOX and are unlikely to be a true 
reflection. In an appropriate model of chronic DOX-induced cardiotoxicity using clinically 
relevant concentrations of the drug, the true role of Akt and Erk1/2 can be elucidated. As pro-
survival kinases, it is speculated that Akt and Erk1/2 will increase in a time- and dose-dependent 
manner during treatment with DOX, in order to confer protection. Based on the literature, TNF-α 
is likely to exert beneficial effects through TNFR2 in this context, however, this will depend on 
how much TNF-α is present in this model of chronic cardiotoxicity. Since DOX-induced 
cardiotoxicity and ischemia-reperfusion injury share common characteristics, namely ROS 
production, cardiomyocyte death, and the progression to heart failure, it is possible that the 
protective pathways activated during ischemia reperfusion may also be activated following 
exposure to DOX. TNF-α is likely to be present in this model but the effects it exerts will likely 
be dependent on which of its two receptors it binds to. Seeing that exogenous TNF-α can mimic 
ischemic pre-conditioning during reperfusion in a time and dose dependent manner, it is possible 
that TNF-α may confer protection during DOX-induced cardiotoxicity too and subsequently 
activate the SAFE pathway. It is not known whether TNF-α may in fact also trigger the RISK 
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pathway, but there is evidence that this pathway is activated via cross-talk with the SAFE 
pathway. It is known that components of the RISK pathway are present during DOX-induced 
cardiotoxicity, but whether they are up- or –down-regulated depends on the model in question. 
Most studies have used concentrations of DOX that are unattainable in a clinical setting and 
therefore generate inaccurate and intensified results. Furthermore, very few studies have focused 
on chronic-cardiotoxicity, which is the most debilitating, life-threatening form. Since 
cardiotoxicity develops as a result of chronic and cumulative exposure to DOX, we have 
employed an in vitro model that simulates this scenario. By treating two different cell lines daily 
for 5 days, our results will provide insight into the dose-dependent, damaging effects of DOX. 
To further add to the novelty of our model, we have employed concentrations that are well 
within the clinical range in order to generate more realistic results. It is important to note that 
when referring to our in vitro study, the term ‘cytotoxicity’ is used, whereas when referring to 
the human DOX-induced cardiovascular condition, the term ‘cardiotoxicity’ is used. 
DOX has the potential to improve cancer survival and quality of life in our country’s cancer 
patients, yet currently causes severe side effects such as cardiotoxicity, that pose a threat to their 
survival. It is therefore the intention of this study to identify the roles of two potentially 
protective pathways (the SAFE and RISK) as an alternative mechanism to reducing DOX-
induced cardiotoxicity and what role they play in this context. In addition, it is of interest to 
determine what role TNF-α plays and whether it triggers the aforementioned pathways in this 
scenario. The aim of identifying pathways that could provide protection during cardiotoxicity is 
an important one, as a patient cured of cancer today does not want to be a patient of heart failure 
a few years down the line. With this in mind it is therefore vital to understand the cellular and 
molecular dynamics of DOX-induced cardiotoxicity in the hope of identifying signaling 
mechanisms that will offer cardioprotection while still eradicating the tumor. 
1.11 Research Problem 
The SAFE pathway, activated via TNF-α, and the RISK pathway are stimulated as a possible 
protective mechanism during chronic DOX-induced cytotoxicity.  
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1.12 Research Aims 
 To determine the activity of the SAFE pathway by measuring TNF-α production and the 
protein expression of Jak2 and STAT3 in an in vitro model of chronic DOX-induced 
cytotoxicity 
 To assess the activity of the RISK pathway (Erk1/2/Akt) in this model 
Figure 1.7: A schematic diagram summarizing the approach used to achieve the research aims 
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CHAPTER 2 
2.1 Materials and Methods 
2.1.1 Cell culture model 
H9c2 cells, derived from embryonic rat cardiomyocytes, were purchased from American Type 
Culture Collection (ATCC, Manassas, Virginia, USA; CRL-1446) The cells were grown and 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco, 41965-039), 
supplemented with 10% fetal bovine serum (FBS) (Invitrogen Gibco, 10270-106) and 1% 
Antibiotic-Antimycotic (AA) (Gibco, 15240-062), hereafter collectively referred to as growth 
medium, in a humidified atmosphere of 5% CO2 at 37 °C. Cells were routinely sub-cultured by 
trypsinsation (0.25% Trypsin-EDTA, Gibco, 25200-012), upon reaching 70 - 80% confluency 
(Figure 2.1A), where after they were seeded at appropriate densities into culture plates (refer to 
appendix B, protocol 1) 
Mouse skeletal muscle cells (C2C12, ATCC, Manassas, Virginia, USA; CRL-1772,) were grown 
and maintained under the same conditions. Subsequent to reaching ± 80% confluency (Figure 
2.1B), C2C12 myotube differentiation was induced by replacing growth medium with 
differentiation medium: DMEM supplemented with 2% horse serum (Biochrom, S9133). Cells 
were maintained in differentiation medium for the duration of the experiment. Differentiation 
medium was refreshed every 48 hours, whilst myotube formation was examined using a light 
microscope (Figure 2.1C). 
 
 
 
 
Figure 2.1 A, B and C: Images of H9c2 and C2C12 cells. A: H9c2 cells upon reaching 80% confluency 
(10x). B: C2C12 cells shown at low density in the myoblast stage (20x) and C: C2C12 cells at high 
B C A 
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density as differentiated myotubes after 5 days of differentiation (4x).Black arrows indicate myotubes. 
Scale bar: 1000 µm 
2.1.2 Treatment of Cells with Doxorubicin 
3 mM DOX stock (Sigma-Aldrich, D1515) was prepared in sterile DMEM and stored at -20 °C, 
protected from light, until needed. Treatments were prepared on the day of experimentation. 
Fully differentiated C2C12 cells and 80% confluent H9c2 cells were treated daily with 
increasing concentrations of DOX (0.2 – 1 µM) for a total period of 120 hours (24 – 120 hours), 
simulating cumulative, chronic DOX-induced cardiotoxicity. For example, treatment with 0.2 
µM every day for five days (120 hours) results in a cumulative dose of 1 µM, whereas treatment 
with 0.2 µM for 48 hours results in a cumulative dose of 0.4 µM. 
2.1.3 Assessment of Cell Viability (MTT Assay) 
Cell viability of H9c2 and differentiated C2C12 cells was determined using the 3-[4, 5-
dimethylthiazol-2-yl]-2, 5-diphenyl tetrazolium bromide (MTT) assay as previously described 
(Mosmann, 1983). This assay makes use of the principle whereby viable cells reduce yellow 
MTT into purple formazan crystals, thus giving an indication of cell death. MTT (Sigma-
Aldrich, M2128) was prepared as a 0.01 g/mL solution in sterile phosphate buffered saline (PBS) 
at room temperature. The MTT solution was further sterilised by filtration, where after 500 µL of 
the 0.01 g/mL MTT stock solution was added to each well. After 2 hours incubation at 37 °C, the 
supernatant was carefully discarded and 500uL of Isopropanol (1%)/Triton (0.1%) solution was 
added to each well. Following a short agitation period, absorbance was determined at 540 nm 
using the EL800 Universal Microplate reader (Bio-Tek Instruments Inc., Vermont, USA). Cell 
viability was expressed as the percentage of treated cells relative to untreated (control) cells.  
2.1.4 Determination of Caspase Activity (Caspase-Glo
®
3/7 Assay) 
The Caspase-Glo
®
 3/7 Assay (Promega, G8091) is a standardized, luminescent assay that 
measures the activity of caspase-3 and -7. Caspase-3 and -7 are members of the cysteine aspartic 
acid-specific protease family and play key roles as effector caspases during apoptosis. The assay 
provides a luminogenic caspase-3/7 substrate (containing the tetrapeptide sequence DEVD) that 
is cleaved by caspases, resulting in a luminescent signal produced by luciferase (Figure 2.2). The 
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level of luminescence is directly proportional to the amount of caspase cleavage, therefore giving 
an indication of the level of apoptotic cell death taking place. 
 
 
 
 
 
 
 
 
Figure 2.2: Caspase-Glo reaction. Caspase-3/7 cleaves the luminogenic substrate (DEVD sequence), 
resulting in light production. Promega Caspase-Glo 
®
3/7 Assay protocol. 
Each assay consisted of a blank reaction (Caspase-Glo
®
3/7 reagent, culture medium and no 
cells), a negative control (Caspase-Glo
®
3/7 reagent and cells in culture medium) and DOX-
treated samples. Following treatment with DOX, 100 µL Caspase-Glo
®
3/7 reagent was added to 
each well containing 100 µL culture medium and incubated for 1 hour at room temperature with 
gentle mixing. Luminescence was then measured using the GloMax® 96 Microplate 
Luminometer (Promega, Wisconsin, USA). 
2.1.5 Cytotoxicity Assay (Lactate Dehydrogenase Assay) 
The CytoTox 96
®
 Non-Radioactive Cytotoxicity Assay (Promega, G1780) is a colorimetric assay 
that quantitatively measures lactate dehydrogenase (LDH), a soluble, cytosolic enzyme that is 
released following damage to the plasma membrane. LDH catalyzes the oxidation of lactate to 
pyruvate, resulting in the production of NADH. A tetrazolium salt (INT) is then converted to red 
formazan, using the previously formed NADH. LDH released into cell culture medium is 
measured by this enzymatic assay. The amount of color formed is directly proportional to the 
number of lysed cells, therefore giving an indication of necrotic cell death. Following treatment, 
10 µL lysis solution was added to the wells of a 96-well plate containing 100 µL culture medium 
and incubated for 45 minutes at 37 °C. After substrate mix was added to each well, the plate was 
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covered with foil and incubated for a further 30 minutes at room temperature. Following the 
incubation period, stop solution was added to each well and absorbance was read immediately at 
490 nm using the EL800 Universal Microplate reader (Bio-Tek Instruments Inc., Vermont, 
USA). 
2.1.6 Quantification of TNF-α in cell culture medium (ELISA) 
TNF-α is a pleiotropic cytokine that is involved in several pathological conditions such as 
asthma, arthritis, obesity, diabetes and cancer. Quantikine
®
 rat and mouse ELISAs (R&D 
Systems, RTA00 and MTA00B) were used to measure the levels of TNF-α in cell culture 
medium. The immunoassay employs the sandwich, enzyme-linked immunosorbent assay in 
which a monoclonal TNF-α antibody has been pre-coated into the wells of a microplate. TNF-α 
present in samples, standards and controls is bound by the antibody. After the addition of a TNF-
α polyclonal antibody and a substrate colour solution, the reaction yields a blue product which 
turns yellow upon addition of the stop solution. The intensity of the yellow colour is directly 
proportional to the amount of TNF-α which was bound in the first step. The plate is read at 450 
nm and the values are read off a standard curve. Prior to the assay, culture medium was collected 
after each day of treatment with DOX, for a total of five days, and placed into pre-chilled falcon 
tubes. The tubes were immediately placed into a -20 °C freezer. On the last day of collection the 
assay was performed. Samples were thawed immediately prior to starting the assay. The ELISA 
was carried out three times in triplicate according to the manufacturer’s instructions. (Refer to 
Appendix B, Protocol 8). 
2.1.7 Determination of Anti-oxidant Capacity (ORAC assay) 
Oxidative stress is a physiological condition that results due to an imbalance between ROS and 
antioxidants. Under normal conditions, ROS production is compensated for by the activity of 
antioxidant enzymes; however, excessive ROS production leads to DNA, protein and membrane 
damage. All of this ROS-induced injury has been implicated in the development of several 
disease states such as cancer, CVD and neurodegenerative disease. In order to evaluate the 
capacity of cellular antioxidant systems to overcome the deleterious effects of DOX-induced 
oxidative stress in H9c2 and C2C12 cells, the Oxygen Radical Absorbance Capacity (ORAC) 
assay was used, as previously described (Ou et al., 2001). The assay is based on the oxidation of 
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the fluorophore ‘fluorescein’ by the peroxyl radical 2,2’-azobis (2-methylpropionamidine) 
dihydrochloride (AAPH). Antioxidants in the assay block the oxidation of the fluorophore until 
the antioxidant activity in the sample is depleted. The samples’ antioxidant capacity correlates 
with the fluorescence decay curve, represented as the area under the curve (AUC), which is 
compared to the standard curve of the vitamin E analog ‘Trolox™’ (Sigma, 238831) and 
expressed as µmol Trolox standard equivalents per gram. The Fluoroskan Ascent™ microplate 
fluorometer (Thermo Fisher Scientific, Massachusetts, U.S.A.), equipped with an incubator, was 
set at 37 ◦C. A fluorescein stock solution (Sigma, F6377) was prepared in phosphate buffer and 
further diluted for use in the assay. AAPH (Sigma, 440914) (25 mg/mL in phosphate buffer) and 
fluorescein were added to each well with a multichannel pipette. The fluorescence of each well, 
containing 12 μL sample, was read every 5 minutes for 2 hours. Fluorescence filters with an 
excitation wavelength of 485 nm and emission wavelength of 538 nm were used. Final ORAC 
values were calculated using the regression equation y = ax
2
 + bx + c between Trolox 
concentration (μM) and the area under the curve. (Refer to Appendix B, protocol 9). 
2.1.8 Measurement of Lipid Peroxidation (TBARS assay) 
It is well known that lipid peroxidation causes cell damage in both plants and animals. Lipid 
peroxides can be used as indicators of oxidative stress in cells as they decompose to form stable 
complexes such as MDA. Measuring the natural bi-products of lipid peroxidation, like MDA, is 
a commonly used assay to assess oxidative damage and therefore the levels of oxidative stress. 
Thiobarbituric acid reactive substances (TBARS) is a widely used assay for assessing lipid 
peroxidation since MDA forms a 1:2 adduct with TBA which can be measured colorimetrically. 
Cell samples were resuspended in butylated hydroxytoluene (BHT) on ice in order to prevent 
oxidation during processing, sonication and storage. Samples were centrifuged at 2000 rpm, 4 
°C, for 15 minutes. A serial dilution of MDA (Merck, 805797) was prepared. Unknown MDA-
containing samples as well as known standards were incubated with TBA reagent (Sigma, 
T5500) at 90 °C for 45 minutes. After cooling in an ice bath, butanol and saturated salt were 
added to each sample to separate the phases. The top phase of samples and standards were 
transferred to a 96-well plate and the absorbance was measured at 532 nm in the Multiskan
®
 
Spectrum microplate spectrophotometer (Thermo Fisher Scientific, Massachusetts, USA). (Refer 
to Appendix B, protocol 10) 
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2.1.9 Assessment of Antioxidant Status (Glutathione Assay) 
The ratio of GSH and GSSG was determined according to the method previously described by 
Asensi et al., (1999). In a clear, 96-well plate, 1U glutathione reductase (Sigma, G3664), 50 µL 
0.3 mM DTNB (Sigma, D21820) and 50 µl sample for GSH (Sigma, G4251) or 50 µl sample 
treated with M2VP (Sigma, 69701) for GSSG were incubated at 25 °C for 5 min. The reaction 
was then initiated with 50 µL 1mM NADPH (Sigma, N6785) and measured at 412 nm for 5 
minutes at 30 second intervals in a Multiskan
®
 Spectrum microplate spectrophotometer (Thermo 
Fisher Scientific, Massachusetts, USA). The concentration of total glutathione, GSH and GSSG 
were determined using GSH as standard. (Refer to Appendix B, protocol 11). 
2.1.10 Western Blot Analysis 
2.1.10.1 Preparation of cell lysates 
For protein isolation, cells were incubated in 50 µL modified radio-immunoprecipitation (RIPA) 
buffer (pH 7.4) containing Tris-HCL 2.5 mM, EDTA 1 mM, NaF 50 mM, dithiothreitol 1 mM, 
phenylmethylsulfonyl fluoride (PMSF) 0.1 mM, benzamidine 1 mM, 4 mg/ml SBTI, 10 mg/ml 
leupeptin, 1% NP40, 0.1% SDS and 0.5% Na deoxycholate. Cells were scraped using a sterile 
cell scraper, and contents were placed into chilled eppendorf tubes on ice. Cell lysates were 
sonicated for 15 seconds with an Ultrasonic Liquid Processor (Misonix), in order to rupture cell 
membranes. Lysates were then centrifuged at 8000 rpm (5900 x g) for 10 minutes, where after 
protein concentration was determined using the Bradford method, as previously described 
(Bradford, 1976), with bovine serum albumin (BSA) used as a standard. Protein samples were 
prepared in Laemmli’s loading buffer and stored at -80 °C until needed. 
2.1.10.2 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
Samples were thawed and then boiled at 95 ˚C for 5 minutes. 50 µg protein of each sample was 
separated by 12% SDS-PAGE for 10 minutes, at 100 V, 400 mA (constant), followed by 200 V 
for 50 minutes. Proteins were transferred onto polyvinylidene fluoride (PVDF) membranes 
(Trans-Blot® Turbo™ Mini PVDF Transfer Packs, Bio-Rad, 170-4156) using the TransBlot® 
Turbo™ Transfer System (Bio-Rad) for 12 minutes at 15 V. PDVF membranes were then 
blocked for 2 hours in 100 mL 5% fat-free milk powder dissolved in Tris Buffered Saline-Tween 
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Solution (TBS-T) at room temperature. After blocking, membranes were rinsed 3 times for 5 
minutes with TBS-T and incubated overnight at 4 ˚C with the respective primary antibodies 
(table 3) diluted 1: 1000 in TBS-T. Subsequent to primary antibody incubation, membranes were 
again washed 3 times with TBS-T and incubated with HRP-linked anti-rabbit/anti-mouse 
secondary antibody for 1 hour at room temperature. Membranes were washed with TBS-T (3 x 5 
minutes) and incubated with Pierce ECL western blotting substrate (Thermo Scientific, #32106). 
Bands were detected using the ChemiDoc™ XRS+ System with the Image Lab™ Software (Bio-
Rad). The bands generated were expressed using a volume analysis tool and represented as the 
fold change relative to the control sample (untreated). GAPDH was used as a loading control in 
the H9c2 cardiomyocytes, however, a ponceau stain was used as a loading control in the 
differentiated C2C12 myotubes since GAPDH exhibits poor stability in the differentiation 
process and is therefore an unreliable reference gene (Hildyard and Wells, 2014). Partial, 
representative ponceau images will be displayed with the accompanying blots (refer to the 
appendix for the full ponceau images and to Appendix B, protocols 12 - 14 for the complete 
western blotting protocol). 
Table 3: Primary antibodies used in Western Blot analysis, as well as their respective secondary 
antibodies and appropriate dilutions. 
PRIMARY 
ANTIBODY 
SECONDARY 
ANTIBODY 
2° 
DILUTION 
P-Jak2 Anti-rabbit 1: 2500 
T-Jak2 Anti-rabbit 1.5: 5000 
P-STAT3 Ser 727 Anti-rabbit 1: 10000 
P-STAT3 Tyr 705 Anti-rabbit 1: 10000 
T-STAT3 Anti-mouse 1.5: 5000 
TNFR2 Anti-rabbit 1: 10000 
P-Akt Anti-rabbit 1: 2500 
T-Akt Anti-rabbit 1: 10000 
TNFR1 Anti-mouse 1: 10000 
P-Erk Anti-rabbit 1: 5000 
T-Erk Anti-rabbit 1: 10000 
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TNF-α Anti-rabbit 1: 2500 
Cleaved caspase-3 Anti-rabbit 1: 10000 
GAPDH Anti-rabbit 1: 10000 
2.1.11 Statistical Analysis 
GraphPad Prism version 5.0.3 (GraphPad Inc., San Diego, CA) was used for visual 
representation and statistical analysis of data. Comparisons between the different groups were 
performed by one-way analysis of variance (ANOVA) followed by Dunnett’s multiple 
comparisons test as post-test. p-values are represented as follows: * p < 0.05; ** p < 0.01; *** p 
< 0.001 versus the control. When comparisons are made to groups other than the control, the 
following symbols are used: ● p< 0.05, ●● p< 0.01, ●●● p<0.001. Unless otherwise indicated, 
all experiments were conducted in at least duplicate and three independent experiments were 
carried out for each technique. All data are presented as mean ± SEM. 
  
Stellenbosch University  http://scholar.sun.ac.za
 46 
 
CHAPTER 3 
Results Part I 
Pilot Study 
A pilot study was initially conducted in which H9c2 cells and differentiated C2C12 myotubes 
were treated with increasing concentrations of DOX for a total period of five days, in order to 
simulate cumulative, chronic DOX-induced cardiotoxicity. Our preliminary work was to 
establish the most appropriate treatment concentrations whilst still keeping within clinically 
relevant levels. The effects of DOX on the viability of these cell types was determined using the 
MTT assay, whereas the extent of apoptosis and necrosis was investigated using the Caspase Glo 
and LDH assays, respectively. H9c2 cells were employed in this study because they are an 
animal-free alternative, easy to maintain and extensively used in various other laboratories. 
However, it has not yet been established whether H9c2 cells accurately mimic the responses of 
primary cardiac myocytes. To address this limitation, this study compared the responses of H9c2 
cells with differentiated C2C12 myotubes. These cells share similar characteristics with primary 
cardiac myocytes in that they have the ability to form myotubes which have been demonstrated 
to undergo pre-conditioning in a similar manner to that of the whole heart (Lecour et al., 2005). 
3.1 Results 
3.1.1 DOX Concentrations 
In this study, the concentrations of DOX that were employed were based on a review by Minotti 
et al., (2004a). Many in vitro studies that have reported on the mode of action of anthracyclines 
have been performed at concentrations that were too high when compared to the peak (5 μM) or 
steady state (25 – 250 nM) concentrations observed clinically in patients. Since plasma 
concentrations generally fall between 1 – 2 μM, it was suggested that studies investigating the 
detrimental effects of anthracyclines (particularly DOX), should not exceed this range. Based on 
this information, this study performed a dose- and time-response curve using increasing 
concentrations of DOX (0.2 – 1 μM). Since chronic cardiotoxicity is believed to develop in direct 
proportion to the total cumulative dose of DOX (Montaigne et al., 2012), this study administered 
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these concentrations on a daily basis for a total of 120 hours to simulate this condition. Therefore 
for example, treatment of cells for 120 hours with 1 µM will result in a cumulative dose of 5 µM, 
whereas treatment of cells with 0.2 µM for 72 hours will result in a cumulative dose of 0.6 µM. 
Seeing that DOX is known to concentrate within cardiomyocytes, the intracellular concentrations 
of DOX are believed to be greater than the extracellular concentrations (Takemura and Fujiwara, 
2007). However, despite this it is believed that the intracellular concentration of DOX will not 
exceed the cumulative concentrations of this study due to its relatively short half-life of 
approximately 25 hours (Mross et al., 1988). Acute cardiotoxicity does not present as a major 
clinical problem, however, chronic cardiotoxicity poses a serious threat to the survival of cancer 
patients since it is associated with a much larger risk of morbidity and mortality (Swain et al., 
2003). For this reason, a treatment period of 24 – 120 hours was chosen to highlight the 
differences between the acute and chronic effects. For this study, 24 and 48 hours were classified 
as acute, 72 hours was classified as sub-chronic and 96 and 120 hours were classified as chronic. 
3.1.2. DOX reduces cell viability in a time- and dose-dependent manner 
The MTT assay is based on the principle whereby metabolically viable cells reduce yellow MTT 
into purple formazan crystals. The absorbance of each sample is directly proportional to the 
reductive capacity of mitochondria in viable cells and therefore gives an indication of cell 
viability. The capacity of H9c2 cells to reduce MTT (Figure 3.1) became significantly reduced 
by as early as 24 hours [76.49 ± 3.48% (p = 0.0004)] following treatment with 1 µM when 
compared to its respective control (100 ± 4.47%). As the concentration increased cell viability 
declined, reaching its lowest after 96 hours across all concentrations tested. An interesting 
phenomenon, however, occurred after 120 hours: cell viability was substantially improved 
compared to 96 hours, although remaining below control values.  
In differentiated C2C12 myotubes, DOX induced a time- and dose-dependent reduction in cell 
viability (Figure 3.2). Although no significant change was observed after the first 24 hours across 
all concentrations, cell viability gradually declined as the concentration increased. What was 
interesting to note was that a single DOX treatment of 1 µM over 24 hours resulted in no change 
in viability, whereas a cumulative dose of 1 µM DOX over 120 hours (0.2 μM x 5) significantly 
reduced cell viability [78.42 ± 2.10% (p < 0.0001)] compared to the control (100 ± 7.73%). This 
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observation was also noted in the H9c2 cardiomyocytes, where cumulative treatment with DOX 
reduced cell viability more than treatment with a single dose. 
These observations thus demonstrate the detrimental effects of cumulative concentrations of 
DOX and how chronic cardiotoxicity poses a more serious threat to the survival of cancer 
patients than acute cardiotoxicity. 
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Figure 3.1: The effect of DOX on the MTT reductive capacity of H9c2 cells. Cell viability was 
quantified using the MTT assay as described in the methods section. All values are expressed as a 
percentage of the control (100%) and presented as mean ± SEM, n = 4. *p< 0.05, **p< 0.01, ***p< 0.001 
vs control. ●p< 0.05, ●●p< 0.01, ●●●p< 0.001 (96 vs 120 hours). 
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Figure 3.2: The effect of DOX on the MTT reductive capacity in C2C12 myotubes. Cell viability was 
quantified using the MTT assay as described in the methods section. All values are expressed as a 
percentage of the control (100%) and presented as mean ± SEM, n = 3. *p< 0.05, **p< 0.01, ***p< 0.001 
vs control. 
3.1.3 The DOX-induced decrease in cell viability can be attributed to apoptotic cell death 
To determine the relative contribution of apoptotic cell death after DOX treatment, the Caspase-
Glo
®
3/7 assay was employed. Based on the results obtained, caspase-3 and -7 activities were 
significantly up-regulated in the H9c2 cells by as early as 24 hours and remained elevated even 
after 96 hours relative to the control (Figure 3.3). By 120 hours however, caspase activity was 
substantially reduced although remaining above control values. This reduction in caspase activity 
may have accounted for the improved cell viability observed at this point. 
The results for caspase activity in the differentiated myotubes were rather surprising (Figure 3.4). 
Where caspase activity was expected to be significantly elevated, no major changes were 
observed. In fact, caspase activity was substantially reduced by 120 hours after treatment with 
0.6, 0.8 and 1 µM DOX. This observation was rather strange considering the time- and dose-
dependent decline in cell viability. It is therefore possible that at the time of assessment, 
apoptotic damage may have already taken place and thus the activity of the caspases had 
declined. 
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Figure 3.3: Caspase-3 and -7 activities in H9c2 cells after DOX treatment. The luminescent signal 
produced in this assay is directly proportional to caspase 3/7 activity. All values are expressed as a 
percentage of the control (100%) and presented as mean ± SEM, n = 4. *p< 0.05, **p< 0.01, ***p< 0.001 
vs control. ●p< 0.05, ●●p< 0.01, ●●●p< 0.001 vs 120 hours. 
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Figure 3.4: Caspase-3 and -7 activities in differentiated C2C12 cells after DOX treatment. The 
luminescent signal produced in this assay is directly proportional to caspase3/7 activity. All values are 
expressed as a percentage of the control (100%) and presented as mean ± SEM, n = 3, *p< 0.05, **p< 
0.01, ***p< 0.001. RLU = relative light units. 
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3.1.4 Necrosis was observed in the chronic setting in C2C12 myotubes but not in H9c2 
cardiomyocytes 
In order to investigate whether necrotic cell death plays a role in DOX-induced cytotoxicity, the 
LDH assay was employed. The release of LDH from cells as a result of membrane damage is 
often used as an indicator for necrotic cell death (Horenstein et al., 2000). As indicated in Figure 
3.5, necrotic cell death did not play a major role in this model of cardiotoxicity as much of the 
LDH detected remained below baseline values for the entire treatment duration. 
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Figure 3.5: Lactate dehydrogenase assay of H9c2 cells after treatment with DOX. The LDH assay 
was employed as an indicator of necrosis since LDH is released in response to cell membrane damage. 
All values are expressed as a percentage of the control (100%) and presented as mean ± SEM, n = 4, 
*p< 0.05, **p< 0.01, ***p< 0.001. AU = arbitrary units. 
A similar effect was observed in the differentiated C2C12 myotubes (Figure 3.6), however, the 
levels of LDH were substantially higher than the respective controls after treatment with 0.2 – 
0.8 µM for 120 hours. Treatment with a single (24 hours) dose of 1 µM DOX resulted in no 
significant change in LDH release, yet a cumulative dose of 1 µM DOX over 120 hours (0.2 µM 
x 5) significantly increased LDH levels [118.8 ± 0.67% (p = 0.0017)] when compared to the 
control (100 ± 4.08%). Other than indicating the sensitivity of these cells to cumulative doses of 
DOX, this observation also emphasizes the detrimental effects of chronic DOX treatment as 
opposed to acute treatment. 
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Figure 3.6: LDH assay of C2C12 myotubes after treatment with DOX. The LDH assay was employed 
as an indicator of necrosis since LDH is released in response to cell membrane damage. All values are 
expressed as a percentage of the control (100%) and presented as mean ± SEM, n = 4, *p< 0.05, **p< 
0.01, ***p< 0.001. AU = arbitrary units. 
Based on the above results, all subsequent experiments in this study were conducted using the 
0.2 and 1 µM concentrations of DOX. The 0.2 µM dose was chosen since it is still clinically 
relevant after 120 hours. For example, treatment with 0.2 µM every day for 120 hours results in a 
cumulative dose of 1 µM, which is still within the clinically relevant range as suggested by 
Minotti et al., (2004a). Although the 1 µM dose no longer falls within the clinically relevant 
range after 120 hours (5 µM), this concentration was chosen to indicate the adverse effects of 
DOX when the recommended clinical doses are exceeded. 
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CHAPTER 4 
Results Part II 
4.1 Caspase cleavage is evident in the differentiated C2C12 myotubes 
Since caspase activity did not change significantly in the Caspase-Glo
®
3/7 assay when compared 
to the control, the protein expression of cleaved caspase-3 was determined in the differentiated 
C2C12 myotubes. As observed in Figure 4.1, the treatment of differentiated C2C12 myotubes 
with the low concentration of DOX (0.2 µM) did not significantly change the expression of 
cleaved caspase-3 compared to the control. However, when the concentration was higher (1 µM), 
cleaved caspase-3 expression was up-regulated acutely (24 and 48 hours), significantly more 
than the control. Over time the expression of this protein declined, reaching a minimum after 120 
hours [0.44 ± 0.19 AU (p = 0.0305)]. 
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Figure 4.1: Caspase-3 cleavage in C2C12 myotubes after treatment with DOX. The lane profile 
analysis (A) and western blots (B) are represented. The fold change relative to the control was 
calculated. All values are presented as mean ± SEM, arbitrary units (AU), n = 3, *p< 0.05, **p< 0.01, ***p< 
0.001. Ponceau was used as a loading control. 
4.2 Chronic DOX treatment stimulates TNF-α production 
TNF exerts both physiological and pathological effects including tumor cell necrosis and 
apoptosis, immunity and cell survival (Chu, 2013; Locksley et al., 2001). One of the aims of this 
study was to investigate whether DOX induces an inflammatory response, mediated by TNF-α. 
TNF-α is notorious for being the central mediator of inflammation, however, its role in this 
context is relatively unknown. Therefore, to establish the levels of TNF-α produced after DOX 
treatment, Quantikine
®
 ELISA kits were employed. 
In response to a low concentration of DOX (0.2 µM), TNF-α production in the H9c2 
cardiomyocytes (Figure 4.2) was significantly up-regulated after 120 hours [3.82 ± 0.07 pg/mL 
(p = 0.0304)] when compared to the control (3.63 ± 0.01 pg/mL). In response to a higher 
concentration of DOX, a larger and biphasic pattern of TNF-α release was observed. TNF-α was 
first significantly elevated after 24 hours [4.24 ± 0.004 pg/mL (p < 0.0001)] with a return to 
insignificant levels thereafter, when compared to the control. The second peak in TNF-α was 
observed after 96 hours [4.04 ± 0.03 pg/mL (p< 0.0001)], which remained elevated even after 
120 hours of treatment [4.22 ± 0.15 pg/mL (p = 0.006)] compared to the control.  
C 24 48 72 96 120
0.2 µM 1 µM
Cleaved 
Caspase 3
Ponceau
C 24 48 72 96 120
19 kDa
B
Stellenbosch University  http://scholar.sun.ac.za
 55 
 
Control 24 48 72 96 120
3.6
3.8
4.0
4.2
4.4
0.2 M DOX
1 M DOX
***
***
*
**
Treatment duration (hours)
T
N
F
- 
 p
ro
d
u
c
ti
o
n
 (
p
g
/m
L
)
 
Figure 4.2: Determination of TNF-α production by H9c2 cells after treatment with DOX. TNF-α in the 
cell culture medium was quantified using an ELISA kit. All values are presented as mean ± SEM, n = 3, 
*p< 0.05, **p< 0.01, ***p< 0.001. 
In the differentiated C2C12 myotubes (Figure 4.3), TNF-α production was dependent on both a 
high concentration of DOX and a longer treatment period. TNF-α was significantly up-regulated 
after 120 hours of treatment with 0.2 µM DOX [9.33 ± 0.31 pg/mL (p = 0.0004)] compared to 
the control (7.97 ± 0.16 pg/mL). However, when treatment concentrations of DOX were high (≥ 
1 µM), TNF-α was constantly produced at significantly high levels.  
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Figure 4.3: Quantification of TNF-α production by C2C12 myotubes after DOX treatment. TNF-α in 
cell culture medium was quantified using an ELISA kit. All values are presented as mean ± SEM, n = 3, 
*p< 0.05, **p< 0.01, ***p< 0.001. 
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4.2.1 TNF-α is expressed in a time- and dose-dependent manner  
TNF-α is a pleiotropic cytokine that is produced as a 26 kDa plasma membrane-associated 
protein, which can be cleaved into a 17 kDa soluble subunit. In addition to the ELISA, this study 
wanted to determine the protein expression of this protein. As indicated in Figure 4.4, TNF-α 
protein expression was significantly up-regulated in a time- and dose-dependent manner in the 
H9c2 cells. What was interesting to note was the relatively lower levels of TNF-α expression 
when treatment concentrations were high, compared to when they were lower. In addition, 
significantly more TNF-α was produced after treatment with 0.2 µM for 120 hours (resulting in a 
cumulative dose of 1 µM) compared to a single treatment of 1 µM for 24 hours. 
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Figure 4.4: Evaluation of TNF-α protein expression in H9c2 cardiomyocytes. The lane profile 
analysis (A) and western blots (B) are represented. The fold change relative to the control was 
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calculated. All values are presented as mean ± SEM, arbitrary units (AU), n = 3, *p< 0.05, **p< 0.01, ***p< 
0.001 vs control. ●●p < 0.01 120h (0.2 µM) vs 24h (1 µM). GAPDH was used to correct for any loading 
discrepancies. 
The response in the differentiated C2C12 myotubes was different (Figure 4.5), as TNF-α 
expression was delayed and peaked only after 48 hours when compared to the control. This 
increased expression remained significantly elevated through-out the treatment period at both 
concentrations of DOX. However, by 120 hours, after treatment with 1 µM DOX, TNF-α 
expression had returned to baseline. Significantly more TNF-α was again observed after 
cumulative treatment with 0.2 µM for 120 hours (1 µM) than after a single treatment of 1 µM for 
24 hours. Furthermore, while the 17 kDa fragment of TNF-α was detected in the H9c2 
cardiomyocytes, the 25 kDa fragment was detected in C2C12 myotubes.  
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Figure 4.5: Analysis of TNF-α protein expression in differentiated C2C12 myotubes. The lane profile 
analysis (A) and western blots (B) are represented. The fold change relative to the control was 
calculated. All values are presented as mean ± SEM, arbitrary units (AU), n = 3, *p< 0.05, **p< 0.01, ***p< 
0.001 vs control. ●●p < 0.01: 120h (0.2 µM) vs 24h (1 µM). Ponceau was used as a loading control. 
4.2.2 TNF-α functions via two receptors 
TNF-α functions through two distinct receptors, TNFR1 and TNFR2, found on the surface of 
almost every nucleated cell type (Vandenabeele et al., 1995). While the affinity of TNF-α for 
TNFR2 is almost 5 times that for TNFR1, it is TNFR1 that performs the majority of biological 
activities (Tartaglia and Goeddel, 1992) Although TNF-α can exert both beneficial and 
detrimental effects depending on which receptor it activates, the overall effects of TNF-α appear 
to be dependent on the concentration of the cytokine (Tracey et al., 1989). 
On the one hand our results illustrate that TNF-α receptor expression was heavily influenced by 
the dose and duration of treatment in the H9c2 cardiomyocytes (Figure 4.6). Significant TNFR1 
expression was evident by 48 hours and gradually increased as the concentration increased. 
These results mimicked those observed for TNF-α expression (Figure 4.4) in the H9c2 cells. A 
significant increase in TNFR1 expression was also observed after chronic treatment with 0.2 µM 
(giving a cumulative dose of 1 µM) compared to acute treatment with 1 µM, suggesting that in 
chronic cytotoxicity TNF-α exerts detrimental effects through TNFR1 signaling. 
In the differentiated C2C12 myotubes, TNFR1 was significantly down-regulated by 120 hours 
irrespective of the treatment concentration (Figure 4.7). Although a significant increase was 
observed after 72 hours of treatment with 0.2 µM DOX [1.61 ± 0.11 AU (p = 0.0046)], this 
effect was transient and was thus not maintained. 
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Figure 4.6: Evaluation of TNFR1 expression in H9c2 cardiomyocytes treated with DOX. The lane 
profile analysis (A) and western blots (B) are represented. The fold change relative to the control was 
calculated. All values are presented as mean ± SEM, arbitrary units (AU), n = 3, *p< 0.05, **p< 0.01, ***p< 
0.001 vs control. ●● p< 0.01 120h (0.2 µM) vs 24h (1 µM). TNFR1, tumor necrosis factor receptor 1. 
GAPDH was used as a correction for any loading discrepancies. 
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Figure 4.7: Analysis of TNFR1 protein expression in differentiated C2C12 myotubes. The lane 
profile analysis (A) and western blots (B) are represented. The fold change relative to the control was 
calculated. All values are presented as mean ± SEM, arbitrary units (AU), n = 3, *p< 0.05, **p< 0.01, ***p< 
0.001. A Ponceau stain was used as a loading control. 
On the other hand, TNFR2 expression in the H9c2 cardiomyocytes remained below baseline for 
the first 48 hours at both concentrations of DOX (Figure 4.8). However, a unique observation 
was noted after 48 hours; TNFR2 expression was severely down-regulated at both the low and 
high concentration [0.04 ± 0.01 AU and 0.05 ± 0.01 AU (p < 0.0001) respectively]. As treatment 
continued, TNFR2 became significantly expressed, reaching a maximum after 96 hours of 
treatment with 0.2 µM [2.17 ± 0.26 AU (p = 0.0007)] and 1 µM [1.78 ± 0.17 AU (p = 0.0006)]. 
A significant difference was again observed between chronic treatment with a low dose and 
acute treatment with a high dose. This suggests that during chronic treatment with DOX, TNFR2 
C 24 48 72 96 120
0.2 µM DOX 1 µM DOX
TNFR1
Ponceau
C 24 48 72 96 120
55 kDa
B
Stellenbosch University  http://scholar.sun.ac.za
 61 
 
signaling is also up-regulated in an attempt to oppose the detrimental effects associated with 
TNFR1. 
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Figure 4.8: Evaluation of TNFR2 expression in H9c2 cardiomyocytes treated with DOX. The lane 
profile analysis (A) and western blots (B) are represented. The fold change relative to the control was 
calculated. All values are presented as mean ± SEM, arbitrary units (AU), n = 3, *p< 0.05, **p< 0.01, ***p< 
0.001 vs control. ●●p< 0.01 120h (0.2 µM) vs 24h (1 µM). TNFR2, tumor necrosis factor receptor 2. 
GAPDH was used to correct any loading discrepancies. 
TNFR2 was barely detectable in the differentiated C2C12 myotubes (Figure 4.9), with receptor 
expression being down-regulated for the majority of the treatment period. It was interesting to 
note that both receptors in this cell line were below control levels for the majority of the 
treatment duration. This may suggest either receptor saturation or receptor shedding (Zhang et 
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al., 2001) as a result of the elevated TNF-α levels detected, as well as highlighting TNF-α’s 
ability to function independently of its receptors. 
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Figure 4.9: Analysis of TNFR2 protein expression in differentiated C2C12 myotubes. The lane 
profile analysis (A) and western blots (B) are represented. The fold change relative to the control was 
calculated. All values are presented as mean ± SEM, arbitrary units (AU), n = 3, *p< 0.05, **p< 0.01, ***p< 
0.001. TNFR2, tumor necrosis factor receptor 2. A Ponceau stain was used to correct for loading 
discrepancies. 
4.3 DOX treatment is (un)SAFE for the heart 
The JAK-STAT pathway has been evolutionarily conserved from slime molds to humans and 
facilitates intercellular communication (Aaronson and Horvath, 2002). Once activated by 
cytokines such as TNF-α, the JAK-STAT pathway modulates proliferation, differentiation, cell 
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migration and apoptosis, ultimately providing a mechanism to transduce extracellular signals into 
transcriptional responses (Rawlings et al., 2004). Since TNF-α was detected in this model of 
cytotoxicity, this study investigated whether the SAFE pathway was also activated in the context 
of cytotoxicity. 
In H9c2 cardiomyocytes, p-Jak2 expression was increased significantly in a time- and dose-
dependent manner after treatment with the low dose of DOX (Figure 4.10A and B). This effect 
was however lost after treatment with the high concentration (1 µM) of DOX. Treatment with 
the low dose of DOX not only affected Jak2 phosphorylation but also had a positive impact on 
total Jak-2 protein expression (Figure 4.10C). A 2.5 – to 3-fold increase in total Jak2 protein 
expression was observed compared to the control, suggesting that treatment with low doses of 
DOX up-regulates the protein synthesis of Jak2. No changes in total protein expression were 
observed following treatment with the high concentration of DOX when compared to the control. 
Figure 4.10D represents the phosphorylated protein to total protein ratio. From this graph it is 
clear that Jak-2 was activated in the chronic setting but not in the acute setting following 
treatment with the low dose of DOX, however, treatment with the high concentration (1 µM) did 
not induce Jak-2 phosphorylation. A similar pattern was also observed in TNFR2 expression, 
suggesting that TNF-α-TNFR2-Jak2 signaling may have contributed to the increase in cell 
viability and the decrease in apoptotic cell death that was observed at this point in the H9c2 
cardiomyocytes. 
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Figure 4.10A and B: Protein expression of p-Jak2 and T-Jak2 in H9c2 cells. The lane profile analysis 
of p-Jak-2 (A) and western blots of p-Jak2 and T-Jak-2 (B) are represented. The fold change relative to 
the control was calculated. All values are presented as mean ± SEM, arbitrary units (AU), n = 3, *p< 0.05, 
**p< 0.01, ***p< 0.001. p-Jak2, phospho-Jak2, T-Jak2, total-Jak2. GAPDH was used to correct for any 
loading discrepancies. 
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Figure 4.10C: Protein expression of T-Jak2 in H9c2 cells. The lane profile analysis of T-Jak-2 is 
represented. The fold change relative to the control was calculated. All values are presented as mean ± 
SEM, arbitrary units (AU), n = 3, *p< 0.05, **p< 0.01, ***p< 0.001. GAPDH was used to correct for any 
loading discrepancies. 
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Figure 4.10D: Protein expression of Jak2 in H9c2 cells. The lane profile analysis of phosphorylated 
protein to total protein ratio of Jak2 is represented. The fold change relative to the control was calculated. 
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All values are presented as mean ± SEM, arbitrary units (AU), n = 3, *p< 0.05, **p< 0.01, ***p< 0.001. 
GAPDH was used to correct for any loading discrepancies. 
Treatment with DOX significantly down-regulated the protein expression of p-Jak2 compared to 
the controls in the differentiated C2C12 myotubes (Figure 4.11A and B) and this effect was 
noted in every treatment group. No significant differences were observed in the protein 
expression of total Jak2. Analysis of total Jak2 can be found in appendix A, page 129. 
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Figure 4.11A and B: Protein expression of p-Jak2 and T-Jak2 in differentiated C2C12 myotubes. 
The lane profile analysis (A) and western blots (B) of Jak2 are represented. The fold change relative to 
the control was calculated. All values are presented as mean ± SEM, arbitrary units (AU), n = 3, *p< 0.05, 
**p< 0.01, ***p< 0.001. Ponceau was used to correct for loading discrepancies. 
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STATs reside as inactive transcription factors in the cytoplasm, until they are activated by 
several growth factors and cytokines such as TNF-α (Levy and Darnell, 2002). STATs are 
phosphorylated at a single tyrosine residue which is essential for activation (Levy and Darnell, 
2002). Phosphorylation at this site allows STAT to homodimerize and translocate to the nucleus 
where it stimulates transcription (Paulson, 1999). In addition, ligand-dependent phosphorylation 
at serine 727 is thought to enhance transcriptional activation of STAT3 (Levy and Darnell, 
2002). 
As indicated in the figures below, STAT3 phosphorylation was significantly up-regulated in the 
H9c2 cardiomyocytes at both tyrosine 705 (Figure 4.12A and B) and serine 727 (Figure 4.12C 
and D) when compared to the control. This effect was however only noted with low 
concentrations of DOX. High concentrations of DOX significantly reduced the phosphorylation 
of both STATs, possibly as a result of the decreased phosphorylation of Jak2 (Figure 4.10). 
When two bands were present in p-STAT3 expression, the lane profile analysis was calculated as 
a sum of the 79 kDa and 86 kDa fragments. Total protein expression remained unchanged 
throughout the treatment regime. Analysis of total STAT3 expression can be found in appendix 
A, page 129. 
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Figure 4.12A and B: Protein expression of p-STAT3 
Tyr705
 and T-STAT3 in H9c2 cells. The lane 
profile analysis (A) and western blots (B) are represented. The fold change relative to the control was 
calculated. All values are presented as mean ± SEM, arbitrary units (AU), n = 3, *p< 0.05, **p< 0.01, ***p< 
0.001. GAPDH was used as a loading control to correct for any discrepancies. 
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Figure 4.12C and D: Protein expression of p-STAT3 
Ser727
 in H9c2 cells. The lane profile analysis (C) 
and western blots (D) are represented. The fold change relative to the control was calculated. All values 
are presented as mean ± SEM, arbitrary units (AU), n = 3, *p< 0.05, **p< 0.01, ***p< 0.001. GAPDH was 
used as a loading control to correct for any discrepancies. 
In the differentiated C2C12 myotubes treatment with 0.2 µM DOX resulted in relatively no 
change in STAT3 
Tyr705
 phosphorylation (Figure 4.13A and B). When the concentration of DOX 
was higher (1 µM), p-STAT3 
Tyr705
 expression increased as the concentration increased, reaching 
maximum after 96 hours of treatment [2.22 ± 0.13 AU (p = 0.0007)]. p-STAT3 
Ser727
 was acutely 
activated following treatment with the low dose of DOX (Figure 4.13C and D), but activation of 
this residue declined significantly by 120 hours [0.56 ± 0.03 AU (p = 0.0002)]. Phosphorylation 
on serine727 decreased in a time- and dose-dependent manner after treatment with the high dose 
of DOX, when compared to the control. When two bands were present in p-STAT3 expression, 
the lane profile analysis was calculated as a sum of the 79 kDa and 86 kDa fragments. Total 
protein expression remained unchanged throughout the treatment regime. Analysis of total 
STAT3 expression can be found in appendix A, page 130. 
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Figure 4.13A and B: Protein expression of p-STAT3 
Tyr705
 and T-STAT3 in C2C12 myotubes. The 
lane profile analysis (A) and western blots (B) are represented. The fold change relative to the control 
was calculated. All values are presented as mean ± SEM, arbitrary units (AU), n = 3, *p< 0.05, **p< 0.01, 
***p< 0.001. Ponceau was used as a loading control to correct for any discrepancies. 
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Figure 4.13C and D: Protein expression of p-STAT3 
Ser727
 in C2C12 myotubes. The lane profile 
analysis (C) and western blots (D) are represented. The fold change relative to the control was 
calculated. All values are presented as mean ± SEM, arbitrary units (AU), n = 3, *p< 0.05, **p< 0.01, ***p< 
0.001. Ponceau was used as a loading control to correct for any discrepancies. 
Based on these results it is clear that activation of the SAFE pathway is the presence of DOX is 
quite distinct between the two cell lines. While the SAFE pathway in the H9c2 cardiomyocytes 
was activated after chronic exposure to low doses of DOX, activation of this pathway in the 
presence of high concentrations of DOX was not evident. In the differentiated C2C12 myotubes, 
STAT3 activation occurred independently of Jak2 phosphorylation. Furthermore, 
phosphorylation of the tyrosine residue required chronic, high levels of DOX treatment whereas 
phosphorylation of the serine residue required acute low levels of DOX. 
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4.4 The ‘RISK’ associated with DOX-induced cytotoxicity 
Ischemic pre- and post-conditioning have been shown to activate the pro-survival kinases of the 
RISK pathway, Erk1/2 and Akt (Hausenloy and Yellon, 2004). Like the SAFE pathway, 
activation of the RISK pathway reduces the amount of reperfusion-injury related myocardial 
damage. Both of the above mentioned kinases are members of pro-survival pathways and it is 
believed that activation of these pathways confers protection through phosphorylation and 
inhibition of several pro-apoptotic proteins (Hausenloy and Yellon, 2004). Since oxidative stress 
and apoptosis mediate the damage induced by reperfusion injury, we proposed that the RISK 
pathway might also be activated in response to DOX treatment, seeing that apoptosis and 
oxidative stress are the two main role players in this scenario. 
In the H9c2 cardiomyocytes, protein expression of p-Akt was significantly greater than that of 
the control during the first three days of treatment with 0.2 µM DOX (Figure 4.14A and B). 
Thereafter phosphorylation declined significantly by 120 hours when compared to the control. 
Treatment with 1 µM DOX did not affect Akt phosphorylation after the first 24 hours, however, 
expression was significantly down-regulated as the concentration of DOX increased, reaching a 
minimum after 120 hours [0.24 ± 0.09 AU (p = 0.0002)]). Total Akt expression remained 
unchanged throughout the treatment period. Analysis of total Akt can be found in appendix A, 
page 130. 
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Figure 4.14A and B: Protein expression of p-Akt and T-Akt in H9c2 cells after DOX treatment. The 
lane profile analysis (A) and western blots (B) are represented. The fold change relative to the control 
was calculated. All values are presented as mean ± SEM, arbitrary units (AU), n = 3, *p< 0.05, **p< 0.01, 
***p< 0.001. p-Akt, phospho-Akt. T-Akt, total-Akt. GAPDH was used to correct for loading discrepancies. 
In the differentiated C2C12 myotubes, phosphorylation of Akt was significantly increased during 
the first 72 hours of treatment with the low dose of DOX, however, this effect had returned to 
control levels by 120 hours (Figure 4.15A and B). While acute treatment with the high dose of 
DOX did not cause any changes in Akt phosphorylation during the first 24 hours, Akt 
phosphorylation increased significantly as treatment continued, reaching a maximum after 96 
hours [1.73 ± 0.12 AU (p = 0.0035)]. Again, p-Akt expression returned to baseline by 120 hours 
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after treatment with this dose. Total Akt protein levels were also affected by treatment with DOX 
as noted by the significant decrease in expression after treatment with the low dose of DOX and 
an increasing trend in total Akt expression at the high dose of DOX (Figure 4.15C). Analysis of 
the phosphorylated Akt to total Akt ratio (Figure 4.15D) revealed an increase after treatment 
with the low dose of DOX, suggesting that although the total protein was down-regulated, the 
majority of this protein was phosphorylated. However, treatment with the high concentration of 
DOX did not induce significant changes, therefore suggesting that DOX prevented Akt 
phosphorylation of the newly synthesized protein. 
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Figure 4.15A and B: Analysis of p-Akt and T-Akt in C2C12 myotubes. The lane profile analysis (A) 
and western blots (B) are represented. The fold change relative to the control was calculated. All values 
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are presented as mean ± SEM, arbitrary units (AU), n = 3, *p< 0.05, **p< 0.01, ***p< 0.001. Ponceau was 
used as a loading control to correct for any discrepancies. 
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Figure 4.15C: Analysis of T-Akt in C2C12 myotubes. The lane profile analysis (C) is represented. The 
fold change relative to the control was calculated. All values are presented as mean ± SEM, arbitrary 
units (AU), n = 3, *p< 0.05, **p< 0.01, ***p< 0.001. Ponceau was used as a loading control to correct for 
any discrepancies. 
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Figure 4.15D: Analysis of the ratio of phospho/total-Akt in C2C12 myotubes. The lane profile 
analysis is represented. The fold change relative to the control was calculated. All values are presented 
as mean ± SEM, arbitrary units (AU), n = 3, *p< 0.05, **p< 0.01, ***p< 0.001. Ponceau was used as a 
loading control to correct for any discrepancies. 
In the H9c2 cardiomyocytes, Erk1/2 phosphorylation remained unchanged during the first 48 
hours of treatment with 0.2 µM DOX (Figure 4.16A and B). However, as the treatment 
continued, Erk1/2 phosphorylation significantly declined. This observation was also noted when 
a high concentration (1 µM) of DOX was used. In all instances, only the 42 kDa band was 
detected. Since the expression of both the 42 kDa and the 44 kDa fragments varies between cell 
and tissue types, the possibility exists that only one of the two bands is expressed in response to 
DOX treatment, which is consistent with Zhu et al., (1999). Total Erk1/2 expression remained 
unchanged throughout the treatment regime. Analysis of total Erk1/2 can be found in appendix 
A, page 131. 
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Figure 4.16A and B: Protein expression of p-Erk1/2 and T-Erk1/2 in H9c2 cells after DOX treatment. 
The lane profile analysis (A) and western blots (B) are represented. The fold change relative to the 
control was calculated. All values are presented as mean ± SEM, arbitrary units (AU), n = 3, *p< 0.05, 
**p< 0.01, ***p< 0.001. p-Erk1/2, phospho-Erk1/2. T-Erk1/2, total Erk1/2. GAPDH was used to correct for 
any loading discrepancies. 
In the differentiated C2C12 myotubes, Erk1/2 phosphorylation was down-regulated for the 
majority of the treatment regime (Figure 4.17A and B). A significant increase in phosphorylation 
was only observed after 96 hours of treatment with the low dose [1.28 ± 0.07 AU (p = 0.0117)] 
when compared to the control. Treatment with the high dose of DOX caused an increase in p-
Erk1/2 expression after 24 hours, though this was not significant. Further treatment with the low 
concentration of DOX significantly down-regulated p-Erk1/2 expression. The expression of total 
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Erk1/2 remained unchanged throughout the treatment protocol. Analysis of total Erk1/2 can be 
found in appendix A, page 131. 
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Figure 4.17A and B: Analysis of p-Erk1/2 and T-Erk1/2 expression in differentiated C2C12 
myotubes. The lane profile analysis (A) and western blots (B) are represented. The fold change relative 
to the control was calculated. All values are presented as mean ± SEM, arbitrary units (AU), n = 3, *p< 
0.05, **p< 0.01, ***p< 0.001. A Ponceau stain was used to correct for any loading discrepancies. 
Based on the above results, it is clear that the RISK pathway is more sensitive to DOX treatment 
than the SAFE pathway, since it is easily inactivated. This is particularly evident after chronic 
treatment with the low dose or when the dose of DOX exceeds 1 µM. The inhibition of both pro-
survival kinases by DOX may therefore contribute to its cardiotoxic effects. 
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4.5 DOX-induced cytotoxicity is associated with oxidative stress and an antioxidant deficit 
4.5.1 Treatment with DOX is accompanied by an increase in oxidative stress 
It is well known that treatment with DOX results in the production of ROS including peroxyl 
radicals and hydrogen peroxide. These then mediate the conversion of unsaturated membrane 
fatty acids into lipid peroxides, which quickly decompose into products such as MDA 
(Zimmermann et al., 1973). Therefore, in order to determine the extent of ROS-induced damage 
throughout the course of the treatment period, MDA, as measured by the TBARS assay, was 
assessed. 
In H9c2 cardiomyocytes, lipid peroxidation was detected later after treatment with the low dose 
of DOX and earlier after treatment with the high dose of DOX (Figure 4.18). Treatment with 0.2 
µM DOX caused a significant increase in lipid peroxidation after 96 hours [0.38 ± µM (p = 
0.0201)] and 120 hours [0.31 ± 0.0 µM (p = 0.0002)]. Treatment with 1 µM DOX also induced 
oxidative stress, however, at this concentration a significant level of lipid peroxidation was 
evident by as early as 72 hours [0.39 ± 0.02 µM (p = 0.0025)] and was maintained until after 96 
hours [0.30 ± 0.04 µM (p = 0.0055)], when compared to the control (0.13 ± 0.03 µM). Although 
lipid peroxidation had declined by 120 hours, the level was still above that of the control. This 
decline may be explained by low cell numbers as suggested by the significant decrease in cell 
viability. A significant increase in lipid peroxidation was also observed between chronic 
treatment with 0.2 µM (giving a cumulative dose of 1 µM) and acute treatment with 1 µM, 
emphasizing how chronic cardiotoxicity is more detrimental than acute cardiotoxicity. 
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Figure 4.18: TBARS assay as an indicator of lipid peroxidation in H9c2 cells. H9c2 cells were 
treated with two concentrations of DOX for a total of 120 hours. The presence of MDA in this assay is a 
sign of membrane damage. All values are presented as mean ± SEM, n = 3, *p< 0.05, **p< 0.01, ***p< 
0.001 vs control. ●p < 0.05 120h (0.2 µM) vs 24h (1 µM). 
In differentiated C2C12 cells, significant amounts of lipid peroxidation were observed at both 
low and high doses of DOX, across all time points (Figure 4.19). This response showed that 
differentiated C2C12 cells were more sensitive to DOX-induced oxidative stress and experienced 
more membrane damage during treatment than the H9c2 cardiomyocytes. Similarly to the H9c2 
cardiomyocytes, the level of lipid peroxidation in the C2C12 myotubes had declined to control 
levels by 120 hours after treatment with the high concentration. This may also be due to low cell 
numbers as suggested by the significant reduction in the MTT reductive capacity of these cells. 
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Figure 4.19: TBARS assay as an indicator of lipid peroxidation in differentiated C2C12 myotubes. 
Differentiated C2C12 cells were treated with two concentrations of DOX for a total of 120 hours. High 
levels of MDA produced in this assay indicate significant membrane damage. All values are presented as 
mean ± SEM, n = 3, *p< 0.05, **p< 0.01, ***p< 0.001. 
4.5.2 DOX treatment affects the antioxidant capacity in both cell lines 
Antioxidants are associated with a reduced incidence of cancer and heart disease (Rautenbach et 
al., 2010), however, treatment with many drugs including DOX can reduce these endogenous 
defense systems (Olson and Mushlin, 1990). Using the ORAC method for determining anti-
oxidant capacity, no change in antioxidant capacity was detected at the acute (24 and 48 hours) 
and sub-chronic (72 hours) time points in H9c2 cardiomyocytes (Figure 4.20). This was followed 
by a significant increase in antioxidant capacity after treatment with 0.2 µM DOX for 96 and 120 
hours [557.7 ± 2.91 µmol TE/L (p = 0.0053) and 553.2 ± 1.55 µmol TE/L (p = 0.0192)], 
respectively and after 1 µM for 96 hours [543.7 ± 2.98 µmol TE/L (p = 0.0053)]. This increase in 
anti-oxidant capacity occurred at the same time as the increase in lipid peroxidation. 
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Figure 4.20: Determination of antioxidant capacity of H9c2 cells after treatment with DOX. 
Antioxidant capacity was assessed using the ORAC assay, whereby the antioxidants in a sample 
scavenge a free radical until the reaction is complete. All values are presented as mean ± SEM, n = 3, 
*p< 0.05, **p< 0.01, ***p< 0.001. 
The opposite effect was observed in the differentiated C2C12 myotubes (Figure 4.21). Initially, 
treatment with 0.2 µM DOX caused a significant increase in antioxidant capacity after 24 and 48 
hours [378.2 ± 6.23 µmol TE/L (p = 0.0032) and 382.4 ± 8.32 µmol TE/L (p = 0.0022)], 
respectively. Longer exposure at the same concentration then caused a significant reduction in 
antioxidant capacity, as did treatment with the high dose (1µM) at all 5 time points  
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Figure 4.21: Antioxidant capacity of differentiated C2C12 myotubes after treatment with DOX. 
Antioxidant capacity was assessed using the ORAC assay, whereby the antioxidants in a sample 
scavenge a free radical until the reaction is complete. All values are presented as mean ± SEM, n = 3, 
*p< 0.05, **p< 0.01, ***p< 0.001. 
4.5.3 DOX treatment decreases the ratio of GSH: GSSG 
GSH is one of the most important antioxidants in a cell since it eliminates and detoxifies 
peroxides and maintains α-tocopherol and ascorbate in their reduced forms (Jones, 2002; Valko 
et al., 2007). In doing so, GSH is converted to its disulphide form, GSSG, which accumulates 
within a cell. Thus, the ratio between GSH and GSSG is a widely used indicator for reflecting 
the level of oxidative stress in a cell (Jones, 2002). 
In H9c2 cells, the ratio of GSH to GSSG was significantly reduced throughout the treatment 
duration, indicative of high levels of oxidative stress in these cells (Figure 4.22). Chronic 
treatment with 0.2 µM DOX increased this ratio, though not significantly, coinciding with the 
increased ORAC value at this point. In differentiated C2C12 cells, significant amounts of GSSG 
were detected in the cells and therefore resulted in a significantly reduced ratio of GSH: GSSG at 
every time point treated with 0.2 µM DOX (Figure 4.23). This ratio remained significantly 
reduced after acute treatment with 1 µM, however, a significant increase in the ratio of GSH: 
GSSG was observed at 72 hours (21.64 ± 4.04%), followed by a return to baseline. 
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Figure 4.22: Determination of glutathione content in response to DOX treatment in H9c2 cells. 
GSH is an important antioxidant in eukaryotic cells and its ratio to GSSG gives an indication of oxidative 
stress. GSH content is presented as the ratio of reduced to oxidized glutathione. All values are presented 
as mean ± SEM, n = 3, *p< 0.05, **p< 0.01, ***p< 0.001. 
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Figure 4.23: Determination of glutathione content after DOX treatment in C2C12 myotubes. GSH is 
an important antioxidant in eukaryotic cells and its ratio to GSSG gives an indication of oxidative stress. 
GSH content is presented as the ratio of reduced to oxidized glutathione. All values are presented as 
mean ± SEM, n = 3, *p< 0.05, **p< 0.01, ***p< 0.001. 
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Based on these results it is clear that treatment with DOX caused significant oxidative stress, but 
more specifically damage to the cell membrane. This may be due to the reduced ratio of GSH to 
GSSG, which indicates an increase in the oxidized version of glutathione in the cell. A further 
explanation for the reduced amount of GSH is that DOX has been shown to inhibit the action of 
GSH-Px1 (Doroshow et al., 1980). The reduced ratio of GSH to GSSG may also account for the 
limited antioxidant capacity in both cell lines. 
Table 4: Summary of results in H9c2 cardiomyocytes and differentiated C2C12 myotubes 
 H9c2 cardiomyocytes Differentiated C2C12 myotubes 
DOX 0.2 – 1 µM 0.2 – 1 µM 
Cell viability Time-/dose-dependent ↓ Time-/ dose-dependent ↓ 
Apoptosis ↑ 24 – 96 hr, ↓ at 120 hr Apoptosis evident in western blots at 1 µM 
Necrosis No major necrotic cell death Necrosis evident after 120 hr 
     
DOX 0.2 µM 1 µM 0.2 µM 1 µM 
ELISA ↑ at 120 hr ↑ 24/96/120 hr ↑ at 120 hr ↑ 
TNFR1 ↑ ↑ ↓ after 120 hr ↓ 
TNFR2 ↑ chronically ↑ chronically ─ ─ 
SAFE ↑ ─ 
─ Jak2 
─ STAT3 Tyr705 
↑ STAT3 Ser727 
─ Jak2 
↑STAT3Tyr705 
─ STAT3 Ser727 
RISK 
↑ Akt until 72 hr 
─ Erk1/2 
─ Akt 
─ Erk1/2 
↑ Akt until 120 hr 
─ Erk1/2 
↑ Akt until 120 hr 
─ Erk1/2 
TBARS ↑ chronically ↑ chronically ↑ ↑ 
ORAC ↑ chronically ↑ chronically ↑ acutely ↓ 
GSH: GSSG ↓ ↓ ↓ ↓ 
Key: ↓ decrease; ↑ increase; ─ no significant change in expression; hr - hours 
Stellenbosch University  http://scholar.sun.ac.za
 86 
 
CHAPTER 5 
Discussion 
Introduction 
DOX remains one of the most widely used and effective anthracyclines despite causing severe 
cardiotoxicity. Approximately 2000 analogues of DOX have been produced in an attempt to 
reduce the side effects associated with these drugs whilst still effectively preventing tumor cell 
growth. Unfortunately, none have proved to be superior to DOX with regards to cytotoxicity and 
cardiac tolerability (Weiss, 1992). It is therefore imperative to try to fully understand the 
mechanisms by which cardiotoxicity occurs and to identify better strategies for reducing the 
DOX-induced side effects. In order to do this, it is often useful to turn to seemingly unrelated 
models to formulate a platform from where to start so we therefore used myocardial infarction as 
an example. Restoring oxygenated blood to the heart after a myocardial infarction results in a 
phenomenon known as lethal reperfusion injury (Braunwald and Kloner, 1985), The activation of 
intrinsic survival pathways such as the RISK and SAFE pathways during pre- and post-
conditioning were shown to protect the heart from this lethal reperfusion injury (Hausenloy, 
2009; Zhao et al., 2003).  
TNF-α has previously been shown to contribute to various pathophysiological conditions, 
however recent studies have shown that it may contribute to the heart’s adaptive response to 
stress (Mann, 2003). Seeing that TNF-α is a primitive cytokine that has been conserved 
throughout evolution for nearly 600 000 million years and is observed in nearly all forms of 
cardiac injury, it is possible that it confers some or other survival benefit (Mann, 2003) which is 
likely dependent on its concentration. In fact, it has previously been shown that pharmacological 
pre-conditioning with TNF-α protects the heart against ischemia reperfusion injury and its knock 
out abrogates this protection (Lacerda et al., 2009). One of the mechanisms by which TNF-α 
confers protection is through activation of the SAFE (JAK2/STAT3) pathway (Lecour, 2009a), 
which, once activated, is implicated in cell survival. Since DOX-induced cardiotoxicity and 
ischemia-reperfusion injury are often characterized by elevated oxidative stress and apoptosis, 
this study was thus designed to: (i) determine whether TNF-α is produced in response to DOX, 
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(ii) investigate whether or not the RISK and SAFE pathways also play a role in this context and 
(iii) provide in-depth insight into the signaling pathways that may contribute to DOX-induced 
cardiotoxicity. 
DOX-induced cytotoxicity is associated with a reduction in cell viability and an increase in 
cell death 
Cardiotoxicity is believed to arise after recurrent damage to cardiomyocytes in direct proportion 
to the cumulative dose of DOX (Allen, 1992). Our cell viability results support this observation 
since the greatest proportion of cell death took place at the most cumulative doses of DOX in 
both cell lines (Figures 3.1 and 3.2). Our findings are in agreement with work by Liu et al., 
(2008) who also reported a time-dependent decrease in cardiomyocyte viability after treatment 
with 1 µM DOX for 1 – 48 hours. Similarly, Das et al., (2011) reported a dose-dependent 
decrease in cell viability after treatment with 0.1 – 2 µM DOX. While these studies have 
reported similar findings, no other in vitro study has been performed that is as chronic as our 
own. Furthermore, the above mentioned studies only administered a single treatment of DOX 
which was followed by various incubation times, as opposed to our own study in which cells 
were treated daily.  
Several theories have been proposed regarding the mechanisms of DOX-induced cardiotoxicity 
including calcium overload (Wang and Korth, 1995), the release of cardiotoxic cytokines (Li et 
al., 2006) and lipid peroxidation (Siveski-Iliskovic et al., 1994). These mechanisms contribute to 
cardiomyocyte death and over the last several decades, most in vitro and in vivo studies have 
pointed towards apoptosis (Arola et al., 2000; Gamen et al., 2000; Ueno et al., 2006) and 
necrosis (Sugimoto et al., 2002; Zhang et al., 2009). DOX-induced apoptosis has been 
extensively studied in both acute and chronic models of cardiotoxicity, results of which have 
shown that multiple signaling pathways are involved (Kawamura et al., 2004; Kim et al., 2006; 
Liu et al., 2008). It is again important to note that such studies have used of a wide variety of 
treatments (multiple versus single doses), different cumulative doses, species and cell types. In 
addition, many of these studies have been performed at concentrations of DOX that are not 
clinically relevant. Furthermore, since chronic cardiotoxicity poses a serious threat to the 
survival of cancer patients, it is important that studies employ chronic models of cardiotoxicity, 
as opposed to acute cardiotoxicity, which does not present as a major clinical problem.  
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In the H9c2 cardiomyocytes (Figure 3.3), a potent increase in apoptosis was observed during the 
first 96 hours of treatment, however, apoptosis declined after 120 hours and returned to control 
levels. This observation correlated with an improvement in cell viability at this time point, 
suggesting that the slight increase in cell viability was due to a reduction in apoptotic cell death. 
However, apoptotic cell death remained significantly below control levels which may have been 
as a result of the substantial damage induced by DOX and therefore low cell numbers by this 
time. In support of our observations, Arola et al., (2000) reported significant apoptosis between 
24 and 72 hours after a single DOX injection (2.5 mg/kg) in rats. However, by day 7, apoptotic 
activity had declined to baseline levels. This study has therefore also demonstrated that low cell 
numbers and extensive damage induced by DOX at this time are possible explanations for the 
decline in apoptosis. In addition, since apoptosis is an energy-dependent process, it is highly 
possible that by 120 hours after treatment, cellular ATP was depleted and a switch to an energy-
independent form of cell death had taken place. 
In contrast to the results obtained for the H9c2 cardiomyocytes, apoptosis was not observed in 
differentiated C2C12 myotubes (Figure 3.4), as suggested by the lack of caspase-3 and -7 
activities in the Caspase Glo assay. This was a surprising finding, since cell viability was 
significantly decreased in the myotubes despite no evidence of apoptosis. A possible explanation 
for this is that because the C2C12 cells were differentiated into myotubes in 96-well plates for 
this assay, limited space caused some of the cells to lift which would have subsequently lead to a 
smaller cell number in those wells. In addition, since the assay was performed at the end of the 
120 hour treatment period, caspase-3 and -7 activities may have already declined by the time the 
assay was performed. These results therefore prompted us to assess the protein expression of 
cleaved caspase-3 using western blotting. Protein expression of cleaved caspase-3 was increased 
after acute treatment with high concentrations of DOX (Figure 4.1), but not at low concentrations 
of DOX. This increase was followed by a significant decline in cleaved caspase-3 expression by 
120 hours, suggesting a switch to a different form of cell death in the chronic setting as no 
improvement in cell viability was observed. Interestingly, Hayward et al., (2013) reported 
significantly more DOX accumulation in cardiac muscle compared to smooth and skeletal 
muscle and thus possibly explains why substantially more apoptotic activity was observed in the 
cardiomyocytes compared to the myotubes.  
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Since apoptosis was not observed in the chronic setting of both cell lines, we hypothesized that 
necrotic cell death may have been active at this point. Necrotic cell death is an irreversible form 
of cell death that has been implicated in the context of cardiotoxicity. During necrosis, 
intracellular proteins such as LDH are released from compromised cell membranes and the 
detection of these proteins can be used as an indicator of cellular injury and consequently 
necrotic cell death (Horenstein et al., 2000). This study illustrated that necrotic cell death did not 
contribute to the decline in cell viability in H9c2 cardiomyocytes as evident by the significantly 
low levels of LDH (Figure 3.5). It is therefore possible that other forms of cell death such as 
autophagy (Dirks-Naylor, 2013), senescence (Zhang et al., 2009) and mitotic catastrophe (Eom 
et al., 2005) contributed to the reduction in cell viability in the chronic setting in H9c2 
cardiomyocytes. In contrast, our results indicated that necrosis may have contributed to the 
reduction in cell viability in the chronic setting in C2C12 myotubes, since an increase in LDH 
was observed after 120 hours of treatment with most of the concentrations of DOX that were 
tested (Figure 3.6). This is in accordance with Franco (2006) who reported that necrotic cell 
death was more prevalent than apoptotic cell death following longer exposure and higher 
concentrations of DOX, however, this observation was reported in H9c2 cardiomyocytes. 
Nevertheless, since DOX induces mitochondrial damage and renders the electron transport chain 
dysfunctional, depletion of ATP will result in necrotic cell death as opposed to ATP-dependent 
apoptosis (Zhou et al., 2001). 
TNF-α is produced during chronic DOX-induced cytotoxicity 
TNF-α has been implicated in several pathological conditions such as inflammation, infection 
and malignancies (Bradley, 2008) and release of this cardiotoxic cytokine might be implicated in 
the pathogenesis of DOX-induced cardiotoxicity (Mohamed et al., 2004). However, research has 
also shown that that endogenous TNF-α exerts a protective effect against DOX-induced 
cytotoxicity (Watanabe et al., 1996). Low level TNF-α exposure for a short period of time may 
provide the heart with an adaptive response to stress, but high levels of TNF-α for extended 
periods of time can induce apoptosis and inflammation (Lien et al., 2006; Sack et al., 2000). 
These paradoxical reports clearly demonstrate that this pleiotropic cytokine exerts both 
beneficial and detrimental effects that are concentration and time dependent.  
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In our models of chronic cytotoxicity, we expected H9c2 cardiomyocytes and differentiated 
C2C12 myotubes to produce TNF-α in response to DOX treatment. TNF-α was produced by 
both cell types (Figure 4.2 and Figure 4.3) and its production appeared to coincide with chronic, 
high doses of DOX. In the H9c2 cardiomyocytes, TNF-α production was significantly increased 
after 120 hours of treatment with the low dose of DOX. However, treatment with the high dose 
of DOX elicited a biphasic response, peaking after 24 hours and again after 96 and 120 hours. 
Yokoyama et al., (1997) reported a similar biphasic response in TNF-α in a mouse model of 
renal disease and suggested that the second increase in TNF-α was in proportion to the severity 
of renal tissue injury. This may provide an explanation for our findings, since the greatest 
reduction in cell viability was observed at the same time as the second increase in TNF-α. 
Likewise, Reil et al., (2007) demonstrated the biphasic pattern of TNF-α release in a murine 
model of reperfusion and suggested that the initial release of TNF-α protected the heart during 
early reperfusion but the larger subsequent release of TNF-α was thought to account for its 
detrimental effects. This may explain the pattern observed in our own results since the initial 
increase may have provided slight protection from the toxic effects of DOX by activating the 
SAFE pathway, whereas the second increase may have contributed to the DOX-induced decrease 
in cell viability.  
Compared to the inflammatory response observed in the H9c2 cardiomyocytes, the response to 
DOX in the C2C12 myotubes was much greater, as evident by the significant increase in TNF-α 
when the high dose of DOX (1 µM) was used, but also after 120 hours of treatment with the low 
dose (0.2 µM). This suggests that the C2C12 myotubes are more sensitive to DOX and thus elicit 
a greater inflammatory response.  However, Cacciapaglia et al., (2014) demonstrated that 0.01 
ng/mL TNF-α could pre-condition cardiomyocytes to high levels of TNF-α, thereby conferring a 
protective effect. Since 0.01 ng/mL (10 pg/mL) was the concentration of TNF-α produced by the 
differentiated C2C12 myotubes in our study, we can speculate that this pre-conditioned and 
hence protected these cells, against increasing levels of TNF-α, until this protective mechanism 
was overcome. It is possible that treatment with DOX initiates cell death, causing the cells to 
produce TNF-α as a protective mechanism. TNF-α then stimulates a host of beneficial signaling 
pathways, however, when the DOX-induced damage becomes too severe, these adaptive 
mechanisms are overcome. Furthermore, it is highly plausible that TNF-α, beyond a certain 
threshold, contributes to the detrimental effects of DOX. 
Stellenbosch University  http://scholar.sun.ac.za
 91 
 
Since the ELISA was employed to measure ‘released’ TNF-α, western blot analysis was 
employed to determine the protein expression of the total TNF-α produced. In both cell lines 
(Figure 4.4 and Figure 4.5), the protein expression of TNF-α was increased significantly at both 
concentrations of DOX in a time- and dose-dependent manner. A significant difference between 
acute and chronic treatment with DOX was also observed, since chronic treatment with 0.2 µM 
(giving a cumulative dose of 1 µM) resulted in significantly more TNF-α production than acute 
treatment with 1 µM. This observation emphasizes the significance of the time factor in the 
development of DOX-induced cardiotoxicity and why it is chronic cardiotoxicity that bares the 
greatest risk.  
In cells, TNF-α is synthesized as a 26 kDa membrane-bound protein from which a 17 kDa 
soluble form is cleaved (Chu, 2013; Hehlgans and Pfeffer, 2005). Both membrane-associated and 
soluble TNF-α exist as biologically active trimeric proteins (Cabal-Hierro and Lazo, 2012), 
though each may exert distinct biological functions (Bradley, 2008). The majority of TNF-α’s 
activities have been attributed to the soluble form, since it is involved in acute and chronic 
inflammation (Richter et al., 2012) and therefore associated with negative effects. In contrast , 
the membrane-bound form exerts distinct beneficial functions such as controlling infection 
(Garcia et al., 2011) and offering protection against inflammation and auto-immunity (Richter et 
al., 2012). Interestingly, TNF-α in DOX-treated H9c2 cardiomyocytes revealed that only the 
soluble form of TNF-α  (17 kDa) was expressed, whereas in C2C12 myotubes it was the 
membrane-bound form (26 kDa) that was expressed. From this evidence it is possible that TNF-α 
signaling may be adding to the negative effects induced by DOX in the H9c2 cardiomyocytes but 
may be providing some form of protection in the C2C12 myotubes, albeit non-effective in the 
presence of DOX. 
Based on the results of the ELISA and the western blots, it is clear that a few discrepancies exist 
between the results of the two techniques. In the H9c2 cardiomyocytes, TNF-α protein 
expression was evident from as early as 24 hours post treatment at both doses and continued to 
increase throughout the treatment period, however, the ELISA showed that TNF-α was only first 
produced after 120 hours at the low dose. Furthermore, while the H9c2 ELISA elicited a biphasic 
response at the high dose of DOX, the results of the western blot indicate a time- and dose-
dependent response. In the C2C12 ELISA, significance was only obtained after 120 hours with 
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the low dose of DOX whereas the high dose gave significance at all time points. In contrast, 
protein expression increased with time at both of the doses in the C2C12 myotubes. The western 
blots of both cell lines therefore give an indication of a greater TNF-α response compared to the 
ELISA, but there are several explanations for this: i) the ELISA was employed to determine the 
amount of TNF-α produced by the cells in response to DOX, however, it is likely that even 
though TNF-α was produced, it was not excreted into the culture medium. The ELISA will then 
only measure what is released into the culture medium if the cell membrane is compromised. 
Western blots make use of whole cell lysates, measuring the total protein content. They therefore 
give a more pronounced response, ii) upon production, TNF-α will be bound by its receptors, 
therefore the ELISA will not measure TNF-α that is membrane-bound even though it was 
produced and iii) ELISAs work on perfectly folded, native proteins while westerns work on 
denatured proteins, therefore if the TNF-α had even slightly denatured during the 120 hours of 
processing, the ELISA would not detect that protein and the results would be underestimated. 
Since TNF-α has a half-life of only 6 – 18 minutes, this is not impossible (Beutler et al., 1985; 
Oliver et al., 1993). Although the results of the ELISA and the western can’t be directly 
compared, they each give an indication of the inflammatory response to DOX, however one is on 
a cellular level and the other is on a protein level. The ELISA provides a more quantitative 
measurement of TNF-α, while the western provides a qualitative image. 
Depending on the cell type and the context in which the TNF-α receptors are activated, TNFR1 
and TNFR2 can trigger both cell death or survival pathways (Cabal-Hierro and Lazo, 2012). 
DOX may therefore induce cardiotoxicity by affecting TNF-α signaling pathways mediated by 
the TNF-α receptors. In H9c2 cardiomyocytes, the protein expression of TNFR1 (Figure 4.6) 
increased in a time- and dose-dependent manner. This supports the argument that TNF-α 
signaling through TNFR1 is detrimental since this time- and dose-dependent increase in receptor 
expression may be associated with the decrease in cell viability and increase in apoptosis 
observed in this cell line. This observation is in agreement with Chiosi et al., (2007) who 
reported a significant increase in TNFR1 expression in H9c2 cardiomyocytes after acute 
treatment with 1 µM DOX. A similar effect was observed in TNFR2 protein expression (Figure 
4.8), however, a decline in protein expression was observed after 120 hours. Expression of 
TNFR1 remained elevated at this point, suggesting that in the most chronic conditions of DOX 
treatment, TNFR1 still exerts its effects. Again, the differences between acute and chronic DOX 
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treatment were evident, since TNFR2 was significantly expressed after 120 hours of treatment 
with 0.2 µM (cumulative dose of 1 µM) but significantly down-regulated after 24 hours with 1 
µM. This suggests that chronic treatment with a low concentration of DOX causes the cells to 
up-regulate signaling through TNFR2 in an attempt to overcome the toxic effects of DOX. 
However, TNFR1 expression remained significantly elevated at both low and high 
concentrations of DOX, suggesting that DOX-induced damage may occur via TNFR1 regardless 
of the concentration or duration of exposure to DOX. 
In differentiated C2C12 myotubes, TNFR1 protein expression (Figure 4.7) was down-regulated 
during most of the treatment regime. This observation supports the presence of membrane-bound 
TNF-α, since a lack of TNFR1 may confer protection in these cells, which would be mediated by 
the membrane TNF-α. However, protein expression of TNFR2 was also down-regulation for the 
majority of the treatment period (Figure 4.9), suggesting that TNF-α may mediate its effects 
independently of its cell surface receptors (Dudich et al., 1999). Further support for our findings 
is provided by Lacerda et al., (2010) who showed that administration of TNF-α to cardiac 
mitochondria obtained from TNFR1 and TNFR2 knock out mice induced several beneficial 
effects on mitochondrial respiratory function. This is possible due to a mitochondrial binding 
protein that traffics TNF-α directly to the mitochondria, by-passing its cell surface receptors 
(Ledgerwood et al., 1998). Whether TNF-α provides an innate defense mechanism against DOX 
or whether it aids in the pathogenesis of cardiotoxicity remains to be elucidated. It is possible 
that TNF-α does exert a beneficial effect until its concentrations become too high or are 
sustained for too long, however, further research is needed to determine when the switch 
between good and bad occurs. 
DOX-induced cytotoxicity and the SAFE pathway 
During ischemia reperfusion the SAFE pathway (Jak2 and STAT3) is triggered via TNF-α as a 
protective mechanism against oxidative stress and apoptosis. Upon ligand binding, Jaks become 
phosphorylated and subsequently catalyze the phosphorylation of tyrosine residues on the 
receptor (Leonard, 2001). This promotes the binding and phosphorylation of STAT proteins, 
which translocate to the nucleus to induce the transcription of target genes (Leonard, 2001). The 
Jak-STAT pathway is therefore a rapid means by which to induce a signal from the membrane to 
the nucleus. Seeing that both Jak2 and STAT3 are found within the heart (Boengler et al., 2008) 
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and TNF-α was produced in this model, this study assessed whether the SAFE pathway is active 
under conditions of cytotoxicity induced by DOX. 
Based on our observations, DOX did trigger the activation of the SAFE pathway, however, 
above a certain concentration of DOX, both Jak2 and STAT3 were significantly down-regulated. 
In H9c2 cardiomyocytes, protein expression of p-Jak2 (Figure 4.10) revealed a time- and dose-
dependent increase after treatment with the low dose of DOX. Similarly, analysis of total Jak2 
revealed a significant increase in total protein as early as 24 hours after treatment with this dose. 
This suggests that the low dose of DOX presented a toxic challenge to which the cells still had 
the ability to adapt to, causing them to increase the protein synthesis of Jak2. One would 
therefore expect the ratio of phosphorylated Jak2 to total Jak2 (phospho/total) to also increase 
over time, since a greater amount of phosphorylation can take place if there is a greater amount 
of Jak2. However, analysis of this ratio revealed significantly less Jak2 phosphorylation during 
the first 72 hours of treatment, where after an increase was observed in the chronic setting. These 
results indicate that the rate of degree of phosphorylation was not greater than the rate of degree 
of protein synthesis during the earlier time points. Although DOX caused the cells to increase 
protein synthesis of Jak2, this additional protein was not phosphorylated. At the high dose of 
DOX, protein expression of p-Jak2 was significantly down-regulated, while the total protein 
remained unchanged. It seems as if chronic administration of a low dose of DOX induces Jak2 
activation, however doses exceeding 1 µM completely stunt this activation. Although this 
observation suggests that the high dose of DOX was too noxious for the cells to adapt, DOX may 
also actively suppress the activation of Jak2 at this concentration. Furthermore, chronic treatment 
with 0.2 µM (cumulative dose of 1 µM) stimulated Jak2 phosphorylation, whereas acute 
treatment with 1 µM down-regulated p-Jak2 expression, highlighting the differences between 
acute and chronic treatment with DOX. 
A similar effect on tyrosine phosphorylation of STAT3 was observed. In a time- and dose-
dependent manner, protein expression of p-STAT3 
Tyr705
 (Figure 4.12A) was significantly 
increased in H9c2 cardiomyocytes treated with 0.2 µM DOX, despite a reduction in p-Jak2 
expression. This may suggest that STAT3 phosphorylation in this context can occur 
independently of Jak2 activation. In addition, cross-talk between the RISK and SAFE pathways 
has been suggested (Somers et al., 2012) and therefore could have accounted for the activation of 
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STAT3, irrespective of Jak2 inactivity. Phosphorylation of STAT3 on serine 727 is not required 
for STAT3 activation but it does enhance transcriptional activity (Kisseleva et al., 2002). We 
observed elevated protein expression of p-STAT3 
Ser727
 (Figure 4.12C) in the H9c2 
cardiomyocytes following treatment with the low dose of DOX, but once again, doses exceeding 
1 µM significantly down-regulated the protein expression of both p- STAT3 
Tyr705 
and p-STAT3 
Ser727
. These findings are in agreement with those obtained by Mitra et al., (2007) who reported a 
decrease in both Jak2 and STAT3 phosphorylation in a rat model of DOX-induced 
cardiotoxicity. More specifically, Jak2 phosphorylation was significantly decreased as early as 
two days post-injection, whereas STAT-3 only declined by day 8. Based on these observations, 
high concentrations of DOX (˃ 1 µM), regardless of exposure time, significantly down-regulate 
the SAFE pathway and may thus be a mechanism by which cardiotoxicity develops. Since the 
SAFE pathway has been shown to promote cell survival, down-regulation of this pathway will 
likely promote cell death. The manner by which this occurs is based on the function of STAT3. 
STAT3 mediates cell survival by promoting the transcription of the anti-apoptotic gene Bcl-2 
and down-regulation of the pro-apoptotic gene Bax (Hattori et al., 2001). Furthermore, the 
function of STAT3 is determined by the intensity and duration of STAT activity, as well as the 
amount of STAT proteins ready to be activated (Kunisada et al., 2000). It is then likely that DOX 
reduces the transcription of STAT3 mRNA which subsequently reduces the amount of STAT3 
protein in a cell. However, in our study, total STAT3 protein expression was not statistically 
different from the control, suggesting that DOX does not affect the STAT3 mRNA in this model 
but rather prevents its phosphorylation or degradation. This appears to be concentration 
dependent, since phosphorylation of STAT3 became significantly reduced as the concentration 
of DOX increased. 
p-Jak2 protein expression in the differentiated C2C12 myotubes was severely down-regulated 
irrespective of the dose, cumulative concentration and duration of treatment (Figure 4.11) and 
thus implies a potent inhibitory effect by DOX on Jak2 activation. Despite the absence of Jak2 
activation, STAT3 was again still phosphorylated, emphasizing a Jak2-independent pathway to 
STAT3 activation. In contrast to what was observed in H9c2 cardiomyocytes, the expression of 
p-STAT3 
Tyr705 
in the C2C12 myotubes
 
was not pronounced at the low concentration of DOX but 
rather significantly elevated at the high concentration (Figure 4.13A). The expression of p-
STAT3 
Ser727
,
 
however, was up-regulated following treatment with low concentrations of DOX 
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but down-regulated when the concentrations increased (Figure 4.13C). These results suggest that 
in this cell line the activation of STAT3, either on the tyrosine or serine residue, is dependent on 
the concentration of DOX or that phosphorylation of these residues functions in a compensatory 
manner so that when one residue is inactive, the other can dominate. 
Interestingly, the expression and phosphorylation of STAT3 was found to be significantly down-
regulated in the myocardium of patients with dilated cardiomyopathy (Podewski, 2003) and may 
therefore contribute to the development of heart failure in these patients (Hilfiker-Kleiner et al., 
2004). Since the end result of DOX-induced cardiotoxicity is also heart failure, down-regulation 
of the SAFE pathway by DOX, as observed in our study, may contribute to the mechanisms by 
which DOX mediates its cardiotoxic effects. In an in vivo  study by Jacoby et al., (2003), a 
cardiac-specific STAT3 knock out model was employed to determine the susceptibility of mice 
to DOX-induced heart failure, however, heart failure was evident even before DOX treatment. 
Treatment with DOX caused a greater decline in cardiac function compared to the wild type 
mice, and this observation was associated with a higher level of apoptosis. This study provides 
insight into the beneficial roles of both Jak2 and STAT3, however, very little is known about this 
pathway in the context of DOX-induced cardiotoxicity. We can speculate that DOX-induced 
down-regulation of the SAFE pathway contributes to cardiomyocyte apoptosis and makes 
cardiomyocytes more susceptible to DOX-induced injury. Therefore, stimulating this pathway 
may potentially promote cell survival during cytotoxicity. Our own work as well as that of others 
highlights the importance and benefit of a functional SAFE pathway during DOX treatment and 
demonstrates that stimulation of this pathway is an avenue worth exploring. 
Weighing out the RISKs: DOX and the Erk1/2 and Akt kinases 
The RISK pathway involves the activation of the pro-survival kinases Erk1/2 and Akt, both of 
which are involved in promoting cell survival by inducing anti-apoptotic pathways (Cross et al., 
2000). It is therefore not surprising that a number of studies have examined the protein 
expression of Erk1/2 and Akt as pro-survival kinases during treatment with DOX, however their 
roles in a chronic model of cardiotoxicity have not been determined.  
In our models of DOX-induced cytotoxicity, the Erk1/2 leg of the RISK pathway was not 
activated in response to DOX treatment (Figure 4.16 and Figure 4.17) since a down-regulation in 
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Erk1/2 phosphorylation, and thus activation, was observed in both cell lines, irrespective of dose 
and exposure time. This finding suggests that DOX-induced Erk1/2 inactivation occurs 
irrespective of cell type. This finding is in agreement with Lou et al., (2005) and Li et al., (2006) 
who reported that Erk1/2 phosphorylation was significantly inhibited in rat and mice models of 
DOX-induced cardiomyopathy, respectively. Since Erk1/2 inhibition enhanced Daunomycin-
induced apoptosis of cardiomyocytes (Zhu et al., 1999), it is possible that the inhibition of 
Erk1/2 phosphorylation by DOX, as observed in our own study, may also account for the 
observed cardiomyocyte death. Activation of the Erk1/2 survival pathway protects cell from 
apoptosis and may therefore be a possible target for DOX during cardiotoxicity. This may also 
occur indirectly through DOX-induced apoptosis, since activated caspase-3 can cleave and 
inactive Raf-1, an upstream activator of Erk1/2 (Widmann, 1998). Hence, an increase in DOX-
induced caspase-3 activation may indirectly inhibit the pro-survival function of Erk1/2 by 
preventing its activation.  
Although Erk1/2 was not activated in response to DOX treatment, Akt phosphorylation was 
evident and possibly implies that this survival kinase compensated for the lack of Erk1/2 
phosphorylation. In the H9c2 cardiomyocytes, significant Akt phosphorylation (Figure 4.14) 
occurred during acute (24 and 48 hours) and sub-chronic (72 hours) exposure to the low 
concentration of DOX (0.2 µM). As the exposure to DOX became longer and the concentration 
became higher, Akt phosphorylation was significantly down-regulated. These findings are 
consistent with those of Das et al., (2011) who reported significantly down-regulated Akt 
phosphorylation in cardiomyocytes exposed to 1 µM DOX for 24 hours. Similarly, we observed 
that Akt activation was significantly up-regulated following treatment with low concentrations of 
DOX in the C2C12 myotubes (Figure 4.15), but remained unchanged compared to the control at 
the higher concentrations of DOX. These observations were based on the ratio of phosphorylated 
Akt to total Akt, since DOX treatment also caused significant changes in total protein expression. 
In the presence of low concentrations of DOX, total Akt expression was significantly reduced, 
whereas in the presence of high concentrations of DOX, total Akt expression was elevated. 
These findings suggest that the initial exposure to DOX induced a potent increase in Akt 
phosphorylation in an attempt to overcome the toxic effects of DOX. However, when the 
concentrations of DOX became too high, phosphorylation did not occur despite an increase in 
total protein levels. These observations can be explained by the fact that the inactivation/de-
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phosphorylation of Akt is regulated by Serine/Threonine protein phosphatases, PP1 and PP2 
(Andreozzi et al., 2011) and Fan et al., (2008) have reported that DOX significantly up-regulates 
protein phosphatase PP1. As a result, after chronic exposure to high concentrations of DOX, 
cells are unable to maintain the phosphorylated state of Akt due to an increase in DOX-induced 
PP1 expression, thus rendering Akt inactive (Andreozzi et al., 2011). Phosphorylated Akt is 
usually responsible for phosphorylating and inhibiting Bad (Downward, 2004) and in this 
manner prevents caspase-3 activation (Li et al., 2013). Therefore, DOX-induced inhibition of 
Akt phosphorylation likely contributed to the increased apoptosis by preventing Akt 
activation/phosphorylation. DOX thus mediates cardiotoxicity by preserving the pro-apoptotic 
function of Bad and induces cardiomyocyte apoptosis by increasing caspase activity. An 
interesting finding was reported by Hausenloy et al., (2004), who suggested that cross-talk exists 
between the two legs of the RISK (Erk1/2 and Akt) pathway. It was shown that when Erk1/2 
activity was inhibited, Akt phosphorylation was increased, and vice versa. This study therefore 
concluded that although Akt was found to be the dominant kinase in promoting cell survival, 
activation of both kinases is required to provide protection during ischemic post conditioning. 
This too is consistent with our results, since the lack of Erk1/2 activation was accompanied by an 
increase in p-Akt expression at the low concentration of DOX. However, activation of Akt, 
without the activation of Erk1/2, was not sufficient to protect the cells from the toxic effects of 
DOX. 
Our study therefore demonstrates that treatment with DOX significantly affects cell survival at 
least in part by down-regulating the pro-survival kinases of the RISK pathway during chronic 
cytotoxicity. While our own findings demonstrated a reduction in both Erk1/2 and Akt 
activation, Gharanei et al., (2013) reported a significant increase in both kinases after treatment 
with 1 µM DOX for 120 minutes in an isolated heart model. Considering the short treatment 
duration, it is possible that Erk1/2 and Akt are increased as an early protective mechanism to 
counteract the damaging effects of DOX. Although relatively few changes were observed in the 
acute setting of our models, distinct changes were observed chronically, emphasizing the severity 
of chronic cardiotoxicity in contrast to acute cardiotoxicity. This study has thus demonstrated 
that Erk1/2 and Akt may be increased as an early survival strategy against DOX, but chronic 
exposure to increasing concentrations of DOX inhibits these pathways. When the toxic effects of 
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DOX become severe, neither Erk1/2 nor Akt can rescue the dying cells, as evident by the dose-
dependent decrease in cell viability. 
Oxidative stress, anti-oxidant capacity and anti-oxidant status 
Despite the years of research, the mechanisms by which DOX induces cardiotoxicity are still not 
well defined, however, undoubtable evidence points towards oxidative stress (Choi et al., 2007; 
Das et al., 2011; Fan et al., 2008; Šimùnek et al., 2009). The chemical structure of DOX lends 
itself to the production of free radicals in a process known as redox cycling (Keizer et al., 1990). 
Superoxide radicals produced in this process can damage cell components wherever they are 
formed (Benchekroun et al., 1993), including the heart. This is of particular importance seeing 
that the heart has a high level of oxidative metabolism, but limited antioxidant defenses 
compared to other organs (Choi et al., 2007; Doroshow et al., 1980). It has been previously 
shown that superoxide radicals can decompose to form hydroxyl radicals, peroxyl radicals and 
hydrogen peroxides (Olson et al., 1981). These in turn are able to convert membrane unsaturated 
fatty acids into lipid peroxides.  
Lipid peroxides decompose into products such as MDA, which can therefore be used as an 
indicator of the level of lipid peroxidation taking place (Rautenbach et al., 2010). The heart is so 
susceptible to DOX-induced damage because several enzymatic reactions necessary for 
regulating redox state are inhibited. GSH-Px1 is an important enzyme for protecting cells against 
oxidative damage because it assists in the detoxification process. Studies have shown that when 
GSH is depleted, cells are more susceptible to oxidative-stress induced damage. Enhanced lipid 
peroxidation occurs in the heart if the activity of GSH-Px1 is reduced (Simmons and Jamall, 
1989; Siveski-Iliskovic et al., 1994). GSH is one of the most important components of a cells 
antioxidant defense (Jones, 2002; Monostori et al., 2009) and is directly involved in the 
scavenging of ROS and maintenance of thiol proteins in their reduced state (Hampton and 
Orrenius, 1998). It is often used as an indicator of oxidative stress since the amount of GSH will 
decrease as it scavenges ROS, resulting in an increase in GSSG. GSH is oxidized to GSSG 
during the detoxification of ROS in the presence of GSH-Px1 and regenerated back to GSH by 
glutathione reductase (Monostori et al., 2009). Since it is well established that ROS plays a 
causative role in numerous human pathologies, the idea that antioxidants could control the state 
of oxidative stress in various organisms is credible line of defense. Since so many antioxidants 
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exist and it is difficult to measure each one of its own, a useful technique called ORAC was 
developed. This method measures the oxygen-radical absorbing capacity of a sample and 
compares it to a known standard (Cao et al., 1993). 
In the H9c2 cardiomyocytes, lipid peroxidation was not observed during the first 72 hours of 
treatment with the low concentration (0.2 µM) of DOX (Figure 4.18), however, a significant 
increase in MDA was evident after chronic treatment. A significant increase in lipid peroxidation 
was also observed after 72 and 96 hours of treatment with the high dose (1 µM) of DOX. 
Chronic treatment with 0.2 µM also resulted in significantly more lipid peroxidation compared to 
acute treatment with 1 µM, emphasizing how chronic cardiotoxicity is associated with more 
detrimental effects than acute cardiotoxicity. The increase in lipid peroxidation in this study was 
accompanied by a parallel increase in the ORAC value (Figure 4.20) at these times, suggesting 
that H9c2 cardiomyocytes increased their antioxidant capacity in response to high doses of DOX. 
However, treatment with DOX also significantly reduced the ratio of GSH to GSSG (Figure 
4.22), indicating the limited antioxidant defense of these cells against the increasing oxidative 
stress as indicated through lipid peroxidation. In a chronic rat model of DOX-induced 
cardiotoxicity, Zanwar et al., (2013) also reported a significant reduction in cardiac GSH content 
following DOX treatment. Together, the combination of severe oxidative stress and poor 
antioxidant defense most likely contributed to the reduction in cell viability and significant levels 
of apoptosis in the cardiomyocytes.  
As observed in the differentiated C2C12 myotubes, MDA increased almost 4-fold throughout the 
entire treatment period when compared to the control (Figure 4.19), suggesting that a larger 
degree of membrane damage occurred in these cells. The highest level of lipid peroxidation 
occurred during the first 48 hours of treatment with the low dose of DOX and this correlated 
with a significant increase in antioxidant capacity (Figure 4.21) at this time. This suggests that 
the myotubes initially increased their antioxidant defense systems to prevent the oxidation of 
cellular components, however, beyond 48 hours of treatment, as the dose of DOX accumulated, 
the antioxidant capacity was significantly reduced, leading to severe lipid peroxidation. Work by 
Jiang et al., (2008) supports these observations, since they observed a significantly reduced anti-
oxidant capacity in DOX-treated mouse hearts, together with a significant increase in MDA. 
Similarly, Alkreathy et al., (2010) observed a 12-fold increase in plasma MDA of rats treated 
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with a single dose (25 mg/kg) DOX. It has also been well documented that oxidative stress 
activates MAPKs such as Erk1/2 and Akt (Lou et al., 2005). This observation is in agreement 
with our own findings, since the significant increase in oxidative stress caused a parallel increase 
in p-Akt expression, suggesting that oxidative stress within a cell activates this pro-survival 
kinase. In C2C12 myotubes, the ratio of GSH to GSSG was significantly reduced (Figure 4.23), 
therefore explaining the poor antioxidant capacity of these cells. However, loss of GSH can be 
influenced by differentiation and apoptosis (Jones, 2002) and thus in this context, both of these 
events would have contributed to the decreased ratio. Depletion of GSH following DOX 
treatment indicates a loss of antioxidant defense in these cells, and as a result, reduced cell 
viability occurred. 
Our results, together with many others, highlight the contribution of oxidative stress to the 
development of DOX-induced cardiotoxicity. Furthermore, our findings emphasize how DOX 
weakens the ability of antioxidant defense systems to scavenge free radicals, thereby leading to 
cell death. A reduction in antioxidant defense, combined with ROS-induced lipid peroxidation 
and a decrease in GSH, are certain to ensure an apoptotic fate in both cell types. Our results also 
highlight the different responses of these two cell lines to DOX, since C2C12 myotubes 
increased their antioxidant capacity immediately after DOX exposure, whereas H9c2 
cardiomyocytes only increased their antioxidant capacity when lipid peroxidation became severe. 
However, the reduced ratio of GSH in both cell lines suggests that some of the toxic effects of 
DOX will occur regardless of the cell type. However, whether the depletion of antioxidant 
defense systems is a cause or consequence of DOX-induced cardiotoxicity remains to be 
elucidated. Our results have clearly indicated a correlation between lipid peroxidation, a 
reduction in antioxidant capacity and a significant increase in apoptosis. DOX-induced 
cytotoxicity is associated with ROS-induced membrane damage, an antioxidant deficit and a 
compromised antioxidant capacity. The combination of these mechanisms further explains how 
DOX may induce cardiomyocyte death in human patients and thus contribute to the development 
of heart failure. 
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CHAPTER 6 
Conclusion 
DOX is an anthracycline that has been shown to exhibit a greater therapeutic index than any 
other before it. Since its discovery in the 1960s, DOX has drastically improved the outcome of 
patients, both adults and children, suffering from several different malignancies. The efficacy of 
DOX is however limited by the development of severe dose-dependent cardiotoxicity which 
often presents itself years after treatment has ended. As a result, it is chronic cardiotoxicity that 
poses the most serious risk to cancer survivors. While the mechanisms by which DOX mediates 
cardiotoxicity are still under debate, apoptosis and oxidative stress are two that are generally 
agreed upon. An increase in ROS causes damage to DNA, cell membranes and mitochondria, all 
of which will culminate in apoptotic cell death. Similarly, during reperfusion, restoring blood 
flow to an ischemic heart also induces oxidative stress and cell death by apoptosis, which 
together, cause significant myocardial injury. Fortunately, pre- and post-conditioning have been 
shown to reduce reperfusion-related injury by activating the SAFE and RISK pathways. In 
addition, low levels of TNF-α produced by the heart during early reperfusion are thought to be 
responsible for the activation of the SAFE pathway. Based on the above similarities between 
DOX-induced cardiotoxicity and ischemia reperfusion injury, we hypothesized that the SAFE 
and RISK pathways would be stimulated as a protective mechanism during chronic DOX-
induced cytotoxicity, via TNF-α. 
We have confirmed the presence of a time- and dose-dependent relationship between the 
concentration of DOX and a decrease in cell viability in two different cell lines. Treatment with 
DOX was accompanied by an increase in both TNF-α and ROS production, both of which may 
have contributed to cell death. Binding of TNF-α to the death domain of TNFR1 would activate 
the extrinsic apoptotic pathway, while increased ROS would result in cytochrome c release from 
the mitochondria and subsequently activate the intrinsic apoptotic pathway. Both pathways 
converge on caspase-3 which, as also observed in this study, is cleaved in response to DNA 
damaging stimuli. The existence of DOX-induced apoptotic cell death was confirmed in both 
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differentiated C2C12 myotubes and H9c2 cardiomyocytes, while necrosis was only found to play 
a role in cell death in the chronic setting in the C2C12 myotubes. 
A unifying summary of our findings is depicted in Figure 6.1 This study showed that treatment 
with DOX stimulates the production of TNF-α. While mild levels of TNF-α may initially be 
produced as a protective mechanism against DOX by activating the SAFE pathway, high levels 
most likely contribute to DOX-induced cell death. Further research is required to determine 
whether TNF-α is in fact beneficial in this context or whether it adds to the cardiotoxic effect of 
DOX. Furthermore, the exact concentration at which this effect occurs remains to be elucidated. 
Our study demonstrated that both TNF receptors were up-regulated in a time- and dose-
dependent manner in the H9c2 cardiomyocytes, however, their contribution to an adaptive or a 
negative response remains undetermined. TNFR1 and TNFR2 were mostly down-regulated in 
the C2C12 myotubes, suggesting that TNF-α can function independently of its receptors in this 
cell line.  
It is well documented that both DOX and TNF-α can increase ROS production and this 
observation may explain the significant lipid peroxidation and reduced ratio of GSH: GSSG that 
was observed in this study. Our study also demonstrated a reduced antioxidant capacity in both 
cell lines and these observations are in agreement with those in the clinical setting. While small 
amounts of ROS would have activated the RISK pathway, a level of ROS above a certain 
threshold would have triggered the opening of the mitochondrial permeability transition pore and 
sealed the apoptotic fate of both cell lines. Together, the increased oxidative stress and cell death 
observed in our study support the two most widely accepted mechanisms of DOX-induced 
cardiotoxicity. 
The activation of the SAFE and RISK pathways were also observed in our study, however, this 
was only observed at low concentrations of DOX. The dose-dependent increase in TNF-α may 
have activated Jak2 at the low concentrations of DOX in the H9c2 cardiomyocytes. 
Consequently, activated Jak2 then phosphorylated STAT3, as evident in our study. At high 
concentrations of DOX, however, p-Jak2 and both p-STAT3 residues were significantly down-
regulated. Although Erk1/2 was not activated in this cell line, p-Akt was activated after acute 
exposure to low concentrations of DOX. The RISK pathway, like the SAFE pathway, was then 
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down-regulated at high concentrations of DOX and thus identifies a potential mechanism by 
which DOX mediates cardiotoxicity. Phosphorylation of STAT3 on the tyrosine residue in the 
differentiated C2C12 myotubes was expressed at high concentrations of DOX, while 
phosphorylation on the serine residue was down-regulated at high concentrations but increased at 
low concentrations, suggesting that phosphorylation of these residues occurs in a compensatory 
manner. These observations occurred despite the absence of Jak2 phosphorylation suggesting 
that TNF-α can activate STAT3 independently of Jak2 and the TNF receptors. The Erk1/2 leg of 
the RISK pathway was again not activated during DOX treatment in this cell line, while p-Akt 
was only evident at low concentrations.  
 
Figure 6.1: DOX and the RISK and SAFE pathways. This unifying diagram illustrates the activation of 
the SAFE and RISK pathways at low concentrations of DOX but down-regulation of these pathways after 
exposure to high concentrations of DOX. The low dose of DOX caused a mild increase in TNF-α which 
possibly provided protection by activating the SAFE pathway. High concentrations of DOX caused a 
larger increase in TNF-α, which, together with an increase in lipid peroxidation, may have then 
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contributed to the decrease in cell viability. High concentrations of DOX also prevent the activation of the 
SAFE and RISK pathways. 
Although DOX-induced cardiotoxicity is believed to be mediated by large amounts of ROS, 
several studies making use of free radical scavengers have generated poor results. This suggests 
that the development of cardiotoxicity is mediated by alternative mechanisms. Therefore, since 
the SAFE and RISK pathways were shown to be down-regulated during cytotoxicity in this 
study, it is possible that inhibition of these pathways by DOX is another mechanism by which it 
mediates its cardiotoxic effects. Although the SAFE or RISK pathways were transiently 
activated, this activation did not provide sufficient protection due to the fact that activation of 
both pathways simultaneously, is required for full protection. Further studies are required to 
determine the exact roles of the SAFE and RISK pathways, as well as TNF-α, using their 
respective specific inhibitors. In this way, the intracellular signaling pathways associated with 
protection will be brought to light. Furthermore, inhibition of each pathway will provide insight 
into possible cross talk since these two cascades act in concert to promote maximal protection. 
Inhibiting the TNF-α/Jak2/ STAT-3 pathway affects the activation of the PI3K/Akt and vice 
versa. We believe that inhibition of these pathways by DOX may contribute to its cardiotoxic 
effects. Since our study is a simulation of cumulative, dose-dependent cardiotoxicity, we have 
provided a potential mechanism of action for DOX-induced cardiotoxicity, as well as a 
therapeutic target to explore by which to improve the viability of cardiomyocytes. 
To the best of our knowledge, this study is the first to design an in vitro model of chronic DOX-
induced cardiotoxicity. This study also employed two different cell lines in order to assess the 
appropriateness of each model. By treating cells daily, as opposed to once, with increasing 
concentrations of DOX for 120 hours, we have successfully designed a model that simulates the 
cardiotoxic effects of this anthracycline in the clinical setting. While the exact mechanisms of 
cardiotoxicity that occur in a clinical setting will always differ from in vivo or in vitro models, 
this study was able to document the significant apoptosis and oxidative stress that has been 
observed in human patients. The fact that this study made use of a range of clinically relevant 
concentrations of DOX and a chronic treatment, highlights the uniqueness and novelty of this 
model, since we have identified potential mechanisms that may occur in a clinical setting. One of 
the limitations of this study is the fact that two different methods for measuring apoptosis should 
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have been used, however, due to the fact that DOX is the same colour as a PI stain, this was not 
possible. Another limitation is the choice of cell type used in this study, as primary cardiac cells 
would have been a better representation of the cardiotoxic side effects of DOX in human hearts, 
however, due to the chronic nature of this study, we do not believe that primary cardiac cells 
would have survived the 120 hour treatment regime. In addition, it would not have been feasible 
(considering the principle of reduce, replace and refine) as too many animals would have been 
needed in order to obtain enough cells. 
Our study has validated that TNF-α is produced in response to DOX, but it is still unknown 
whether TNF-α exerts beneficial or detrimental effects. Therefore, future studies should aim at 
delineating the role of TNF-α in the context of DOX-induced cardiotoxicity. This could be 
achieved using inhibitors of TNF-α, TNF-α knock out mice and treatment with different 
concentrations of TNF-α both in the presence and absence of DOX. Similarly, the protection 
offered by the SAFE and RISK pathways can be further explored by employing specific 
inhibitors of each pathway and assessing cell viability and cell death markers after treatment with 
DOX. An avenue that is definitely worth exploring would be to stimulate the SAFE and RISK 
pathways in order to determine whether additional protection is afforded. Once the roles of TNF-
α, and the SAFE and RISK pathways have been validated, the study should be repeated in an 
animal model to determine whether their roles are also applicable in vivo. This will identify 
whether these pathways may provide protection during DOX-induced cardiotoxicity in a clinical 
setting. 
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APPENDICES 
Appendix A 
Supplementary Results 
TNFR2 protein expression (H9c2 cardiomyocytes) 
Figures A1 - 3 depict the three independent experiments of TNFR2 protein expression using 
three different samples (n1, n2, n3). The same pattern was observed – protein expression was 
significantly down-regulated after 48 hours. 
 
 
 
Figure A1, 2 and 3: Representative blots of each independent experiment to indicate the same 
phenomenon in TNFR2 expression after 48 hours of treatment in H9c2 cardiomyocytes.
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The SAFE pathway (Total Jak2 in differentiated C2C12 myotubes) 
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Figure A4: Analysis of protein expression of T-Jak2 in differentiated C2C12 cells treated with DOX. 
The lane profile analysis is presented. The fold change relative to the control was calculated. All values 
are presented as mean ± SEM, arbitrary units (AU), n = 3, *p< 0.05, **p< 0.01, ***p< 0.001. Ponceau was 
used to correct for loading discrepancies. 
The SAFE pathway (total-STAT3 in H9c2 cardiomyocytes) 
0.2 1.0
0
1
2
3
4
Control
24 hours
48 hours
72 hours
96 hours
120 hours
DOX Concentration (M)
T
-S
T
A
T
3
 f
o
ld
 c
h
a
n
g
e
 r
e
la
ti
v
e
 t
o
 t
h
e
 c
o
n
tr
o
l 
(A
U
)
 
Figure A5: The analysis of protein expression of total-STAT3 in H9c2 cells. The lane profile analysis 
is represented. The fold change relative to the control was calculated. All values are presented as mean ± 
SEM, arbitrary units (AU), n = 3, *p< 0.05, **p< 0.01, ***p< 0.001. GAPDH was used to correct for any 
loading discrepancies. 
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The SAFE pathway (total STAT3 in differentiated C2C12 myotubes) 
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Figure A6: Analysis of protein expression of T-STAT3 in differentiated C2C12 cells treated with 
DOX. The lane profile analysis is represented. The fold change relative to the control was calculated. All 
values are presented as mean ± SEM, arbitrary units (AU), n = 3, *p< 0.05, **p< 0.01, ***p< 0.001. 
Ponceau was used as a loading control. 
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Figure A7: Protein expression of T-Akt in H9c2 cells in response to treatment with DOX. The lane 
profile analysis is presented. The fold change relative to the control was calculated. All values are 
presented as mean ± SEM, arbitrary units (AU), n = 3, *p< 0.05, **p< 0.01, ***p< 0.001. T-Akt, total-Akt. 
GAPDH was used to correct for any loading discrepancies. 
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The RISK pathway (total Erk1/2 expression in H9c2 cardiomyocytes) 
0.2 1.0
0.0
0.5
1.0
1.5
2.0
Control
24 hours
48 hours
72 hours
96 hours
120 hours
DOX Concentration (M)
T
-E
rk
1
/2
 f
o
ld
 c
h
a
n
g
e
 r
e
la
ti
v
e
 t
o
 t
h
e
 c
o
n
tr
o
l 
(A
U
)
 
Figure A8: Protein expression of T-Erk1/2 in H9c2 cells in response to treatment with DOX. The 
lane profile analysis is presented. The fold change relative to the control was calculated. All values are 
presented as mean ± SEM, arbitrary units (AU), n = 3, *p< 0.05, **p< 0.01, ***p< 0.001. T-Erk1/2, total-
Erk1/2. GAPDH was used to correct any loading discrepancies. 
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Figure A9: Protein expression of T-Erk1/2 in C2C12 myotubes in response to treatment with DOX. 
The lane profile analysis is presented. The fold change relative to the control was calculated. All values 
are presented as mean ± SEM, arbitrary units (AU), n = 3, *p< 0.05, **p< 0.01, ***p< 0.001. T-Erk1/2, 
total-Erk1/2. A Ponceau stain was used to correct any loading discrepancies. 
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Ponceau images in their entirety from C2C12 western blots 
 
A10 A11Gel 1 Gel 2
A12 A13Gel 3 Gel 4
A14 A15Gel 5 Gel 6
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Figures A10 – A20: Ponceau stains of the membranes used in the western blotting of C2C12 myotubes. 
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Appendix B 
Protocols 
Protocol 1: Cell culture 
 Before starting cell culture, hands must be washed, gloved and washed again. Hands must 
be sprayed with 70% ethanol each time before putting them inside the laminar flow to 
ensure a sterile environment. 
 Laminar flow hoods must be sprayed down with 70% ethanol, and all beakers, test tube 
racks, reagents and consumables must also be sprayed. 
Cracking a vile: 
 Remove a vile of cells from the liquid nitrogen tank and thaw at 37 °C. 
 Add 6 mL growth medium into a T25 flask 
 Transfer the contents of the cryovile into the T25 flask 
 Grow cells at 37 °C and 5% CO2 until 70% confluent. 
Maintaining cells: 
 Remove flask of cells from the incubator and examine under a microscope for signs of 
infection. 
 Sub-culture cells upon reaching 70 – 80% confluence or seed at appropriate densities for 
experiments. 
 Discard old culture medium and gently wash cell monolayer with warm, sterile PBS to 
remove any remaining medium. 
 Loosen cells from the surface of the flask using 4 mL of trypsin. 
 Place the flask in a shaking incubator for 2-3 minutes at 37ºC. Check to see if cells have 
loosened under a microscope. If they have not loosened, tap the bottom of the flask 
gently to help the process 
 Once all the cells are loosened, add warm growth medium (double the amount of trypsin) 
to neutralize the trypsin 
 Transfer the cell/trypsin/medium mixture to a sterile 15 mL falcon tube and centrifuge at 
1500 rpm for 3 minutes. 
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 Discard the supernatant and re-suspend the pellet in 4 mL of fresh medium. 
 Count cells by pipetting 20 uL of the cell suspension into each chamber of a 
haemocytometer (protocol 2) 
 Establish the total cell number using a simple calculation (below), where after the desired 
number of cells can be seeded into new culture flasks or plates, depending on the 
experiment. 
Protocol 2: Counting cells using a haemocytometer 
 Before use, the haemocytometer must wiped down with 70% ethanol 
 Briefly breathe on the haemocytometer in order to create a moist surface for the cover 
slip to adhere to. 
 Pipette 20 μl of the re-suspended cells into each chamber of the haemocytometer, under 
the cover slip. Be cautious to avoid air bubbles. 
 Count the total number of cells by counting blocks 1 to 3 on both sides of the counting 
chamber (below). Calculate the average number of cells per block (cells/1 µL). 
 Multiply the average by 10 000 to obtain the number of cells per milliliter of the original 
cell suspension 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B1: haemocytometer counting chamber. Adapted from: www.phe-culturecollections.org.uk 
1 
2 
3 
1 µL 
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Table indicating seeding densities and culture dish for each experiment 
Protocol 3: Cell Freezing 
 Use cells that are approximately 80% confluent 
 Discard the old medium and rinse the cell monolayer with sterile PBS 
 Discard PBS and add 4 mL trypsin (T75) – place into a shaking incubator for 3 minutes 
 Add double the amount of warm medium (8 mL) and transfer the cell suspension to a 
falcon tube 
 Centrifuge at 1500 rpm for 3 minutes 
 Carefully discard the supernatant, leaving just the pellet. 
 Re-suspend the pellet in FBS at a concentration of 1 – 2 million cells per mL. 
 Make up freezing medium (1% DMSO in 1 mL FBS) and add the cells to a cryovile 
 Store cryoviles in -80 °C overnight and transfer to liquid nitrogen the next day. 
Protocol 4: Cell Harvesting 
 Discard the old medium and rinse the cell monolayer three times with cold PBS 
 Add 50 μl of RIPA buffer (appendix B) to each well of a 6-well plate, on ice. 
 Swirl the plate/flask to ensure the whole surface is covered by the RIPA buffer 
 Scrape the cells from the surface using a sterile cell scraper 
 Transfer the cells to chilled Eppendorf tubes on ice 
 The lysates can be stored at -80°C until needed, but no longer than 3 months. 
Experiment Culture Plate Seeding density 
MTT Assay 24-well 50 000/well 
Caspase Glo 96-well 20 000 
LDH 96-well 20 000 
TBARS Assay 6-well 70 000 
ORAC Assay 6-well 70 000 
Western Blotting 6-well 100 000 
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Protocol 5: MTT assay 
Preparation of solutions 
1% Isopropanol = 1ml Concentrated HCL added to 99ml Isopropanol 
0.1 % Triton = 0.1ml Triton-X-100 in 99 ml distilled water 
Isopropanol/ Triton solution (50:1) = 50ml of 1% Isopropanol added to 1mL 0.1% Triton 
0.01g MTT/1ml PBS made fresh before use – cover in foil to protect from light, then filter. 
 Discard old medium 
 Add 1.5ml PBS and 500μl MTT solution to each well. 
 Cover the plate in foil and place in the incubator for 2 hours 
 Discard the MTT and add 500 µL isopropanol/Triton solution to each well. 
 Shake the plates on a belly dancer for 5 minutes to dissolve purple crystals. 
 Read the plate at 595 nm. 
Protocol 6: Caspase Glo (Promega Caspase Glo ® 3/7 Assay) 
 Equilibrate the Caspase Glo® 3/7 buffer and substrate to room temperature before use 
 Transfer the buffer into the bottle of substrate (brown) to form the caspase glo reagent. 
 Mix until thoroughly dissolved, by inverting. 
 Equilibrate the 96-well culture plates containing cells to room temperature 
 Pipette 100 µL reagent into each well containing 100 µL sample 
 Cover the plate with a lid and gently mix on a shaker at 300 – 500 rpm for 30 seconds 
 Incubate at room temperature for 1 hour 
 Measure the luminescence in a plate-reading luminometer. 
Protocol 7: LDH (Promega CytoTox 96® Non-Radioactive Cytotoxicity Assay) 
5 vials substrate mix 
60 mL assay buffer 
25 µL LDH Positive Control 
5 mL lysis solution (10X) 
65 mL Stop solution 
 Equilibrate 12 ml of the assay buffer to room temperature 
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 Prepare an LDH positive control by diluting 2 µl of the Positive Control in 10 mL 
PBS and 1% BSA (1: 5000) 
 Add 50 µl of the LDH positive control to 3 wells that contain no cells 
 Add 5 µl lysis solution to each well containing 50 µl medium 
 Incubate for 45 minutes in a shaker at 37 °C with 5% CO2 
 Add the 12 ml of assay buffer to the bottle of substrate mix (protect from light) 
 Invert gently 
 Add 50 µl of the substrate mix to each well, cover plate with foil and incubate at 
room temperature for 30 minutes 
 Add 50 µl Stop solution to each well 
 Pop any large bubbles with a needle 
 Read the absorbance at 490 nm. 
Protocol 8: ELISA (R&D Systems Quantikine
®
 rat and mouse TNF alpha ELISA kits) 
Contents supplied in the kit (store unopened at 4 °C): 
2 x TNF-α antibody-coated 96-well plates 
3 x vials of TNF-α standard 
3 x vials of TNF-α control 
1 x vial of TNF- α conjugate 
1 x vial of assay diluent 
2 x vials of calibrator diluent 
2 x vials of wash buffer concentrate 
1 x vial of colour reagent A 
1 x vial of colour reagent B 
1 x vial of Stop Solution 
8 x plate sealers 
Contents to be supplied by user: 
Microplate reader capable of measuring absorbance at 450 nm (correction wavelength of 540 
nm). 
Polypropylene tubes for preparing standards and samples 
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Sample collection, storage and preparation: 
Remove any particulates by centrifugation. 
Assay immediately or store at -80 °C (avoid freeze-thaw cycles) 
For the assay, dilute samples for the rat ELISA 3-fold in calibrator diluent (e.g. 50 µL sample in 
150 µL diluent). 
Bring all reagents to room temperature before use 
TNF-α Control: reconstitute in 1 mL of distilled water. 
Wash buffer: add 20 mL of wash buffer concentrate to 480 mL distilled water. 
Substrate solution: Mix A and B together in equal volumes just before use. Protect from light. 
*Rat TNF-α standard: reconstitute in 2 mL calibrator diluent = 800 pg/mL. Allow it to sit for 5 
minutes with gentle mixing. 
**Mouse TNF-α standard: reconstitute with 1 mL distilled water = 7000 pg/mL. 
Dilution of standards: Use polypropylene tubes. 
*Pipette 200 µL calibrator diluent into each tube, then perform the dilution series indicated 
below 
 
 
  
 
 
 
 
*The undiluted standard (800 pg/mL) serves as the high standard and the calibrator diluent 
serves as the zero standard. 
Figure B2: 
Rat TNF-α standards 
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**Pipette 900 µL calibrator diluent into the tube for the 700 pg/mL tube. Pipette 200 µL of 
calibrator diluent into the remaining tubes. Prepare the standards as indicated above. The 700 
pg/mL serves as the high standard and the diluent serves as the zero standard. 
Procedure 
1. Prepare all reagents, standards, control and samples as described above 
2. Remove a microplate from the foil pouch 
3. Add 50 µL assay diluent to each well 
4. Add 50 µL standard/control/sample in duplicate to each well. Mix by gentle tapping for 1 
minute 
5. Cover with an adhesive strip and incubate for 2 hours at room temperature 
6. Aspirate each well and wash with wash buffer (400 µL). Repeat four times. 
7. Add 100 µL TNF-α conjugate to each well. 
8. Cover with a new strip and incubate for 2 hours at room temperature 
9. Wash again as in step 6. 
10. Add 100 µL substrate solution (A+B) to each well. Incubate for 30 minutes at room 
temperature (protect from light!) 
11. Add 100 µL stop solution. Tap gently to ensure mixing. 
12. Read plate at 450 nm with a correction wavelength of 540 nm. 
13. Average the duplicate readings for each standard and sample and subtract the average 
zero optical density 
14. Create a standard curve by plotting the mean absorbance for each standard against the 
concentration. 
15. Multiply by the dilution factor. 
Figure B3: 
Mouse TNF-α standards 
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Protocol 9: ORAC (Oxygen Radical Antioxidant Capacity) Assay 
Black 96-well plate 
**Note: do not use the first two columns and the last column of the plate – inaccurate read 
Switch on the plate reader and the Fluoroskan program 30 minutes before read 
 Grow and treat cells in 6-well plates. 
 Wash cells 3 x with cold PBS 
 Add 75 µL PBS to each well and scrape off cells using a cell scraper 
 Lyse cells using sonication for 15 seconds 
 Centrifuge for 10 minutes at 10 000 x g at 4 °C 
 Store the supernatant for future use 
Phosphate buffer 75 mM, pH 7.4: 
Weigh 1.035g sodium di-hydrogen orthophosphate-1-hydrate in 100 mL ddH2O and mix until 
dissolved (solution 1). 
Weigh 1.335g di-sodium hydrogen orthophosphate dehydrate (Merck #5822880EM) in 100 mL 
ddH2O and mix until dissolved (solution 2). 
Mix 18 mL of 1
st
 solution with 82 mL 2
nd
 solution 
Check pH – adjust with phosphate buffer 
Store at 4 °C 
Fluorescein Stock: Sigma #F6377 
Dissolve 0.0225g in 50 mL phosphate buffer (above) 
Store at 4 °C in a brown bottle (reused for 1 year) 
Fluorescein Working Solution: 
Take 10 µL of the stock and add it to 2 mL phosphate buffer (epi) 
Then take 240 µL of this and dilute in 15 mL phosphate buffer (15 mL falcon) 
Peroxyl radical: Sigma #440914 25 mg/mL 
Weigh 150 mg of AAPH into a 15 mL falcon tube 
Only add solute later on 
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Trolox (standard): 250 µM stock Sigma # 238831 
Weigh 0.00312 g and add 50 mL phosphate buffer 
Mix until dissolved 
Should give an absorbance of 0.670 at 289nm 
Procedure: 
Spin down samples – they must not be turbid 
Add 6 mL phosphate buffer to the AAPH weighed earlier, mix well. 
Put in water bath at 37 °C 
Label 6 epi’s A – F 
Prepare standards as follows: 
 Concentration 
(uM) 
Trolox stock 
(uL) 
Phosphate buffer 
(uL) 
Well 
A 0 0 750 A1-3 
B 83 125 625 A4-6 
C 167 250 500 A7-9 
D 250 375 375 A10-12 
E 333 500 250 B1-3 
F 417 625 125 B4-6 
 
 Add 12 µL standards to each well 
 Add 12 µL of controls per well 
 Add 12 µL of samples per well in triplicate 
 Add 138 µL of fluorescein working solution to each well using a multichannel 
 Add 50 µL of the AAPH solution to each well using a multichannel (AT the plate reader) 
 Put the plate into the plate reader 
 Read for 2 hours 
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Protocol 10: TBARS Assay (Thiobarbituric Acid Reactive Substances) 
 Grow and treat cells in 6-well plates 
 Harvest cells in PBS 
 Sonicate the cells on ice and store the whole homogenate for use in the assay 
 
Set waterbath to 90/100 °C at 80% water capacity 
Use 2 mL epi’s and punch holes in their lids 
 
 Put 50 µL of sample into an epi. 
 Add 6.25 µL of BHT dissolved in 100% EtOH (to give a concentration of 4mM) to each 
sample 
 Add 50 µL ortho-phosphoric acid (0.2M) to each sample 
 Vortex 
 Add 6.25 µL TBA reagent to each sample (concentration of 0.11M in 0.1M NaOH) 
 Vortex 
 Heat at 90 °C for 45 minutes (be strict with time and degrees for each repeat) 
 Place samples on ice for 2 minutes (or until needed) 
 Add 300 µL butanol to each sample 
 Prepare saturated salt by adding NaCl to a tube of water until it no longer dissolves 
 Add 50 µL of the saturated salt to each tube. 
 Vortex and then centrifuge at 14 000 rpm for 2 minutes. 
 Transfer the top phase of each sample to a clear, 96-well plate 
 Read at A532 – A572 
Protocol 11: Glutathione Assay (Antioxidant status) 
Reagents: 
Buffer A (500 mM Na3PO4, 1mM EDTA, pH 7.5) 
NADPH (1mM, 0.83 mg/mL) in buffer A (add 12 mL directly to vial)* NADPH, disodium salt, 
Cat nr. N6785 (10 vials) Sigma 
Stellenbosch University  http://scholar.sun.ac.za
 144 
 
M2VP (30 mM in 0.1 M HCL )  measures GSSG Cat nr. 69701 (100mg) Sigma 
DTNB (0.3 mM (0.12 mg/mL) in buffer A)    (Sigma, D21820) 
Standard solution (GSH - 3 µM, Sigma, G4251) in buffer A 
Glutathione reductase (16 µL in 984 µL buffer = 1 mL)    x5 for one plate Cat nr. G3664 (500 
Units) Sigma 
Procedure: 
Prepare standards as follows: 
 Blank 1 2 3 4 5 
GSH (µL) 0 167 333 500 667 833 
Buffer A (µL) 1000 833 667 500 333 167 
 
 Split sample into two epi’s. 
 Add 10 µL M2VP to the samples that will be used for measuring GSSG. 
 Sonicate samples for 10 minutes and then centrifuge at 14 000 rpm for 2 minutes. 
 Add 50 µL standards/samples (GSSG and GSH) to the wells of a 96-well plate 
 Add 50 µL of the DTNB using a multichannel 
 Add 50 µL of the glutathione reductase using a multichannel 
 Mix briefly and incubate for 5 minutes at 25 °C in a preheated BioTek plate reader 
 Add 50 µL NADPH to each well as quickly as possible (30 seconds max) 
 Measure absorbance at 412 nm every 30 seconds for 3 minutes 
 Use linear slope of the standards to calculate concentration of samples 
*10 mg per vial 
10 mg/x mL = 0.83 mg/1mL 
X = 12 mL 
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Protocol 12: Protein extraction from lysates 
 Work on ice at all times to prevent protein degradation 
 Thaw lysates (protocol 4) and sonicate at amplitude of 15, for 10 - 15 seconds, in order to 
rupture cell membranes 
 Rinse the tip of the sonicator between each sample. 
 After sonication, centrifuge the lysates at 8000rpm for 10 minutes, at 4 °C. 
Protocol 13: Protein determination using the Bradford method 
 Protein determination is carried out on ice to ensure that proteins are not denatured 
 Bradford reagent is prepared according to protocol in appendix B. 
 Set up a standard curve as follows, using 2 mg/mL BSA: 
Standard µL of BSA (2 mg/mL) µL lysis buffer Final Concentration (µg/mL) 
#1 0 1000 0 (blank) 
#2 125 875 5 
#3 250 750 10 
#4 375 625 15 
#5 500 500 20 
#6 625 375 25 
#7 750 250 30 
#8 1000 0 40 
 Pipette 5 µL of each standard (1 – 8) and samples into the wells of a 96-well plate. 
 Add 250 µL Bradford reagent to each well and read immediately at 595 nm. 
 Enter values into an Excel sheet to produce a standard curve (see example below).  
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
 146 
 
 The formulae will generate the concentration of protein in each sample 
 Choose desired protein concentration (20 or 50 µg). 
 Pipette the calculated volumes of each sample into new eppendorf tubes 
 Add the Laemlli’s loading buffer (appendix B) 
 Pierce Eppendorf tubes with a teasing needle and boil at 95 °C for 5 minutes 
 Samples can be stored at – 80 °C until needed 
Protocol 14: Western Blotting 
Preparation of assembly and gels 
 Clean glass plates with 70% alcohol and place into casting frames 
 Clean rubber with 70% alcohol to remove any debris 
 Place the frames with rubber gaskets into casting stands and firmly clip into place. 
 Check for leaks with distilled water, then discard water 
 Make up the separating gel (% determined by size of proteins) (Appendix B) 
 Using a Pasteur pipette, pour the separating gel between the glass plates, to the top of the 
green door - avoid making bubbles by pipetting into the corner of the plate 
 Pour a layer of iso-butanol onto the gel to prevent oxidation and to ensure a straight line 
 Allow the gel to set (+- 30 minutes) 
 Wash off the iso-butanol using distilled water 
 Prepare the 4% stacking gel (Appendix B) 
 Using a Pasteur pipette, pour the stacking gel onto the top on the separating gel 
 Immediately insert the appropriate comb (10- or 15-well) 
 Allow to set for +-30 minutes. 
 Denature samples by boiling at 95 °C for 5 minutes (punch a hole in the eppi). 
 Centrifuge samples briefly. 
 Carefully remove combs from the set gel. 
 Place gels into the U-shaped adaptor. 
 Place the apparatus into a tank and add running buffer (Appendix B) into the middle 
compartment until it overflows into the wells 
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Loading samples 
 Pipette 10 µL BLUeye Prestained protein ladder into the first well of the gel 
 Pipette samples in the rest of the wells using a new tip for each one. 
 Once all samples are loaded, pour running buffer into the outer compartments 
 Place a lid onto the tank and ensure the electrodes are correctly orientated – red to red 
and black to black 
 Run samples for 10 minutes at 400mA and 100V (constant) 
 Then run samples at 400 mA, 120V for about 50 minutes 
 Membrane transfer 
 Open a “transfer pack” and place the blotting paper marked ‘bottom’ onto the cassette. 
 Roll out any air bubbles 
 Carefully place the gel on top of the membrane. 
 Again roll out any bubbles 
 Place the blotting paper marked ‘top’ on top of the gel 
 Roll out any bubbles 
 Put the lid back on and lock into place. 
 Set the transfer for 7 – 12 minutes. 
 Once the transfer is complete, put the membrane into blocking solution (Appendix B) 
Antibodies 
 Wash the membrane 3 x 3 minutes with TBS-T (Appendix B). 
 Make up the primary antibody solution (Appendix B) in a 50 mL falcon tube and roll the 
membrane inside the tube 
 Rotate in a 4 °C fridge overnight. 
 Wash 3 x 3 minutes with TBS-T. 
 Make up secondary antibody solution (Appdenix B) in a 50 mL falcon tube and roll the 
membrane inside the tube 
 Leave on roller for 1 hour at room temperature 
Exposure 
 Wash membrane 3x 3 minutes with TBS-T 
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 Prepare a 1:1 solution of Pierce ECL substrate (must be room temperature) 
 Evenly pipette the ECL over the membrane 
 Expose in the ChemiDoc until desired bands appear. 
Stripping membranes 
 Wash membrane for 5 minutes in distilled water 
 Wash for 5 minutes in NaOH 
 Wash for 5 minutes in distilled water. 
OR 
 Wash membrane in stripping buffer for 2 x 5 minutes (Appendix C) 
 Wash for 2 x 10 minutes in distilled water 
 Block in milk solution 
  
Stellenbosch University  http://scholar.sun.ac.za
 149 
 
Appendix C 
Reagent Preparation 
Protocol 1: Growth Medium 
500 mL DMEM 
50 mL FBS (10%) 
5 mL PenStrep (1%) 
 All components must be thawed in the waterbath at 37 °C. 
 Under sterile conditions, remove 55 mL of DMEM from the bottle. 
 Add the FBS and PenStrep and invert to mix. 
 Aliquot into 50 mL tubes and store at 4 °C. 
Protocol 2: Differentiation Medium 
500 mL DMEM 
10 mL horse serum (2%) 
5 mL PenStrep (1%) 
 All components must be thawed in the waterbath at 37 °C. 
 Under sterile conditions, remove 15 mL of DMEM from the bottle. 
 Add the HS and PenStrep and invert to mix. 
 Aliquot into 50 mL tubes and store at 4 °C. 
Protocol 3: Doxorubicin stock 
Doxorubicin Hydrochloride (MR = 579.98 g/mol)  3.4 mM 
 Under sterile conditions, dissolve 10 mg Doxorubicin in exactly 5.071 mL medium. 
 Vortex, filter-sterilize, protect from light and store in aliquots at -20 °C. 
Protocol 4: Phosphate Buffer Saline 1X (PBS) 
Dissolve the following in 1L of distilled water: 
16 g NaCl 
0.4 g KCl 
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2.88 g Na2HPO4 
0.48 g KH2PO4 
 Adjust the pH to 7.4 
 Fill up to the 2L mark with distilled water 
 Autoclave 
Protocol 5: 95% alcohol (1L) 
 Dilute 950 mL 100% ethanol in 50 mL distilled water 
Protocol 6: 70% alcohol (1L) 
 Dilute 700 mL 100% ethanol in 300 mL distilled water 
Protocol 7: RIPA Buffer (100 mL) 
 Prepare 50 mM Tris-HCl: add 790 mg Tris to 75 mL distilled water. Add 900 mg NaCl 
and stir. Adjust pH to 7.4 using HCl. Pour the prepared Tris-HCl into a 100 mL beaker. 
 Add the following in the same order that they appear: 
 Volume Final Concentration 
NP-40 10 mL 1% 
Na-deoxycholate 2.5 mL 0.25% 
EDTA 1 mL 1 mM 
Phenylmethylsulponyl Fluoride (PMSF) 1 mL 1 mM 
Leupeptin 1 µL 1 µg/mL 
SBTI-1 80 µL 4 µg/mL 
Benzamidine 100 µL 1 mM 
Na3VO4 1 mL 1 mM 
NaF 500 µL 1 mM 
 
 Add 1000 µL Triton-X-1000 to the solution and fill up to the mL mark with distilled 
water. 
 Mix thoroughly. 
 Aliquot the RIPA into 1 mL Eppendorf tubes and store at -20 °C. 
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Protocol 8: Bovine serum albumin (BSA) 
 To prepare a 2 mg/mL stock of BSA, weigh off 20 mg and mix thoroughly in 10 mL 
distilled water. 
 Freeze in aliquots of 1 mL. 
Protocol 9: Bradford Reagent 
 Weigh off 200 mg Coomassie Brilliant Blue G250 and add to 100 mL 95% EtOH (95 mL 
ETOH, 5 mL water) 
 Mix on the magnetic stirrer 
 Add 200 mL 85% O-phosphoric acid (170 mL O-phosphoric acid, 30 mL water) 
 Put into a brown bottle 
 Add 1.7L distilled water 
 Filter until reddish-brown (+- 7 times) 
Protocol 10: Laemmli’s Sample Buffer (stock) 
 3.8 mL distilled water 
 1 mL 0.5M Tris-HCl, pH 6.8 
 0.8 mL glycerol 
 1.6 mL 10% (w/v) SDS 
 0.4 mL 0.05% (w/v) Bromophenol blue 
Note: For use in western blotting, make a working solution by adding 150 µL β-
mercaptoethanol to 850 µL Laemmli’s stock solution. 
Protocol 11: 10% Sodium dodecyl sulphate (SDS) 
 Weigh out 50 g SDS and add 500 mL distilled water 
Protocol 12: 10X Running Buffer 
 Weigh off 60.6 g Tris 
 Weigh off 288 g glycine 
 Add to ± 1.5L distilled water 
 Add 20 g SDS 
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 Adjust the pH to 8.6 
 Fill up to the 2L mark with distilled water. 
Protocol 13: 10X TBS 
 Dissolve 24.2g Tris and 80g NaCl in 600 mL distilled water. 
 Adjust pH to 7.6 with HCl 
 Fill up to 1L mark with distilled water. 
 For use in Western Blotting, make up 1X TBS-T by thoroughly mixing 100 mL TBS in 
900 mL distilled water, with 1mL Tween 
Protocol 14: 10% Ammonium persulphate 
 Weigh out 0.1 g APS into an Eppendorf tube and add 1000 µL distilled water 
Protocol 15: Tris pH 8.8 
 Weigh out 68.1 g Tris (1.124M) and 1.5 g SDS (0.3%) and place into a beaker 
 Add 400 mL distilled water, mix and then adjust pH to 8.8 using HCl 
 Make the final volume up to 500 mL 
Protocol 16: Tris pH 6.8 
 Weigh out 30.3 g (0.5M) Tris and 2 g SDS (0.4%) and place into a beaker 
 Add 400 mL distilled water, mix and adjust pH to 6.8 with HCl 
 Make final volume up to 500 mL 
Protocol 17: Tris pH 6.7 
 Weigh out 6.057 g Tris (100 mM) and place in a beaker 
 Add 400 mL distilled water, mix and adjust the pH to 6.7 using HCl 
 Make final volume up to 500 mL 
Protocol 18: Acrylamide Resolving Gels (makes enough for 2 gels) 
Gel Constituent 6% 8% 10% 12% 15% 
dH2O 5.88 mL 7.84 mL 9.8 mL 11.76 mL 14.70 mL 
30% Acrylamide 3 mL 4 mL 5 mL 6 mL 7.5 mL 
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1.5M Tris-HCl, pH 8.8 3 mL 4 mL 5 mL 6 mL 7.5 mL 
20% w/v SDS 60 µL 80 µL 100 µL 120 µL 150 µL 
10% w/v APS 60 µL 80 µL 100 µL 120 µL 150 µL 
TEMED (last!!) 24 µL 32 µL 40 µL 48 µL 60 µL 
Protocol 19: 4% Acrylamide Stacking Gel (makes enough for 2 gels) 
Gel Constituent  
dH2O 7.5 mL 
30% Acrylamide 1.5 mL 
0.5M Tris-HCl, pH 6.8 3 mL 
20% w/v SDS 60 µL 
10% w/v APS 80 µL 
TEMED (last!!) 40 µL 
Protocol 20: Milk blocking solution 
 Weigh out 5 g fat-free instant milk powder and add 100 mL of TBS-T 
 Mix well on a magnetic stirrer 
 This is enough for one membrane 
Protocol 21: Primary (1°) Antibody 
 Pipette 5 µL of the primary antibody into a falcon tube containing 5 mL TBS-T. 
 Prepare just before use 
Protocol 22: Secondary (2°) Antibody 
 Pipette 0.5 µL secondary antibody into a falcon tube containing 5 mL TBS-T. 
Protocol 23: Stripping Buffer 
 7.5 g glycine 
 0.5 g SDS 
 5 mL Tween 
 Dissolve in +- 300 mL distilled water 
 Adjust pH to 2.2 
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 Fill up to the 500 mL mark with dH2O 
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Appendix D 
Reagents 
Reagents Catalogue # Company 
2-Propanol UN1219 Merck 
32% Hydrochloric acid UN1789 Merck 
2,2’-Azobis (2-methylpropionamidine) dihydrochloride (AAPH) 440914 Sigma-Aldrich 
Absolute alcohol 32221 Riedel deHaën 
Acrylamide UN3426 Merck 
Acrylamide A3699 Sigma-Aldrich 
Ammonium Persulphate (APS) UN1444 Merck 
Antibiotic antimycotic (AA) 15240-062 Gibco 
Bovine Serum Albumin A4503 Sigma-Aldrich 
Bromophenol Blue 32400A UnivAR 
Caspase Glo 3/7 G8091 Promega 
Coomassie Brilliant Blue G 27815 Fluka 
D-(+)-Glucose G7021 Sigma-Aldrich 
Di-sodium hydrogen orthophosphate dehydrate 5822880EM Merck 
Doxorubicin D1515 Sigma-Aldrich 
DTNB D21820 Sigma-Aldrich 
Dulbecco’s Modified Eagles Medium (DMEM) D5796 Sigma-Aldrich 
Fetal Bovine Serum 10270-106 Invitrogen Gibco 
Fluorescein sodium salt F6377 Sigma-Aldrich 
Glutathione standard G4251 Sigma-Aldrich 
Glutathione reductase (GR) G3664 Sigma-Aldrich 
Glycerol G5516 UnivAR 
Glycine G8898 Sigma-Aldrich 
Horse Serum S9133 Biochrom 
Iso-butanol UN1212 Merck 
LDH Cytoxicity Kit G1780 Promega 
Malondialdehyde 805797 Merck 
Methanol UN1250 Merck 
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Mouse Quantikine TNF-α ELISA Kit MTA00B R&D Systems 
MTT (Thiazolyl Blue Tetrazolium Bromide M2128 Sigma-Aldrich 
M2VP 69701 Sigma-Aldrich 
NADPH disodium salt N6785 Sigma-Aldrich 
Ortho-phosphoric acid UN1805 Merck 
PenStrep 15140-122 Invitrogen Gibco 
Pierce® ECL Western Blotting Substrate 32106 Thermo Scientific 
Ponceau S Solution P7170 Sigma-Aldrich 
Rat Quantikine TNFα ELISA Kit RTA00 R&D Systems 
Sodium Dodecyl Sulphate (SDS) L3771 Sigma-Aldrich 
Thiobarbituric acid T5500 Sigma-Aldrich 
TEMED T9281 Sigma-Aldrich 
TNF-α 400-14 PeproTech Inc. 
Trolox 238831 Sigma-Aldrich 
Triton-X-100 BB306324 BDH 
Trizma-Base 93304 Fluka 
Trypsin EDTA 25200-012 Invitrogen Gibco 
Tween®20 P1379 Sigma-Aldrich 
β-Mercaptoethanol M3148 Sigma-Aldrich 
 
Antibody Size Species Catalogue # Company 
Cleaved caspase 3 17/19 Rabbit 9661S Cell Signaling 
Cleaved PARP 89/25 Rabbit Ab32064 Abcam 
GAPDH 37 Rabbit Ab37168 Abcam 
IgG, HRP-linked  Anti-Rabbit 7074S Cell Signaling 
LC3 14/16 Rabbit 4108S Cell Signaling 
P62 62 Rabbit Ab91526 Abcam 
P-Akt 60 Rabbit 9271S Cell Signaling 
P-Erk 42/44 Rabbit 4370S Cell Signaling 
P-Stat 705 79/86 Rabbit 9131S Cell Signaling 
P-Stat 727 86 Rabbit 9134S Cell Signaling 
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T-Akt 60 Rabbit 9272S Cell Signaling 
T-Erk 42/44 Rabbit 4695S Cell Signalling 
TNF-a 17/25/28 Rabbit 11948S Cell Signalling 
TNFR1 55 Mouse SC-8436 Santa Cruz 
TNFR2 75 Rabbit 3727S Cell Signalling 
T-Stat3 79/86 Mouse 9139S Cell Signalling 
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